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Summary
The main aim of the present series of experiments was to assess the influence of selected 
candidate genes on several adiposity-related phenotypes in a large cohort of toddlers and 
preschoolers from Greece using both genotype- and haplotype-based approaches. 
Investigating the impact of genetic polymorphisms on adiposity in the young may reveal 
stronger associations than in older ages since the environment has had less time to take 
effect. Anthropometric measurements and buccal cell samples, from where genomic DNA 
was extracted, were obtained from 2374 children aged 1-6 years, all in public and private 
nurseries in Greece.
The aim of the first experiment (Chapter 3) was to assess developmental changes in 
adiposity in the present population of Greek toddlers and preschoolers. This was achieved 
by determining the prevalence of overweight and obesity in this population using specific 
BMI cut-off points based on UK and US national reference data. On average and 
irrespective of gender, 13.6% and 10.2% of children were found to be overweight and 
obese, respectively. These rates of obesity were comparable with those found in other 
national studies with high prevalence of overweight and obesity. When compared to the 
normative data from British children, Greek children were much taller and heavier and 
they showed excess BMI with advancing age. The present cohort of Greek children also 
showed gender- and age- related differences in several anthropometric indices, but similar 
patterns of growth as US preschool children with increased adiposity.
The aim of the second experiment (Chapter 4) was to assess the potential influences of 
ACE I/D polymorphism and its interaction with age and/or gender on adiposity-related 
phenotypes in the cohort of Greek toddlers and preschoolers. A significant main effect of 
the ACE I/D polymorphism on BMI and significant interactions between I/D genotype and 
age for the same phenotype were revealed. In boys and girls 1-2 years, the II genotype was
viii
significantly associated, in a D-dominant fashion, with higher BMI. This association 
accounted for 6.4% of the variance and was not in accordance with previous studies in 
adolescents and adults. However, in the 4-6 years age group, subjects (mainly girls) with 
the DD rather than II genotype had higher BMI confirming the significant interaction 
between age and 1/D genotype. The age, at which this alteration in the effect of ACE VD 
polymorphism on adiposity was observed, coincided with the age at which BMI increased 
after its developmental nadir. These results suggest that the ACE I/D polymorphism 
associates with developmental changes in adiposity during early childhood in an age- and 
possibly gender-specific manner.
The aim of the third experiment (Chapter 5) was to investigate the potential influence of 
five genetic polymorphisms in ADRB genes on adiposity-related phenotypes in the Greek 
children and their potential interactions with age and/or gender. Significant main effects of 
ADRBl C16 on waist and hip circumferences and significant interactions between C l6 
genotypes and age for the same phenotypes were revealed. Significant interactions were 
also observed between C16 genotypes and gender. In boys and girls aged 4-6 years, the 
Glyl6 allele was significantly associated in an additive fashion with higher waist 
circumference and this association explained 1.2% of the variance. As far as ADRBl C27 
polymorphism is concerned, a significant main effect of C27 genotypes on hip 
circumference and significant interactions between these genotypes with age and gender 
for the same phenotype were observed. In boys, the Gln27 allele was significantly 
associated, in an additive fashion, with higher hip circumference at the age of 2-3 years 
that explained 6% of the variance. No significant main effects of ADRBl C49 and C389, as 
well as ADRB3 C64 polymorphisms on adiposity-related phenotypes were found. 
Haplotype-based analysis did not reveal stronger associations compared to individual 
genotypes. ADRBl gene polymorphisms have subtle effects on adiposity in early childhood 
and these influences are manifested in a gender- and age-related manner.
ix
The aim of the fourth and final experiment (Chapter 6) was to assess the influence of two 
polymoiphisms in PPARy gene on adiposity-related phenotypes in the Greek toddlers and 
preschoolers. Genetic analysis based on Pro 12Ala genotypes revealed that the rare Ala 12 
and T1431 alleles had no significant main effect on adiposity-related phenotypes. 
Interactions with age and/or gender were either not significant. A synergistic effect of 
PPARy Pro 12Ala and ADRB3 Arg64Trp polymorphisms, as well as a modulating eefect of 
BMI on the establishment of associations previously observed in adults was not confirmed 
in this study. Haplotype-based analysis including both PPARy polymorphisms revealed no 
stronger associations of PPARy diplotypes with adiposity-related indices compared to 
individual genotypes. Variation in the PPARy seems not to contribute significantly to the 
high prevalence of early-onset obesity possibly due to differences in the dietary 
composition between children and adults.
The findings from the genetic analyses suggested that allelic variations in candidate genes 
simply predispose to the obesity phenotype. With well-conducted genetic studies and with 
thorough examination of the information with respect to genetic associations, progress in 
understanding and management of obesity can be foreseen.
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haplotypes. Individuals with the Pro-C/Pro-C diplotype are 
homozygotes for the Pro-C haplotype. Invididuals with the Pro- 
C/Pro-T and Pro-T/Pro-T diplotypes are heterozygotes and 
homozygotes for the Fro-T haplotype respectively, while those 
with the Pro-C/Ala-C and Ala-C/Ala-C are heterozygotes and 
homozygotes for the Ala-C haplotype respectively. The Ala-T 
haplotype group includes individuals with Pro-C/Ala-T, Pro- 
T/Ala-T, Ala-C/Ala-T, Ala-T/Ala-T diplotypes. The level of LD 
between the two polymorphisms is also shown.
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Chapter 1
General Introduction
1.1 Childhood obesity
Obesity can be defined as an excess accumulation of body fat that leads to increase risk of 
morbidity and/or premature mortality (Reilly, 2005). The health consequences of 
childhood obesity can be categorized into short- and long-term effects and include 
psychosocial ill health, asthma, increased cardiovascular risk factors such as hypertension, 
dyslipidaemia and insulin resistance, as well as persistence of obesity and cardiovascular 
risk profiles into adulthood (Dietz, 1998;Reilly, 2005). Previous reports indicate a dramatic 
increase in the prevalence of overweight and obesity in recent decades (Ebbeling et al.,
2002). Rates have increased 2.3-fold to 3.3-fold in the USA from 1971 to 1994 and 2.0- 
fold to 2.8-fold in England from 1984 to 1994 (Ebbeling et al., 2002). Increasing obesity 
rates are not only observed in Europe (Lissau, 2004) and in the USA (Nicklas et al., 2001) 
but also in other countries such as China and Egypt (Ebbeling et al., 2002) and there is 
general agreement that this is due to a changing environment, which favours sedentary 
lifestyles and over-consumption of high energy-dense foods rather than changing genetic 
influences (Hill et al., 2003).
A consistent positive correlation between child and adult overweight and obesity has been 
seen with both parents of obese children being obese in almost 30% of the cases 
(Bouchard, 1997). Family and twin studies have shown heterogeneous estimates of 
heritability for BMI (Body Mass Index) and body fat distribution ranging between 10% to 
80% (Bouchard and Perusse, 1988;Bouchard, 1995) and supported the notion of a strong 
genetic component in the development of obesity that involves the synergistic interaction 
between a number of genes important for adipogenesis and adipose tissue metabolism 
(Marti et al., 2004). Variation in obesity-related phenotypes cannot soley be attributable to 
genetic effects, but also environmental or lifestyle influences such as overfeeding (Koivisto 
Hursti, 1999) and lack of exercise (Meirhaeghe et al., 1999). Nevertheless, the alarming 
rates of obesity have occured in a constant pool of genes and thus, the influence of
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environmental or behavioural changes on adiposity becomes progressively stronger 
(Prentice and Jebb, 1995). hi Britain, for example, the consumption of a high fat diet has 
increased by 50% over a period spanning from 1940 to 1990, while the increase of physical 
inactivity, as indicated by proxy measures such as car ownership and hours of television 
viewing, seems to be the primary cause for the observed changes in the prevalence of 
obesity (Prentice and Jebb, 1995). However, these genetic and environmental interactions 
can exert a variable effect on adiposity with age as indicated in longitudinal studies (Maes 
et al., 1997) and this effect has been postulated to be due to different gene expression 
profiles at different ages, or to age-related variability in exposure to environmental 
influences (Maes et al., 1997). Moreover, genetic influences on phenotype may be stronger 
in young individuals, as the environment or behaviour has less time to take effect than at 
later ages (Maes et al., 1997) and therefore the study of young children becomes crucially 
important when attempting to quantify the extent of genetic predisposition to obesity.
The preschool years have been identified as a critical time for the development of adiposity 
later in life, since crucial behavioural and developmental processes occur during this 
period. In particular, habits related to food intake and physical activity become established 
and a decrease in BMI, preceding adiposity rebound, is observed (Dietz, 1997). Body 
composition undergoes marked changes during the first decade of life in absolute and 
relative proportions of water, lipid, protein and mineral mass; at birth, for example, 
approximately 80% of lean tissue is water, declining to approximately 75% at the end of 
the first decade (Fomon et al., 1982). Quantifying the main body components (i.e. body fat, 
lean mass, muscle mass, skeletal frame) is integral to the study of obesity in children 
(Pietrobelli et al., 2003) and studying quantitative traits that show high heritability and can 
be measured easily and accurately is particularly advantageous in large cohort studies 
(Newton-Cheh and Hirschhorn, 2005). BMI for age is a well-established diagnostic tool for 
obesity and its diagnostic accuracy depends on whether national BMI reference data or the 
international (lOFT) definitions of overweight and obesity in children are used (Reilly,
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2006), Although it cannot distinguish between fat and lean mass (Wells and Fewtrell, 
2006), several studies have shown good correlation between BMI and more direct fat 
measures obtained by methods that ai'e highly precise and more accurate but have limited 
applicability to studying large populations (i.e. dual-energy X-ray absorptiometry and 
imaging techniques) (Pietrobelli and Tato, 2005). Skinfolds in the arm (biceps and triceps) 
and in the tnink (subscapular and suprailiac) are reliable indices of subcutaneous fat, while 
waist and hip circumferences are good predictors of abdominal fat (Pietrobelli and Tato, 
2005;Wells and Fewtrell, 2006). Waist-to-hip ratio is a less accurate predictor of visceral 
fat and mortality compared to waist circumference in children (Fredriks et ai., 2005), while 
equations for the prediction of total fat mass from skinfolds ai'e inappropriate as they may 
be valid only in the population from which they were derived and they confound skinfold 
raw values with predictive error (Wells and Fewtrell, 2006).
1.2 Variation in obesity-reiated phenotypes
Obesity is a multifactorial trait and variation in an obesity-related phenotype, known as 
total phenotypic variance, is determined by both genetic and non-genetic factors 
(Bouchai'd, 1995). Total phenotypic variance can be described as the sum of genetic 
variance, environmental and lifestyle influences and gene-environment interactions 
(Bouchard and Perusse, 1988). Genetic vaiiance results from the influence of the diverse 
genetic variants on adiposity (Marti et al., 2004;Rankinen et al., 2006)and can be further 
subdivided into additive, dominance and interaction variances generated by the additive, 
dominant and epistatic effects of alleles on the phenotype respectively, while 
environmental variance represents variation in diet habits or exercise levels. A gene- 
environment effect refers to a phenotype for which the response to an environmental 
influence is significantly influenced by the genotype (Moran et al., 2005). There aie 
several types of variation in the coding and non-coding regions of the human genome, such 
as microsatellites (short tandemly repetitive DNA), short deletions and insertions, that
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account for the inter-individual genetic differences and genomic variability has been 
shown to be population-specific with Africans showing greater gene diversity than 
Europeans or Asians indicative of the recent migration patterns and relationships between 
various populations (Stephens et al., 2001). SNPs are the most abundant (90%) and stable 
single-base changes in the human genome, occuring with an average frequency of 
approximately 1 every 1,000 nucleotides (nucleotide diversity index) (Brookes, 
1999;Twyman and Primrose, 2003) and as such, they have facilitated the ability to map 
genes of complex diseases (Gray et al., 2000;Bhatti et al., 2006). Different alternatives 
(alleles) exist at these single base pair positions with the least frequent allele showing a 
frequency of 1% or more (Brookes, 1999). The frequency of SNPs in coding regions is 
fourfold lower compared to that in noncoding, with about 50% of them resulting in 
variation at the aminoacid level (non-synonymous changes) (Brookes, 1999;Twyman and 
Primrose, 2003). SNPs can affect the protein function if they occur in the coding or 
regulatory regions of the gene, but in many cases they show no functional relevance (Gray 
et ah, 2000). For example, a single-nucleotide substitution (S127L) in the melanocortin-4 
receptor gene has been found to alter the signalling properties of this G protein-coupled 
receptor resulting in severe early-onset obesity (Valli-Jaakola et al., 2004).
In human populations, functional and neutral variants can be associated by LD, which is 
the non-random association (co-segregation) of alleles at different loci (Goldstein, 2001) 
that arises because the variants share a joint population ancestry (Zondervan and Cardon, 
2004). Genome-wide patterns of LD can var y significantly between populations as a result 
of natural selection and local variability in recombination rates, as well as genetic drift and 
population admixture (Cardon and Bell, 2001 ;Goldstein, 2001)and European populations 
generally show lower nucleotide diversity and greater LD than African populations (Ardlie 
et al., 2002). Considering AŒ  (angiotensin l-converting enzyme 1) gene as an example, a 
functional polymorphism has been identified in very strong LD with another marker in 
Caucasian populations (Soubrier et al., 2002). However, the same polymorphisms were not
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found to be in tight LD in Nigerian families (Cox et al., 2002), suggesting that levels of LD 
in ACE gene differ in European and African populations. Furthermore, there is a great 
heterogeneity in the distribution of LD across the genome with GC-poor sequences, for 
example, showing stronger LD due to low recombination rates (Tiret et al., 2002) and 
genomic regions with consistent patterns of LD show reduced numbers of haplotypes; 
these are defined as groups of specific SNP alleles at multiple loci that tend to be co­
inherited and are only rarely disrupted by recombination events (Weiss and Clark, 2002). 
Although there is a strong correlation between the level of LD and physical distance, 
physically close markers are not always in LD with each other (Ardlie et ah, 2002;Tiret et 
ah, 2002). Therefore, the selection of the appropriate SNPs based on the levels of LD is 
crucially important in the design of complex disease association studies, since genotyping 
of a few SNPs can be sufficient to represent most of the diversity in a genomic region 
(Goldstein, 2001)
1.3 Genetic analysis of childhood obesity
Currently, the two dominant strategies for identifying and locating genetic variants that 
contribute to obesity are linkage analyses and association studies (Cardon and Palmer,
2003). Most of the complex traits tend to aggregate in families, but rarely in a classic 
Mendelian fashion (Mayeux, 2005). Linkage analyses search for regions of the genome 
that co-segregate with the disease in many independent affected families or over many 
generations in an extended pedigree (Ardlie et ah, 2002;Carlson et al., 2004)taking 
advantage of the strong correlation between markers in close proximity (Risch, 2000). 
Although linkage analysis has been, together with positional cloning, a powerful tool in 
identifying genetic loci for single-gene disorders, it may be less reliable for the study of 
complex diseases due to high false-positive rate (Risch, 2000) and less power in 
identifying susceptibility genes that have small effects (less than 5-10% of the variance) or 
weak genotype-phenotype correlation (Uhl et ah, 1997;Risch, 2000). Given the fact that
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the genetic element in complex traits is comprised of multiplex genetic variants each 
contributing a small effect (Marti et al., 2004), association studies can have more power in 
detecting genetic effects than linkage analysis, when the candidate gene has already been 
identified (Gray et al., 2000). Association studies can be broadly broken down into family- 
based (extended pedigrees, relative-pairs, parent-child trios, nuclear families) and 
population-based studies (case-control, cohort-based) (Cardon and Palmer, 2003). Family- 
based association studies are more suitable for studies of very rare conditions. Case-control 
studies compare exposure to risk genetic or environmental factors between affected 
subjects and unrelated healthy controls to find associations between risk factors and 
disease risk in relatively rare conditions (Clayton and McKeigue, 2001 ;Zondervan and 
Cardon, 2004), while cohort-based studies mainly attempt to associate polymorphic 
variants in candidate genes with influences on the phenotype of interest (Clayton and 
McKeigue, 2001)
To date, a limited number of population-based association studies have been performed on 
the influence of specific genetic variants on adiposity in young children, despite evidence 
suggesting that studying young cohorts can in some circumstances reveal genotype- 
phenotype associations more effectively than in adults, since confounding effects of the 
environment have had less time to take effect (Maes et al., 1997). Case-control studies in 
French children have shown that variation in the adiponectin encoding gene was associated 
with severe childhood obesity (Bouatia-Naji et a l, 2006), while genetic variability in 
ENPPl (EctoNucleotide Pyrophosphatase Phosphodiesterase) and specifically, one three- 
allele risk haplotype was associated with chromosome 6q-linked childhood obesity (Meyre 
et al., 2005). Furthermore, a cross-sectional study on Scottish children has revealed that the 
PPARy Prol2Ala polymorphism had smaller effects on BMI in younger ages compared to 
adult populations (Cecil et al., 2006). Other studies, however, have failed to reveal 
associations between genetic polymorphisms and increased adiposity in childhood. For 
example, a case-control study in a French population have shown that the Pro 12Ala
 i _ i
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polymorphism in PPARy gene was not associated with childhood obesity (Ghoussaini et 
al., 2005), while variants in the gene encoding for uncoupling protein-1 were not found to 
contribute to juvenile-onset obesity in subjects of Danish ancestry (Urhammer et al., 1997). 
Similarly, the Bogalusa Heait cohort-based study, which has assessed the longitudinal 
effects of an ADRB2 (p2 “Adrenergic Receptor) genetic variant on adiposity from childhood 
to adulthood, has detected no genetic effects on obesity in childhood (Ellsworth et al., 
2002), while the PPARy Prol2Ala variant was found not to contribute significantly to early 
onset obesity in a German population (Hamann et al., 1999).
According to the aforementioned examples, population-based association studies are 
widely applied for characterizing genetic determinants contributing to obesity in young 
children; however, in many cases they may suffer from several limitations that lead to 
inconsistency of the association data. During the case-control approach, although cases and 
controls are readily available and can efficiently be genotyped, several confounders such as 
gender, age and ethnicity differences (population stratification) between cases and controls 
can lead to spurious associations (Risch, 2000). Focusing on homogenous and randomly 
mating populations can overcome confounding by ethnicity, although such populations 
may be more of a theoretical ideal than a reality (Risch, 2000;Cardon and Bell, 2001). 
Furthermore, association studies, widely used to tackle the genetics of complex diseases, 
are usually plagued by the lack of reproducibility due to poor study design, 
overinterpretation of the findings and incorrect assumptions regarding the underlying 
genetic architecture (Cardon and Bell, 2001). For example, the power of association 
studies to detect significant genetic effects diminishes significantly with decrease in LD 
(Risch, 2000), while in cases of low LD, the required increase in sample size is inversely 
proportional to the estimate of LD (Zondervan and Cai'don, 2004). Moreover, sample size 
is considered to be particularly important in association studies for generating robust data 
(Cai'don and Bell, 2001). Considering, for example, the Pro 12Ala polymorphism in PPARy 
gene, a large study of 3000 subjects was necessary to confirm the association of the Pro 12
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allele with increased risk for type H diabetes and demonstrate that this genetic effect was 
more modest than originally described (Altshuler et al., 2000). Therefore, taking into 
consideration the modest effects of genes on the development of obesity, the tendency to 
analyse subgroups of subjects to accommodate age- or gender-related differences and the 
assessment of the genetic influence on phenotypes of variants with uncertain LD from the 
functional variants, sample sizes of 1000 to 10000 individuals may be necessary for 
revealing genuine associations (Cardon and Bell, 2001).
1.4 Candidate genes for obesity
Candidate genes selection can be based on the physiological role of their protein products 
in pathways crucial for the development of the disease. However, this approach can be 
unsatisfactory due to current incomplete knowledge about functional variants (Suh and 
Vijg, 2005). Alternatively, findings from linkage analyses and mouse models can be useful 
for the implication of putative genes (Suh and Vijg, 2005). There have been more than 420 
findings of positive associations between obesity phenotypes and genetic variation in over 
127 candidate genes in children and adult populations (Rankinen et al., 2006). ACE, ADRB 
fp-Adrenergic Receptor) family and PPARy were among the putative genes widely studied 
for influences in obesity-related phenotypes.
t.4 . 1 ACE gene
ACE is a key component of RAS and converts angiotensin I (vasoinactive) into a 
biologically active hormone, angiotensin II (vasoconstrictor) (Bernstein et ah, 1989) 
(Figure 1.1). ACE also has the ability to hydrolyze numerous other peptide substrates 
(Hooper and Turner, 2003). In humans, angiotensin II effects are mediated predominantly 
through two specific receptors, namely ATI (Angiotensin II Type 1 receptor) 
(vasoconstrictor responses) and AT2 (Angiotensin II Type 2 receptor) (vasodilator
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responses), which are G-protein coupled receptors in the plasma membrane (Crisan and 
Carr, 2000;Danser, 2003). Tissue RAS systems with all the necessary components for 
angiotensin H synthesis, have been also identified in a number of peripheral tissues 
including the adipose, the cardiac and the skeletal muscle tissue (Engeli et al., 1999), 
suggesting a paracrine action of the RAS (Lavoie and Sigmund, 2003). In adipose tissue, 
angiotensin II may play an important role in growth and differentiation, blood flow and 
lipolysis; however the exact effects of this hormone on adipose tissue aie not yet 
established (Goossens et al., 2003). Furthermore, no effect of angiotensin II stimulation or 
ACE inhibition on lipolysis was observed in human adipocytes, suggesting that the RAS 
may serve more as regulator of the regional blood flow to adipose tissue rather than 
lipolytic regulator (Townsend, 2001).
The ACE gene is highly polymorphic, with over 100 polymorphisms listed in SNPs 
database twww.ncbi.nlm.nih. gov/SNP/snp ref.cgi?locusID= 1636). Historically, work is 
focused on ACE VD (insertion/deletion) polymorphism, which involves the presence 
(insertion, allele T’) or absence (deletion, allele ‘D’) of a 287bp (base pairs) Alu repeat 
sequence in intron 16 (Rigat et al., 1990). This polymorphism accounts for almost half of 
the variance in semm ACE activity, with homozygotes for the D allele showing higher 
plasma ACE levels than individuals with the ID (intermediate ACE levels) or II (lower 
ACE levels) genotypes (Rigat et al., 1990). However, the association between ACE activity 
levels and the I/D polymorphism was found to be weaker in people of African origin (Cox 
et al., 2002). Therefore, the I/D polymoiphism may not be the causal variant for the 
variation of ACE activity but may be in strong LD with the causal variant in Caucasians 
and not so strong LD with the causal variant in Africans. This notion is also supported by 
the identification of 17 variant sites in tight LD with the ACE I/D polymorphism in 11 
individuals, (5 African-American and 6 European-American) and the inference of 13 
haplotypes suggestive of allelic heterogeneity (Rieder et ah, 1999).
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Previous studies have examined the possible association between the ACE I/D I
polymorphism and obesity in adult and adolescent populations with somewhat contrasting /I 
findings. Associations between RAS and obesity were assessed in a group of 449 Jamaican
individuals, but no consistent differences between ACE genotypes and BMI were found 
(Cooper et al., 1997). However, the ACE I/D polymorphism was associated with variation 
in ACE levels with obese individuals having significantly higher serum ACE and 
angiotensinogen levels. In a study of 155 obese Korean women, no significant association 
between the ACE I/D polymorphism and obesity was found (Um et al., 2003). Other 
studies have demonstrated significant associations between the ACE I/D polymorphism 
and increased adiposity. In particular, the DD genotype was significantly associated with
,overweight and abdominal adiposity in adult Italian men (Strazzullo et al., 2003) and with 
obesity and abdominal fat deposits in a Spanish population with coronary heart disease
:î
,
3(Riera-Fortuny et al., 2005). More recent data on Greek adolescents have also shown that 
the DD genotype is associated with greater triceps and subscapular skinfolds than the other 
I/D genotypes, but only in females who are relatively inactive, suggesting a gender-specific 
effect of ACE I/D polymorphism on obesity-phenotypes, as well as an interaction between 
I/D genotypes and physical activity (Moran et al., 2005),
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Figure 1.1 Role of ACE in the RAS and Kinin-Kaliikrein systems (adapted from Crisan and 
Carr, 2000).
1,4.2 ADRB genes
Among the promising candidate genes for obesity are members of the ADRB family: 
ADRBl f pi-Adrenergic Receptor), ADRB2 and ADRB3 (pg-Adrenergic Receptor). ADRBs 
are G-protein coupled receptors in the plasma membrane and, typically of this superfamily, 
they have an extracellular N-terminus, seven transmembrane-spanning regions, three 
intracellular and three extracellular loops and an intracellular C-terminus (Green et ah,
1993). ADRB are differentially expressed in several tissues throughout the body; ADRBl is 
expressed in cardiac muscle (inotropy and chronotropy), adipose tissue and kidney (renin 
secretion) (Mason et al., 1999), ADRB2 in many cell types including adipocytes and 
ADRBS predominantly in adipose tissue (Small et al., 2003;Leineweber et al., 2004). In 
white and brown adipose tissue, ADRBs promote lipid mobilization and thermogenesis in a 
cascade of reactions (Collins et al., 2004). In particular', endogenous catecholamines 
(adrenaline and noradrenaline) stimulate the beta-adrenocpptors on the surface of
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adipocytes, which signal to the interior of cell via the Gs (stimulatory) proteins that 
activate adenylyl cyclase. As a result, the levels of intracellular cAMP (cyclic-Adenosine 
Monophosphate) (a signaling molecule) are increased and subsequently PKA is activated,
PKA phosphorylation of HSL (Hormone Sensitive Lipase) is followed by its activation and 
translocation to the lipid droplet and lipolysis stimulation (Figure 1.2) (Gonzalez Sanchez 
et al., 2003). ADRBS receptor can couple to both Gs (adenylyl cyclase stimulatory G 
protein) and Gi (adenylyl cyclase inhibitory G protein) (inhibitory) proteins leading to the 
simultaneous transduction of two independent signaling pathways, PKA and ERK/MAP 
(Extracellular signal-regulated kinase/ Mitogen Activated Protein) kinase respectively 
(Collins et al., 2001). This simultaneous activation may promote a more potent stimulation
iof lipolysis, since both pathways result in HLS phosphorylation in white adipose tissue 
(Soeder et al., 1999).
î
Single-nucleotide polymorphisms within the coding region of the ADRB genes can affect 
the expression and function of the gene/receptor and may contribute to the development of 
several disorders, such as hypertension, asthma, congestive heart failure or obesity (Small 
et al., 2003;Leineweber et al., 2004). In ADRBl, two nonsynonymous polymorphisms were 
identified, one in the extracellular N-terminus resulting in substitution of serine for glycine 
at codon 49 (Gly49Ser; C49) (Maqbool et ah, 1999) and one between the seventh 
transmembrane-spanning domain and the intracellular tail of the receptor resulting in 
substitution of glycine for arginine at codon 389 (Arg389Gly; C389) (Maqbool et al., 
1999;Mason et al., 1999). Due to their location, Gly49Ser (rs 1801252) and Arg389Gly 
(rs 1801253) polymorphisms can affect receptor trafficking or expression and Gs-coupling 
respectively. In particular, functional in vitro studies have shown that the Gly49 variant 
was susceptible to enhanced agonist-promoted down-regulation due to decreases in 
mRNA, while the Arg389 valiant exhibited a greater agonist-promoted stimulation of 
adenylyl cyclase than Gly389 receptor (Leineweber et ah, 2004). In ADRB2, a total of 
nineteen variable sites have been identified in the coding region (11 SNPs) and in the 5’
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UTR (8 SNPs) upstream from the ATG start codon (Leineweber and Brodde, 2004). 
Among them, thi’ee non-synonymous polymorphisms have been identified in the coding 
region (Drysdale et al., 2000) and have been shown to have functional significance in vitro 
and in vivo (Small et ah, 2003); work however, is usually focused on two of these SNPs in 
the extracellular region of the receptor, which result in substitution of arginine for glycine 
at codon 16 (Glyl6Arg; C16, rs 1042713) and glutamine for glutamic acid at codon 27
(Glu27Gln; C27, rs 1042714). Functional studies in vitro have revealed that these N- 
terminus polymorphisms resulted in different properties of agonist-promoted down- 
regulation (Glyl6 receptor displaying enhanced down-regulation and Glu27 receptor being 
resistant to such desensitization) and these differences accounted for by altered 
susceptibility to receptor degradation (Green et al., 1994). Moreover, the Glyl6Glu27 and 
Glyl6Gln27 receptors exhibited similar levels of down-regulation between them in vitro 
and both higher when compared to the Argl6Gln27 double mutant receptors (Green et al. 
1994). One major SNP has been described in ADRBS (Clement et ah, 1995;Walston et al., 
1995;Widen et al., 1995) located either to the most distal residue within the first 
transmembrane spanning domain or the most proximal residue of the first intracellular loop 
resulting in a substitution of arginine for tryptophan at codon 64 (Trp64Arg; C64, rs4994). 
The functional significance of this polymorphism though has yet to be determined, since 
conflicting results regarding the Arg64 receptor’s ability to promote cAMP accumulation 
(Leineweber et al., 2004). Numerous studies have examined the relationship between these 
ADRB polymorphisms and adiposity-related phenotypes. Despite the evidence from in 
vitro studies of Arg389Gly being a gain-of-function polymoiphism, the Arg389 rather than 
the Gly389 allele has been associated with higher body weight and BMI, as a result of 
increased fat in Caucasian women (Dionne et al., 2002), whereas this polymorphism was 
found to have no effect on lipolysis regulation (Ryden et al., 2001). Furthermore, the 
ADRBl Gly49 allele, showing increased in vitro desensitization, was associated with 
greater long-term weight-gain and adult-onset overweight in women (Linne et ah, 2005).
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In ADRBl, genotyping of the Gly49Ser and Arg389Gly polymorphisms allows the 
inference of three haplotypes, namely Ser49Arg389, Ser49Gly389 and Gly49Arg389, 
which represent the majority of variation along the complete length of the gene. All four 
alleles in ADRBl gene have been previously associated with increased adiposity. For 
example, in Swedish women the Glu27, but not the Glyl6 allele, was associated with 
increased body fat. In the same population, the Glyl6Arg polymorphism was associated 
with altered ADRBl function, with Argl6 carriers showing a five-fold decrease in agonist 
sensitivity (Large et al., 1997). In contrast, men, but not women, homozygous for the 
Gln27 allele showed higher scores for obesity-related phenotypes and if they were also 
carriers of the Argl6 allele, the risk for obesity was increased (Meirhaeghe et al., 2000b). 
Twelve distinct haplotypes were identified in a population of 4 major ethnic groups 
(Drysdale et al., 2000). Genotyping of ADRBl C16 and C27 polymorphisms revealed the 
occurrence of three haplotypes, namely Argl6Gln27, Glyl6Glu27 and Glyl6Gln27, in 
these populations. As far as ADRBS Trp64Arg polymorphism is concerned, although the 
Arg64 variant has been initially associated with abdominal obesity and insulin resistance, 
as well as increased capacity to gain weight, lower age of onset of non-insulin-dependent 
diabetes mellitus and a lower metabolic rate (Clement et al., 1995;Walston et al., 
1995;Widen et al., 1995), further population-specific and meta-analysis studies, albeit in 
obese and diabetic subjects, revealed conflicting results, with approximately one half of 
them reporting positive associations and another half failing to do so (Small et al., 
2003;Leineweber et al., 2004).
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Figure 1.2 Signal transduction cascades of the ADRBl, ADRB2 and ADRB3 receptors for 
lipolysis regulation by catecholamines. The three ADRBs are coupled to the trimeric Gs, 
which consists of a, p and y subunits, and they transmit an activation signal to adenylyl 
cyclase resulting in increased cAMP production. Then a cAMP-dependent protein kinase 
(PKA) is activated and leads to phosphorylation and activation of HSL and perilipin A in 
adipocytes (adapted from Gonzâlez-Yanes and Sanchez-Margalet, 2006).
1.4.3 PPARy gene
PPARs constitute a subfamily of the nuclear hormone receptor gene superfamily and they 
have a key role in energy metabolism (Evans et al., 2004). PPARy is a ligand-regulated 
transcriptional factor that controls transcription of target genes, such as aP2 (Adipocyte 
fatty-acid binding protein), LPL and ACS (Acyl-CoA synthetase), linked to lipid 
metabolism and energy balance by binding to PPREs located in the promoter or enhancer 
sites of these genes. PPAR heterodimerizes with the RXR to form a complex that binds to 
PPREs (Figure 1.3) (Martin et al., 1998;Gumell, 2005). The activity of PPARy is governed 
by the binding of small lipophilic ligands, mainly fatty acids derived from nutrition and
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metabolism (Auwerx et al., 2003). Studies have shown that PPARy is involved in several 
biological pathways, such as adipocyte differentiation and metabolism, as well as insulin 
sensitivity, type 2 diabetes, atherosclerosis, and cancer (Rosen and Spiegelman, 
2001;Lehrke and Lazar, 2005). The importance of PPARy in adipocyte differentiation is 
underlined by the finding that PPARy can induce adipognenesis in fibroblasts (non- 
adipogenic cells), as well as myoblasts (Fajas et al., 1997). Moreover, targeted deletion of 
PPARy in mice resulted in adipocyte hypocellularity (He et al., 2003), while heterozygous 
PPARy-dùficicnt mice have reduced adiposity (Barak et al., 1999;Rosen et al., 1999). In 
addition to that, antagonists for the PPARy inhibited adipocyte differentiation (Wright et 
al., 2000). Similarly, humans with dominant-negative mutations in PPARy showed partial 
lipodystrophy and severe insulin-resistance because of increased triglycerides and fatty 
acid deposition into skeletal muscle and liver (Savage et al., 2003). These findings make 
PPARy a promising gene for susceptibility to obesity (Auwerx et al., 2003).
The PPARy gene spans more than lOOkb and contains 9 exons, which lead to 4 mRNA 
isoforms (PPARyi, PPARy2 , PPARy3 and PPARy4) by use of alternative promoters and 
differential splicing at the 5’ end of the mRNA (Fajas et al., 1997). All four subtypes 
contain 6 common exons. PPARyi contains also Ai and A2 , PPARy2 exon B and PPARy3  
only exon A2 . PPARy2 , PPARy3 , PPARy4  mRNAs give rise to the same protein (PPARyi) 
encoding by exons 1-6, since exons Ai and A2 are untranslated. In PPARy2 , translation of 
exon B leads to the production of a protein (PPARy2) with an additional 30 amino acids in 
the N terminus in humans (Fajas et al., 1997;Martin et al., 1998). The action of PPARy is 
mediated by these two isoforms; PPARy2 is predominantly expressed in adipocytes, where 
it has a pivotal role in adipocyte differentiation and lipid accumulation (Tontonoz et al.,
1994).
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Figure 1.3 Function of PPARy. In the absence of a ligand, PPARy has the potential to 
actively silence genes, to which is bound, by recruiting transcriptional corepressor 
complexes. Binding of agonist ligands to PPARy triggers a conformation change that 
results in release of corepressors and attracts transcriptional coactivator complexes, which 
promote gene transcription by altering the chromatin structure. These coactivators or 
corepressors exist in multiprotein complexes including histone-modifying enzymes. 
Acétylation of histone proteins is believed to relieve the tightly packed structure of the 
chromatin, allowing RNA polymerase II complex to bind and initiate transcription. RXR, 
PPRE, BTFs (Basal transcription factors) (adapted from Gurnell, 2005).
Research on the genetics of human obesity is continuing rapidly with the main goal being 
the identification of specific causative genes. According to the human Obesity Map 
(http://obesitygene.pbrc.edu), published each year, the number of candidate genes 
associated with human obesity rapidly increases with 113 candidate genes being reported 
in the 2004 update (Perusse et al., 2005) and 127 in the 2005 update (Rankinen et al..
I
I
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Several mutations and polymorphisms in PPARy have been associated with adiposity 
(Meirhaeghe and Amouyel, 2004). A common structural polymorphism has been detected |  
in the coding region of PPARy2 gene consisting of a proline (Pro) to alanine (Ala) 
substitution (Yen et al., 1997) located at codon 12 (Pro 12Ala). Functional in vitro studies 
have shown that Pro 12Ala polymorphism induces a partial loss of function as a result of 
decreased DNA-binding affinity and reduced transcriptional activity (Deeb et al., 
1998;Masugi et al., 2000). The Pro 12Ala polymorphism has been extensively investigated 
for its association with obesity-related phenotypes in lean, obese and type 2 diabetic 
patients (Meirhaeghe and Amouyel, 2004). Inconsistent reports showed that the Alai 2 
allele is associated with a higher (Beamer et al., 1998;Valve et al., 1999;Meirhaeghe et al.,
2000a) and a lower BMI (Deeb et al., 1998;Ek et al., 1999), whereas other studies found no 
association (Deeb et al., 1998;Mori et al., 1998;Hamann et al., 1999;Swarbrick et al.,
2001). The effects of Pro 12Ala polymorphism on adiposity have also been shown to be 
subject to modification by other genetic or environmental factors. For example, Hsueh et |  
al. (2001) and Ochoa et al. (2004) have reported a synergistic contribution of ADRB3 
Trp64Arg and PPARy Prol2Ala polymorphisms to obesity risk. Furthermore, variation in 
the dietary polyunsaturated-to-saturated-fat ratio was shown to influence BMI of Ala 12 
carriers, supporting the notion of gene-nutrient interactions at PPARy locus (Luan et al.,
2001). A second polymorphism has been detected in exon 6 at nucleotide 1431 of PPARy2 
resulting in a silent substitution from C to T (C143 IT). Once again, conflicting results have 
been reported with the T1431 allele being associated with both higher (Valve et al., 
1999;Doney et al., 2002) and lower BMI (Meirhaeghe et al., 1998;Knoblauch et al., 1999).
'43
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2006). These eandidate genes, however, are not deterministic, since they are not sufficient 
individually to express the obese phenotype, but they only predispose individuals to 
particular traits. The current widely accepted hypothesis is that each susceptibility gene 
only has a modest effect on obesity-related phenotypes, while heterogeneity in complex 
phenotypes could suggest that rare genetie variants may also intervene in the predisposition 
to obesity (Marti et al., 2004). The large number of genes associated with obesity reflects 
the complexity of the disease and provides many additional challenges for scientists in 
identifying genetic variants implicated in the development of obesity. Although the 
candidate-gene approach has yielded intriguing insights into the genetics of human obesity, 
association studies often fail to provide convincing evidence of any involvement of a 
variant in the genetic predisposition to obesity. The reasons for the lack of replication of 
results in different populations are several, the most important being insufficient power to 
detect the modest genetic effects, unconsidered multiple testing effects, genotyping errors 
and publication bias (Clement, 2006). Other factors rendering the interpretation of genetic 
studies problematic include ethnic, gender or age differences that may influence the 
development of obesity (Clement, 2006). Designing the appropriate association studies 
using the correct analytical approach and appreciating the advantages and limitations of 
genetic methods as applied to complex diseases is crucial for defining genes involved in 
the development of obesity.
1.4.4 Hypotheses for the effects of each genotype tested on 
adiposity
1.4.4.1 ACE I/D polymorphism
Upon binding to ATI receptor, angiotensin II has been shown to stimulate the production 
of prostacyclin in vitro. Prostacyclin, a local mediator of increased blood flow, regulates 
adipose tissue differentiation and increases the transcription rate of lipogenic enzymes
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leading to elevating triglyceride content (Jones et al., 1997). As such, individuals with the 
DD genotype (higher ACE activity) and therefore higher plasma or tissue-specific 
angiotensin U will show higher adiposity (Hypothesis 1). Furthermore, ACE inhibitors and 
ATI antagonists has been shown to lead to substantial weight loss and to reduce adipocyte 
size in rats fed with a fructose-rich diet. Nutritional status is known to regulate the 
expression of angiotensinogen with fasting resulting in reduced angiotensinogen levels and 
feeding in almost doubled. These effects are accompanied by effects in blood flow with 
reduced aniotensinogen expression leading to increased blood flow (less vasoconstriction) 
and vice versa. Based on these findings and on those from Cooper et al. (1997) study, 
which has found that angiotensinogen and ACE activity was higher in obese individuals, 
DD individuals would be expected to respond to feeding with higher adiposity compared to 
those homozygotes for the I allele. Finally, it has been demonstrated in vivo that reductions 
in locally produced angiotensin II through ACE inhibition were associated with paiallel 
reductions in adipocyte leptin release and plasma leptin concentration under basal 
conditions (Cassis et al., 2004). However, elevations in systemic angiotensin H leads to 
sympathetic stimulation, which was shown to counterbalance the effects of locally 
produced angiotensin II leading to reduced leptin production (Cassis et al., 2004). Based on 
these findings, elevation in systemic angiotensin II (as expected in DD individuals) can 
increase sympathetic drive to adipose tissue, thereby decreasing leptin synthesis and 
release and resulting in higher adiposity.
1.4.4.2 Beta-adrenergic receptors
ADRBs has been found to promote lipolysis and thermogenesis in adipose tissue and mice 
lacking ADRBs were found to have a thermogenically inactive brown adipose tissue and 
were massively obese when fed with a diet high in fat and sucrose similarly to leptin- 
deficiency mice. SNPs affecting the expression or function of these receptors would thus 
have an effect on lipolysis or thermogenesis. Based on the findings from in vitro studies.
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the ancestral ADRBlG\y49, ADRB2G\yl6, ADRB2G\\i21 alleles will be expected to be 
associated with higher adiposity due to a much faster densesitization in the presence of an 
agonist compared to their corresponding modern alleles, which signal for longer, while the 
ancestral form of ADRB1C3S9 (Arg389 receptor) will be expected to be associated with 
higher adiposity, as it signals at a higher level than its modern counterpart (Gly389) (Small 
et al., 2003) (Hypothesis 2). Individuals with different alleles will respond differently to 
environmental stimuli, such as exercise and feeding (Hypothesis 3). For example, a study 
in monozygotic twins have shown that subjects with the Gln27Gln genotype respond to 
100 days of overfeeding and sedentary lifestyle with an increase in subcutaneous fat, 
whereas no ADRB2 Glyl6Arg genotype-specific responses were observed (Ukkola et al., 
2001). In addition to that, inactivity was associated with higher BMI and waist and hip 
circumferences in Gln27Gln individuals than those bearing the Glu27 allele. In the same 
study, the inactive Gln27 carriers showed increased adiposity compared to active Gln27 
carriers (Meirhaeghe et al., 1999), while in Greek adolescents the Glyl6Gly genotype was 
associated with lai'ger triceps in active compared to inactive subjects possibly due to Glyl6 
homozygotes responding less to the presence of catecholamines.
1.4.4.3 Peroxisome-proHferator activated receptor-Y
As far as PPARy is concerned, it is known that it increases the expression of target genes, 
such as LPL and leads to higher production of fatty acids, which are directed into adipose 
tissue resulting in improved insulin-sensitivity in the muscle and increased triglyceride 
content in adipocytes due to increased fatty acid reesterification. Furthermore, synthetic 
ligands for PPARy, such as TZDs, have been shown to increase appetite possibly due to the 
downregulation of leptin by PPARy and treatment with these drugs has been associated 
with weight gain. A direct involvement of PPARy in satiety or food intake though has yet 
to be confirmed. Although the Alai2 allele being associated with lower DNA binding and 
transcription activity would be expected to being associated with lower adiposity, it has
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been postulated that this reduced activity may enhance the action of insulin leading to 
decreased lipolysis, increased accumulation of triglycerides in adipocytes and weight gain 
in the long term (Hypothesis 4). Furthermore, it has been shown that individuals with 
different Prol2Ala genotypes would respond differently to increased energy intake. For 
example, in a French-Canadian population, although Pro 12 carriers had initially lower 
BMI, waist circumference and subcutaneous fat mass than Alal2 carriers, they respond to 
an increase in dietary fat with a gradual increase in BMI. This effect was not observed 
though in Ala 12 carriers. In addition to that, the Alai2 allele was associated with lower 
BMI when subjects followed a diet enriched with unsaturated fatty acids, while it was 
associated with higher BMI when the ration of unsaturated to saturated fatty acids was 
lower (Luan et al., 2001).
1.5 Aims and objectives
In view of all the above, the main objectives of these experiments were:
a. Assess developmental changes in adiposity in a large cohort of Greek toddlers and
preschoolers by:
i. Estimating the prevalence of overweight and obesity by using specific BMI 
cut-off points based on national reference data and comparing these rates with 
findings from previous published reports.
ii. Examining the evolution of various adiposity-related phenotypes with age and 
assessing differences in these growth curves between the two genders.
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iii. Assessing gender and age-related differences in BMI, weight and height 
between the Greek population and normative data from British children of the 
same age obtained 2 decades ago.
iv. Assessing gender and age-related differences in other adiposity-related 
phenotypes between the Greek and similai'ly aged US children.
b. Assess whether variation within selected candidate genes can affect adiposity at 
different ages in a large cohort of Greek toddlers and preschoolers by:
i. Using a candidate gene approach: Candidate genes were ACE, ADRBl, 
ADRBl, ADRBS and PPARy selected on the basis that they are involved in 
biological pathways crucial for the development of obesity.
ii. Using genotype- and haplotype-based approaches to better assess genetic 
variation effects on specific adiposity-related phenotypes in a large cohort of 
Greek toddles and preschoolers.
iii. Estimating the proportion of phenotypic variance explained by the genetic 
variants for significant genotype-phenotype associations and comparing this 
with the proportion of variance previously reported in adolescent and adult 
populations.
iv. Assessing the influence of genotype on the distribution of phenotypes for 
significant genotype-phenotype associations.
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V. Discussing how significant findings could be explained biologically and 
relatively to the findings from in vitro and other eohort studies.
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Chapter 2
General Methods
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2.1 Subject population
The selected cohort comprised 2374 healthy children aged 1 to 6 years attending public 
and private nurseries, as well as day-care centers in five geographical districts of Greece: 
Athens (n=63), Aitoloakarnania (n=22), Thessaloniki (n=8), Halkidiki (n=12) and Helia 
(n=7). These counties are widely scattered across Greece and account for approximately 
70% of the total Greek population (Manios, 2006). The sampling of the nurseries was 
random, multistage and stratified by the total population of children. The regions that took 
part in the study were classified as “large urban” (population >1,000000), “urban” (10,000- 
100,000), as well as “rural and small towns” (<10,000). The proportion of the total nursery 
population sampled was 55.5% (boys) and 56.8% (girls) in “large urban areas”, 23.1% 
(boys) and 21.8% (girls) in “urban areas” and 21.4% (for both genders) in “rural areas and 
small towns”. The prevalence of highly educated parents was higher in “large urban areas” 
compared to “urban areas” and “rural areas and small towns”. Written informed consent to 
the participation of their children in the present study was obtained from all parents. The 
participation rate varied from 54% to 95%, with the highest rates being observed in rural 
areas and the lowest in urban areas (Manios, 2006). The study was approved by the Ethical 
Committee of Harokopio University of Athens and by all municipalities taking part in the 
study. There was no selection of subjects for inclusion on the basis of any phenotypic 
characteristic including health grounds, and the study is thus an unselected, cross-section 
of the general population in that age range.
2.2 Anthropometry
Subjects from each nursery school underwent a physical examination by two trained 
members of the research group in a classroom provided by the school. The protocols and 
equipment used for all measurements were the same for all regions. The physical 
examination included basic body composition measurements (weight, height, waist, hip
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and mid-upper arm circumferences), as well as measurement of body fat at four sites 
(biceps, triceps, subscapular and suprailiac). Weight was measured to the nearest 10 g 
using a Seca digital scale (Seca Alpha, Model 770, Hamburg, Germany). Subjects were 
weighed in their underwear, without shoes. Recumbent length was measured to the nearest 
0.1 cm in all subjects younger than 2 years without shoes using a portable measuring 
wooden board with a stationary headboard, a vertical moving foot piece and a horizontal 
back piece with a measuring tape on it (manufactured for the purposes of this study). 
Standing height was also measured to the neai'est 0.1 cm in all subjects older than 2 yeai’s 
using a commercial stadiometer (Leicester Height Measure, Invicta Plastics Ltd., Oadby, 
UK). Weight and height were converted to BMI using Quetelet’s Index (weight (kg) / 
height^ (m^)) (Garrow and Webster, 1985). Waist, hip and arm circumferences were 
measured to the nearest 0.1 cm using a non-elastic tape (Hoechstmass, Germany). Waist 
circumference was measured at the end of a gentle expiration after placing the measuring 
tape in a horizontal plane around the trunk, midway between the lower rib margin and the 
iliac crest. Hip circumference was measured at the point yielding the maximum 
circumference over the buttocks. Right arm circumference was measured at the midpoint 
of the upper arm, half the distance between the acromion and the olecranon. Biceps and 
triceps skinfolds were measured with the right arm hanging relaxed, while the skinfold was 
picked up about 1cm below the midpoint mark over the biceps and triceps muscle. 
Subscapular skinfold was measured with the shoulders relaxed. After identifying the 
inferior angle of the scapula, the skinfold was picked 1cm below the subscapular mark. 
Suprailiac skinfold was measured just above the iliac crest, along the axis of the anterior 
line. All skinfolds were measured on the right side of the body to the neai’est 0.1 mm using 
a Lange skinfold caliper (Cambridge Scientific industries, Ine. Cambridge, Maryland, 
USA) and two repeated measurements were taken. Total skinfolds were calculated as the 
sum of the skinfolds at the four sites. The right side of the body was chosen for
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anthropometry, as differences between left and right sides seem not to be biologically 
significant in prepubertal children (Moreno et al., 2002).
2.3 Genotyping, phenotyping and haplotype Inference
2.3.1 DNA extraction
according to the manufacturer’s recommendations and stored in eppendorf tubes
Buccal cell samples were obtained noninvasively by cytology brush (Medical Packaging 
Corporation, Camarillo, CA, USA) from 2102 subjects (1095 boys and 1007 girls)
"’3,
containing cell lysis solution (0.1 M EDTA, 1% SDS, 0.1 M Tris HCl, pH 7.6). Genomic 
DNA was extracted using Nucleospin® Tissue columns for 373 samples and 96-Tissue
' Ipurification kit (ABgene, Epsom, Surrey, UK) for the rest. Prior to mass extraction of 
genomic DNA from all samples, four different extraction methods were tested in 2 control 
samples. These methods were CST Genomic DNA purification kit (Invitrogen, Paisley,
UK), Qiagen Blood DNA extraction kit (Qiagen GmbH, Hilden, Germany), Nucleospin 
Blood and Nucleospin tissue (Macherey-Nagel GmbH & Co. KG, Duren, Germany). The 
choice of the best DNA extraction method was based on the cost, as well as the assessmen. 
of the quality and the quantity of the extracted DNA, which was performed after separation 
of the DNA on 1.5% agarose gel. After purification, extracted DNA was stored in 
individual eppendorf tubes and 96-well Thermofast rigid semi-skirted plates (ABgene, 
Epsom, Surrey, UK) at -20°C.
2.3.2 Genotyping reactions
All PCR reactions were carried out on ice in 96-well Thermofast rigid semi-skirted plates 
(ABgene, Epsom, Surrey, UK) in a final volume of 25 pi (for ACE I/D genotyping), or 20 
pi (for ADRB and PPARy genes) comprised of ReddyMix™ PCR Mastermix containing
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1.5mM MgCl2  (ABGene, Epsom, Surrey, UK), 10 pmol of primers (Sigma-Genosys, 
Haverhill, Cambridgeshire, UK) (MWG-Biotech, Ebersberg, Germany), dH20 and 
genomic DNA (approx. 100 ng). All digestions were also carried out in 96-well 
Thermofast rigid semi-skiited plates (ABgene, Epsom, Surrey, UK). Repeating genotyping 
in a randomly selected sample of 60 subjects assessed the validity of the genotyping for 
each polymorphism. Furthermore, after genotyping, allele frequencies were calculated for 
the total population to assess whether the observed genotypes and inferred diplotypes were 
in HWE (Hardy-Weinberg Equilibrium), using appropriate chi-square tests.
2.3.2.1 ACE gene
Primer design was based on NCBI reference sequence AFl 18569. The ACE I/D 
polymorphism was detected by PCR using a three-primer system; a forward primer 
recognizing the deletion (D) sequence, a forward primer specific for the insertion (I) 
sequence and a common reverse primer (Table 2.1). PCR reactions were performed using 
lOpmol of each of the three primers (Sigma-Genosys, Haverhill, Cambridgeshire, UK), 
dH20 and genomic DNA. Thermocycling consisted of 2.5 min at 94°C followed by 35 
cycles of 94°C for 45 sec, 56.5°C for 45 sec and 12°C for 20 sec and was completed with 
10 minutes at 72°C and kept at 4°C prior to further processing. The amplified alleles were 
analyzed on 2% agarose gel. The presence of the I- and D-allele resulted in 252 bp and 197 
bp products respectively (Figure 2.1). The forward D primer also imperfectly recognised a 
second site only present in the I-allele, which could result in the production of a 485 bp 
band. However, this was non-essential for genotyping and inconsistently produced with 
poorer quality DNA samples.
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Figure 2.1 Genotyping of ACE I/D polymorphism. The figure shows an ethidium bromide 
stained 2% agarose gel of the ACE l/D-PCR amplified product. Lane 1:1Kb plus DNA ladder 
(Promega, Southampton, UK). Lane 2: Individual homozygote for the I allele recognized by 
the presence of the 252 bp band and the absence of the 197 bp band. Lane 3: Individual 
homozygote for the D allele recognized by the presence of the 196 bp band and the absence 
of the 252 bp band. Lane 4: Individual homozygote for the I allele recognized by the 
presence of the 252 bp band and the absence of the 197 bp band. Lane 5: Individual 
heterozygote for the I/D polymorphism. The 485 bp band can also be seen in lanes 2 and 4.
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2.S.2.2 ADRB genes
DNA amplification was carried out for five polymorphisms in ADRBl (Gly49Ser and 
Arg389Gly), ADRB2 (Glyl6Arg and Glu27Gln) and ADRB3 (Trp64Arg) genes. Primer 
design was based on NCBI reference sequences NM__000684 (for ADRB/), ACOl 1354 (for 
ADRB2) and X72861.1 (for ADRB3) (Table 2.2 and Table 2.3). Regions containing the 
ADRBl, ADRB2 and ADRB3 polymorphisms were amplified by PCR and genotypes were 
determined by RFLP analysis. For ADRBl Gly49Ser polymorphism amplification, the 
primers contained non-specific T-tails to facilitate their use in a multiplex reaction with the 
ADRB3 Arg64Trp primers; however, due to poor DNA amplification by using this 
multiplex PCR, Gly49Ser and Arg64Trp polymorphisms were finally amplified separately. 
Thermocycling consisted of 5 min at 94°C followed by 35 cycles at 94°C, 60°C and 72°C 
each for 30 sec and was completed with 10 min at 72°C. For RFLP analysis, PCR products 
(5 pi) were then digested with Eco0109l RE (New England Biolabs UK Ltd., Hitchin, 
Hertfordshire, UK) overnight at 37°C in a final volume of 10 pi and separated on 2.5% 
agarose gel (Table 2.2). The Gly49 allele (G-allele) contained a unique restriction site for 
Eco01091 yielding two bands of 119bp and 117bp, whilst the Ser49 allele (A-allele) 
yielded a 236 bp band (Table 2.2, Figure 2.2a).
A 171 bp region, containing both the ADRB2 Glyl6Arg and Glu27Gln polymorphic loci 
was amplified using one set of primers (25 pmol each) (Sigma-Genosys, Haverhill, 
Cambridgeshire, UK) (Table 2.2 and Table 2.3). Thermocycling conditions were 5 min at 
94‘^ C followed by 35 cycles at 94°C, 56.5°C and 72°C each for 30 sec and was completed 
with 10 min at 72°C. The forward primer for the ADRB2 gene polymorphisms 
(Bar2CM26NcoF2) contained a mismatched base that created a Ncol site in conjunction 
only with the Glyl6 allele (Table 2.2).
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Table 2.3 Length and properties of primers used for genotyping of ADRBl, ADRB2 and 
ADRB3 polymorphisms. Melting temperature (Tm), probable secondary structures and GC 
content for each primer were determined by the Sigma-Genosys calculator. Bar1CM33F and 
Bar1CM250R primers contained non-specific T-tails to facilitate their use in multiplex PCR 
with the ADRB3 Arg64Trp primers. However, these multiplexed reactions were not carried 
out here. The non-specific tails were not included in the calculation of Tm for these primers. 
None of the primers form dimmers.
SNP Name of primer Length Tm Secondarystructures
% GC 
content
AD RBl
Gly49Ser
BarlCM33F 23 73.3 Weak 56.5
BarlCM250R 33 77.2 Weak 36.4
AD RBl
Arg389Gly
BaiTCM1030F 19 66.3 Very weak 57.9
ADRB2
BaiTCM1302R 19 68.8 None 63.2
Glyl6Arg Bar2CM26NcoF2 20 70.5 Weak 60.0
ADRB2
GIu27Gln
Bar2CM196R 20 66.8 None 55.00
ADRB3
Bai3CM62F 19 70.5 None 63.2
Arg64Trp Bar3CM271R 20 69.1 None 65.0
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Figure 2.2 (a) Genotyping of rs1801252 {ADRBl C49) polymorphism. The figure shows an 
ethidium bromide stained 2.5% agarose gel of EcoOIOSt digested fragments of the ADRBl 
C49-PCR amplified product. Lane 1: 100 bp DNA ladder (Promega, Southampton, UK). Lane 
2-5: Bands produced by homozygotes for the Ser49-allele (236 bp band). Lane 6: Bands 
produced by a heterozygote (Giy49Ser) individual. Lane 7: Bands produced by an individur* 
homozygote for the Ser49-allele (236 bp band). Lane 8: Bands produced by an individual 
homozygote for the Gly49-allele (119/117 bp doublet).
(b) Genotyping of rs1801253 {ADRBl C389) and rs4994 {ADRB3 C64) polymorphisms. The 
figure shows an ethidium bromide stained 3.5% agarose gel of BstNI digested fragments of 
the ADRBl C3S9/ADRB3 C64-PCR amplified product. Lane 1: 100 bp DNA ladder (Promega, 
Southampton, UK). Lane 2: Bands produced by an individual homozygote for the Arg389- 
allele (273 bp band) and heterozygote for the Arg64Trp (158 bp and 100 bp bands). Lane 3: 
Bands produced by an individual homozygous for the Gly389-allele (140 bp band) and for 
the Trp64-allele (100 bp band). Lane 4: Bands produced by an individual heterozygous for 
both Arg389Gly and Arg64Trp polymorphisms. Lane 5: Bands produced by an individual 
homozygote for Gly389-allele and Trp64-allele. Lane 6: Bands produced by an individual 
heterozygote for the Arg389Gly polymorphism and homozygote for the Trp64-allele. Lane 7: 
Bands produced by an individual homozygote for Arg389-allele and Trp64-allele.
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The amplified 171 bp PCR product was then used for two separate digestions. For 
Glyl6Arg RFLP analysis, 5 pi of PCR product was digested with Ncol RE (New England 
Biolabs UK Ltd., Hitchin, Hertfordshire, UK) overnight at 37°C in a final volume of 10 pi 
and separated on 3.5% agarose gel. The Glyl6 allele (G-allele) yielded two bands of 154 
bp and 17 bp, whilst the Ai’gl6 allele (A-alelle) remained uncut (Figure 2.3a). For 
Glu27Gln polymorphism, 5 pi of PCR product was digested with Bhvl RE (New England 
Biolabs UK Ltd., Hitchin, Hertfordshire, UK) overnight at 37°C in a final volume of 10 pi 
and separated on 2.0% agai'ose gel. The Gln27 allele (C-allele) contained a restriction site 
for Bbvl yielding two products of 109 bp and 62 bp, whilst the Glu27 (G-allele) allele 
remained uncut (Figure 2.3b).
A multiplexed PCR and digestion was carried out for the ADRBl Ai'g389Gly and ADRB3 
Ai'g64Trp polymorphisms. Thermocycling consisted of 5 min at 94°C followed by 35 
cycles at 94°C, 60^C and 72°C each for 30 sec and was completed with 10 min at 72°C. 
BaiTCM1030F and BarlCM1302R amplified a fragment of 273 bp, whilst Bar3CM62F 
and Bar3CM271R a product of 210 bp. A double digestion with B.y/NI RE (New England 
Biolabs UK Ltd., Hitchin, Hertfordshire, ÜK) was carried out at 60°C overnight in a total 
volume of 20 pi (5 pi from each PCR product) (Table 2.2). The Gly389 allele (G-allele) 
contained a unique site for BstNI giving two fragments of 140 bp and 133 bp, whilst the 
Arg389 allele (C-allele) remained uncut (Figure 2.2b). The Trp64 allele (T-allele) 
contained four BstNI sites producing bands of 97, 61, 31, 15 and 6 bp, whilst the Ai’g64 
allele (C-allele) contained three BstNI sites producing bands of 158, 31, 15 and 6 bp 
(Figure 2.2b). Digested products were separated on 3.5% agarose gel. Due to poor 
amplification of Arg64Trp polymorphism for most of the samples, PCR for the ADRB3 
gene was repeated with each reaction containing only the primers specific for the ADRB3 
Arg64Trp region.
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171 bp 
154 bp 171 bp 
109 bp 
62 bp
Figure 2.3 (a) Genotyping of rs1042713 {ADRB2 C l6) polymorphism. The figure shows an 
ethidium bromide stained 3.5% agarose gel of A/col digested fragments of the ADRB2-PCR 
amplified product. Lane 1:1Kb plus DNA ladder (Promega, Southampton, UK). Lanes 2 and 
3: Bands produced by heterozygotes (Gly16Arg) individuals. Lane 4: Band produced by an 
individual homozygote for the Glyl 6-allele (154 bp bands). Lane 5: Band produced by an 
individual homozygote for the Argi 6-allele (171 bp).
(b) Genotyping of rsl 042714 {ADRB2 C27) polymorphism. The figure shows an ethidium 
bromide stained 2.0% agarose gel of Bbvl digested fragments of the ADRB2-PCR amplified 
product. Lane 1: 100 bp DNA ladder (Promega, Southampton, UK). Lanes 2 and 3: Bands 
produced by individuals homozygotes for the Gln27-allele (109 bp and 62 bp). Lane 4: Band 
produced by an individual homozygote for the Glu27-allele (171 bp). Lane 5: Bands 
produced by an individual homozygote for the Gln27-allele (109 bp and 62 bp). Lane 6: 
Bands produced by a heterozygote (Glu27Gln) individual.
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2 3.2.3 PPARy gene
DNA amplification was carried out for both PPARy polymorphisms, Prol2Ala and 
C1431T. Primer design was based on NCBI reference sequence NM_015869.3 (Table 2.4). 
Genotypes for all three polymorphisms were determined by PCR amplification and RFLP 
analysis. PCR reactions were carried out using 10 pmol/pl of each primer (MWG-Biotech, 
Ebersberg, Germany), For Pro 12Ala polymorphism, thermocycling conditions consisted of 
5 min at 94°C followed by 35 cycles at 94°C for 45 sec, 58°C and 72°C each for 30 sec 
and was completed with 10 min at 72°C. The reverse primer used for Pro 12Ala 
amplification, contained a mismatched base that created a Bsll restriction site in 
conjunction only with the Pro 12 allele (Table 2.4). For RFLP analysis of this 
polymorphism, PCR products (5 pi) were digested with 4 Units of BsB RE (New England 
Biolabs UK Ltd., Hitchin, Hertfordshire, UK) overnight at 55°C. The digested fragments 
were resolved on a 3.5% agarose gel. The Pro 12 allele (C-allele) contained a unique 
restriction site for Bsll yielding two products of 168 bp and 17 bp, while the Alal2 allele 
(G-allele) yielded an uncut 185 bp fragment (Figure 2.4a). For C1431T polymorphism, 
thermocycling conditions consisted of 5 min at 94°C followed by 35 cycles at 94°C for 30 
sec, 57°C and 12°C each for 30 sec and was completed with 10 min at 72°C. For RFLP 
analysis, each PCR product (5 pi) was digested with 12 Units of Pmll RE (New England 
Biolabs UK Ltd., Hitchin, Hertfordshire, UK), lOx Nebuffer and 1% BSA in total volume 
of 10 pi at 3TC  overnight to obtain optimal digestion. The digested fragments were 
separated on 3.0% agarose gel. The C-allele contained a unique restriction site for Pml I 
producing two fragments of 146 bp and 57 bp, while the T-allele yielded an uncut 203 bp 
fragment (Figure 2.4b). Due to partial digestion of some samples with Pmll RE, 3 U of 
NlalR RE were used instead when required. The T-allele contained a unique site for NlaXH 
yielding two products of 147 bp and 56 bp, while the C-allele remained uncut (203 bp).
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1 2 3 4 5 6 7 8 9 10111213
185 bp 168 bp 203b146b
57bD
Figure 2.4 (a) Genotyping of rsl 801282 (Pro12Ala) polymorphism. The figure shows an 
ethidium bromide stained 3.5% agarose gel of BsH digested fragments of the Pro12Ala-PCR 
amplified product. Lane 1: 100 bp DNA ladder (Promega, Southampton, UK). Lane 2-7, 9,11,  
12: Bands produced by individuals homozygotes for the Prol 2-allele (168 bp and 17 bp 
bands). Lane 8, 10: Bands produced by an individual heterozygote for the Prol 2Ala allele. 
Lane 13: Bands produced by an individual homozygote for the Alai 2-allele (185 bp band).
(b) Genotyping of rs3856806 (C1431T) polymorphism. The figure shows an ethidium 
bromide stained 3% agarose gel of PmH digested fragments of the C1431T-PCR amplified 
product. Lane 1: 100 bp DNA ladder (Promega, Southampton, UK). Lane 2, 4-7, 9, 12: Bands 
produced by individuals homozygotes for the C-allele (146 bp and 57 bp). Lane 3: Individual 
that the genotyping did not succeed. Lane 8, 10-11: Bands produced by heterozygotes 
individuals. Lane 13: Bands produced by an individual homozygote for the T-allele (203 bp).
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2.4 Statistical analysis
Prior to any analysis, anthropometric data for all subjects were scrutinized for outliers, 
using descriptive statistics and normal probability plots. Outliers, as well as individuals 
with any missing phenotypic data, were identified and excluded from the dataset.
Allele frequencies were calculated for all polymorphisms and chi-square tests (%^) were 
performed to assess whether the observed genotype frequencies were in HWE. Haplotypes 
frequencies were calculated by using Arlequin software (Arlequin 3.01, 2006, CMPG, 
Switzerland). The basie D (Pairwise-disequilibrium coefficient) (defined as the difference 
between the probability of observing two marker alleles on the same haplotype and 
observing them independently), as well as the normalized estimate of LD, D’ (Normalised 
estimate of linkage disequilibrium) (defined as D/Dmax), between the two sites were 
calculated (Zondervan and Cardon, 2004).
GLM (General Linear Model) analysis on the total population was carried out to assess 
whether the genetic effects on the total population were influenced by gender and/or age. 
GLM modelling allows predictor variables to be assessed as factors explaining dependent 
distributions simultaneously. In the present analysis, gender and age were assessed as 
possible confounding factors in the analysis. Initially, the models considered in the current 
analysis were the individual effects of gender, age and genotype, the three two-way 
interactions (gender * age, gender * genotype and age * genotype) and the three-way 
interaction (gender * age genotype). However, due to the fact that models should have as 
few parameters as possible and should have simple types of relationship (the simplest may 
be a power relationship), models were paied down to the minimal adequate model, in 
which most terms were significant. Although all the phenotypes of interest in the present 
study are potentially related, as they are all descriptive of adiposity, different models best
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explained the phenotypes, while unnecessary variables were removed (model 
simplification). If an interaction was found to be significant, then the main effects would 
be considered as being important, regardless of the level of significance of each variable, 
since the interaction includes the main effects of each variable. If significant interactions 
were found between genotype and/or gender, ANOVA (One-way Analysis Of Variance) 
analysis stratisfied by age and/or gender would be carried out. Apart from GLM analysis 
on the total population, an alternative approach involving gender and age subgrouping was 
also employed. This was based on the fact that previous studies, albeit in adolescents and 
adults, have indicated the presence of gender-specific effects of ACE 1/D (ODonnell et al., 
1998), ADRB (Meirhaeghe et al., 2000b;Gonzalez Sanchez et al., 2003) and PPARy 
(Beamer et al., 1998;Valve et al., 1999) gene polymorphisms on phenotype. Subjects from 
each gender were also assigned to single-year age groups; 13-24 months (1-2 years), 25-36 
months (2-3 yeai’s), 37-48 months (3-4 years) and 49-71 months (4-6 years) to account for 
mai'ked changes in body composition during the first decade of life (Fomon et al., 1982) 
and to control for secular trends in adiposity (Manios, 2006). To maintain adequate 
numbers of subjects for analysis within each age group, 4 to 5 years old and 5 to 6 years 
old were grouped together prior to any statistical analysis (Table 2,5). Isolated significant 
findings from this age and gender subgrouping analysis were compared to those from the 
main GLM analysis. Reflection of these isolated significant findings in the main analysis 
could confirm that the isolated findings are not Type I errors.
Phenotypic distributions for the total population or each gender or age gi'oup were tested 
separately for normality using the Ryan-Joiner test and datasets with non-normal 
distributions were transformed by Box-Cox transformation (Table 2.6). Mean values and 
95% Cl (Confidence Interval) for each phenotype were subsequently back-transformed for 
presentational purposes. The influence of the ACE (1/D), ADRB {ADRBl C49 and C389,
44
ADRB2 C16 and C27, ADRB3 C64) and Par (Prol2Ala and C143 IT) genotypes on 
adiposity-related variables was evaluated by one-way analysis of variance (ANOVA) using 
MINITAB 13.30 (Minitab Ltd., Coventry, UK). For PPARy gene, because of the small 
number of individuals homozygous for the less common allele (i.e. Ala 12 and T1431) at 
each locus, these were collapsed with the heterozygous and compared with the 
homozygous for the common alleles for all further analyses. Multiple testing was 
controlled by the use of adjusted P values for significance (the a value) within each gender 
and age group using the Dunn-Sidak method with correction for repeated tests and 
correlations between datasets as implemented on the SISA website (SISA website 
http://home.clara.net/sisa/bonferroni.html). For each age group, the mean correlation (r) 
between the adiposity-related phenotypes evaluated in these analyses was calculated as the 
squai’e root of the mean of the squared partial correlations (coefficients of determination) 
between the assessed phenotypes.
Singificant associations were further assessed by correlation analyses to evaluate possible 
genetic models underlying the association (Moran et al., 2005). The proportion of 
phenotypic vaiiance explained by the ANOVA (rA), which is model-free, was compared to 
the proportion of variance explained under each model by correlation analysis (I'c^ ) 
(MINITAB 13.30, Minitab Ltd., Coventry, UK). The ratio of these proportions {vcEfd 
gives the proportion of the genetic variance at the tested locus explained under a specified 
model. For ACE I/D polymorphism, models tested were the allelic additive model and the 
two fully dominant models. Genotypes were expressed as dummy variables in the 
correlation analysis (0, 1 ,2  for the additive model and 0, 0, 1 or 0, 1, 1 for the dominant 
genetic models depending on which allele was being tested for dominance). The additive 
model is the easiest to explain mechanistically, with the mean of the heterozygotes being 
exactly intermediate to the means of the two homozygotes groups. A dominant model
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explains the data best when the heterozygote mean is close to one of the homozygote 
means. For ADRB polymorphisms, genotypes were also expressed as dummy variables in 
the correlation analysis (0, 1, 2 for the additive model and 0, 0, 1 or 0, 1, 1 for the 
dominant and recessive genetic models). The Gly49, Arg389 (ADRBl), Glyl6, Glu27 
(ADRB2) and Arg64 (ADRB3) alleles were identified as the ancestor variants, after 
comparison of human with other Great Ape sequences (NCBI database; 
http://www.ncbi.nih.gov/). A dominant model explains the data best when the heterozygote 
mean is close to the homozygote for the ancestor allele mean, while a recessive model 
explains the data best when the heterozygote mean is close to the homozygote for the 
modern allele (Ser49, Gly389 for ADRBl, Argl6, Gln27 for ADRB2md Trp64 for ADRB3) 
mean. No genetic models were tested for any of the PPARy polymorphisms, since no 
homozygotes for the rare alleles were identified in some age groups. Odds ratios were 
calculated after dividing the population into 3 groups based on low (0-25%), pooled- 
middle (25-75%) and high (75-100%) quartiles to assess whether the influence of genotype 
on phenotype took place over the whole phenotype range or only at one extreme. Odds 
ratios were calculated as the likelihood of a given genotype being present in a particular 
quartile compared to its likelihood of being in the remaining quartiles. Significant 
associations were assessed by using 2x2 chi-square tests and 95% CIs.
For haplotype-based analysis in PPARy gene, individuals with the Pro-C/Pro-T diplotype 
were combined with those homozygotes (Pro-T/Pro-T) for the Pro-T haplotype, as 
previously suggested (Doney et al., 2002). Furthermore, heterozygotes (Pro-C/Ala-C) and 
homozygotes (Ala-C/Ala-C) for the Ala-C haplotype were also collapsed into a single 
group, whereas double heterozygotes (Pro-C/Ala-T) were combined with heterozygotes 
(Pro-T/Ala-T, Ala-C/Ala-T) and homozygotes (Ala-T/Ala-T) for the Ala-T haplotype 
(Doney et al. 2002). Differences in the phenotypic means by these four diplotype groups
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were assessed by one-way ANOVA using MINITAB 13.30 (Minitab Ltd., Coventry, UK) 
for each age group and gender. Significant associations (P<0.05) were further analyzed by 
performing two-tailed pairwise /-tests, which allowed comparison of Pro-T, Ala-C and 
Ala-T haplotypes with the common Pro-C haplotype.
To evaluate the improvement in the associations with the phenotypes produced by 
assessing diplotypes rather than ADRBl (C49, C389), ADRB2 (C l6, C27) or PPARy 
(Pro 12Ala, C1431T) genotypes, the sum of squares from the individual genotype ANOVA 
was subtracted from the sum of squares from the diplotype ANOVA (as were the degrees 
of freedom) and new F and P values were calculated.
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Table 2.5 Number of boys and girls in each age group. To maintain adequate number of 
subjects for analysis, subjects from 49-60 months and 61-71 months age groups were 
assigned into a single group.
Prior to Grouping After Grouping
Age (months) Boys Girls Boys Girls
13-24 91 90 91 90
25-36 249 202 249 202
37-48 437 384 437 384
49-60 285 298
318 331
61-71 33 33
Total 1095 1007
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Chapter 3
Growth and adiposity in Greek chiidren
50
3.1 Introduction
The prevalence of overweight and obesity has remarkably increased in childhood and 
adolescence over the past three decades (Dehghan et al., 2005). Around 22 million children 
under the age of five are obese worldwide (Miller et al., 2004), while a high prevalence of 
overweight and obesity has been reported in Greek children (Magkos et al., 2005) and 
adolescents (Mamalakis et al., 2000;Krassas et al., 2001). Increased adiposity in childhood 
is predictive for obesity in adulthood (Whitaker et al., 1997;Magarey et al., 2003) and 
accounts for other morbidities in young children, such as dyslipidemia, hypertension, 
insulin resistance, orthopaedic difficulties (Dietz, 1998). Published studies reported 
prevalence of overweight and obesity that vary between most European countries. 
However, it is not clear whether these discrepancies in the findings are due to differences 
in measurements or they represent true results. Furthermore, although a considerable 
number of reports have assessed the rates of overweight and obesity in school-aged 
children, adolescents and adults, there is lack of information regarding the corresponding 
prevalence in very young children.
The aim of this study was to assess the prevalence of overweight and obesity in a lai’ge 
representative population of toddlers and preschoolers from Greece by using specific BMI 
cut-off points based on national reference data and by comparing the rates of overweight 
and obesity in the Greek children with the findings of other published reports. Moreover, 
the evolution of various physiological- and adiposity-related indices with age and 
according to gender in the present cohort of Greek children was described. The final aim of 
this study was to compare specific physiological-related phenotypes from the current 
Greek population with normative data from British and US children.
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3.2 Methods
3.2.1 Subjects and measurements
The number of subjects that took pait in the study, as well as information on the assessed 
adiposity-related phenotypes and the protocols used for anthropometry, are given in 
Chapter 2 (General Methods). British normative data was obtained from the British 1990 
growth reference published by the Child Growth Foundation (2 Mayfield Avenue, London 
W4 IPW). The British growth reference provides anthropometric data (BMI, weight, 
length or height and head circumference) from 17 distinct surveys representative of 
England, Scotland and Wales and includes 37,700 children aged 0 (23 weeks of gestation) 
to 23 years (Cole et al., 1995).
3.2.2 Data analysis
Although BMI cut-off points are well established in adult populations (25 kg/m^ for 
overweight and 30 kg/m^ for obesity), defining childhood overweight and obesity in 
childhood is a more difficult task, since BMI changes substantially with age and there aie 
no internationally accepted definitions. A variety of reference-data sets for BMI in 
childhood exist, such as the British 1990 Growth reference (Child Growth Foundation, 
Chiswick, UK) (Cole et al., 1995), the US CDC 2000 chaits (Kuczmai’ski et ah, 2000) and 
the international BMI reference data by the lOTF (Cole et al., 2000). In the current study, 
the centile-based cut-off points adopted currently by Child Growth Foundation were used 
to analyse prevalence and obesity in the Greek population. Due to significant differences in 
the rates of overweight and obesity between the present population (based on the UK 1990 
reference data) and those reported by Manios, 2006 in a larger subset of the GENESIS 
cohort (based on CDC 2000 percentiles), the CDC 2000 growth charts were also used to
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determine the prevalence of overweight and obesity in the present population. The Nutstat 
module of Epilnfo was used to determine the age- and sex-specific Z-scores for weight, 
height and BMI, according to the CDC 2000 growth chaits. The UK1990 and CDC 2000 
BMI-for-age growth charts were used for classifying the children as overweight (UK1990) 
or at risk of overweight (CDC 2000) (85^^-95‘*' percentile) and as obese (UK1990) or 
ovei*weight (CDC 2000) (>95* percentile). lOFT (hiternational Obesity Task Force) 
definitions of obesity were not preferred in the current study, since they have low 
sensitivity, they are highly sex-specific in comparison to national definitions and they 
don’t extend to children under the age of 2 years (Chinn, 2006;Reilly, 2006).
In the Greek population, mean and standard deviations for all anthropometric were 
estimated for each gender and age group. A randomisation test available by SMART 
(Statistics and Mathematics as Advanced Research Tools) website 
(www.bioss.ac.uk/smart) was used to assess the statistical significance of differences 
between the means of each phenotype in boys and girls; statistical significance was 
accepted at p<0.05. The phenotypic data was not transformed to achieve normality prior to 
the randomisation test, since this test makes no distribution assumptions about the data 
like, for example, r-tests. The descriptive statistics for all anthropometric parameters within 
age group and gender are shown in Table 3.2. The 75*, 50* and 25* percentiles for all 
anthropometric measurements for each gender are shown in Figure 3.1. Growth curves 
were constructed by using MINITAB statistical software (MINITAB 13.30, MINITAB 
Ltd., Coventry, UK).
By using a linked software program provided by the Child Growth Foundation, BMI, 
weight and height were converted into age- and gender-specific standard deviation scores 
(SDS, Z-scores) of their distribution in the British 1990 reference data (Table 3.3 and 3.4). 
Significant differences between the values of each measurement and the reference
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population were assessed by an independent two-tailed Ltest taking into account the fact 
that for the UK 1990 population each SDS has a normal distribution mean of 0.0 and a 
standard deviation of 1.0.
Reference data for specific body composition indices are not available for Greek children. 
Age- and sex-specific data have been compiled for specific anthropometric indices other 
than BMI in the United States and United Kingdom. In the present study, anthropometric 
measurements, such as mid-upper-arm and waist circumferences, as well as triceps and 
subscapular skinfolds, from the Greek children were compared with reference data derived 
from the NHANES III (1988-1994) (Flegal et ah, 2001) by using the Welch's approximate 
Ltest for unequal variances. NHANES III is a stratified, multistage probability design of 
the noninstitutionalised US population aged >2 months conducted by the CDC National 
Centre for Health Statistics (HCHS) (Flegal et al., 2001). Data from this survey, along with 
others, have been used for the development of the US CDC 2000 growth charts 
(Kuczmarski et ah, 2000).
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Table 3.1 Prevalence of overweight and obesity in Greek toddlers and preschoolers based 
on the UK 1990 and CDC 2000 growth reference percentiles.
N
Overweight
(%)UK 1990
At risk of 
overweight
(%) CDC 2000
Obese
(%) UK 1990
Overweight
(%) 
CDC 200Ô
Boys
1-2 years 91 7.7% - 5.5% 12.2%
2-3 years 249 10.8% 10.4% 4.0% 6.4%
3-4 years 437 11.2% 12.1% 8.5% 10.1%
4-5 years 318 12.6% 14.1% 11.9% 12.3%
Girls
1-2 years 90 7.8% - 10% 9%
2-3 years 202 12.4% 13.4% 5.9% 5.4%
3-4 yeai’s 384 10.9% 15.1% 9.6% 10.9%
4-5 years 331 10.3% 16.6% 13.6% 13.9%
Overweight (UK1990) or at risk of overweight (CDC 2000) were defined as a BMI SDS >1.04, 
equivalent to the percentile, while obesity (UK 1990) or overweight (CDC 2000) were defined 
as a BMI SDS > 1.64, equivalent to the 95**^  percentile. N= the total number of subjects in each age 
group. Children up to 24 months were classified as overweight (^95’’^ percentile) using the CDC 
weight-for-length growth charts.
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Table 3.2 Descriptive statistics of anthropometric measurements in each age group for boys 
and girls.
12-24 months Age group Boys Girls P Value 1
Mean age (months) 19.9 19.2
BMI (kgrW ) 16.90 ± 1.52 16.87 ±1.53 0.894
Weight (kgr) 12.56 ± 1.46 11.78 ±1.70 0.001
Height (m) 0.86 ± 0.05 0.83 ± 0.05 <0.001
Arm circumference (cm) 15.47 ± 1.09 15.32 ± 1.28 0.400
Waist circumference (cm) 46.72 ± 2.88 46.34 ±3.36 0.420
Hip circumference (cm) 49.19 ±3.09 49.12 ±4.03 0.895
Biceps skinfold (mm) 5.72 ±1.67 5.39 ± 1.62 0.172
Triceps skinfold (mm) 8.90 ± 2.49 8.80 ± 2.4 0.797
Subscapulai’ skinfold (mm) 6.54 ± 1.67 6.53 ±1.61 0.964
Suprailiac skinfold (mm) 5.24 ±1.64 5.21 ± 1.95 0.929
25-36 months Age group Boys Girls P Value
Mean age (months) 31.7 31.6
BMI(kgr/m^) 16.40 ± 1.37 16.29 ± 1.5 0.403
Weight (kgr) 15.19 ±1.81 14.76 ± 1.98 0.015
Height (m) 0.96 ± 0.04 0.95 ± 0.04 0.009
Arm circumference (cm) 16.11 ±1.19 16.13 ± 1.38 0.859
Waist circumference (cm) 49.61 ± 3.04 49.6 ± 3.54 0.888
Hip circumference (cm) 52.86 ± 3.3 53.17 ±3.69 0.337
Biceps skinfold (mm) 5.79 ± 1.76 5.92 ± 1.87 0.462
Triceps skinfold (nun) 9.43 ± 2.32 9.90 ± 2.76 0.049
Subscapular skinfold (mm) 6.4 ± 1.82 6.98 ± 2.33 0.002
Suprailiac skinfold (mm) 5.35 ± 2.0 5.68 ± 2.26 0.101
37-48 months Age group Boys Girls P Value
Mean age (months) 42.6 42.5
BMI (kgr/m" )^ 16.16 ± 1.61 16.19 ± 1.64 0.806
Weight (kgr) 17.29 ± 2.29 17.1 ±2.55 0.177
Height (m) 1.03 ± 0.04 1.02 ±0.05 0.006
Arm circumference (cm) 16.5 ± 1.45 16.55 ± 1.43 0.580
Waist circumference (cm) 51.6 ±3.84 51.7 ±4.25 0.816
Hip circumference (cm) 55.3 ±4.06 56.1 ±4.4 0.007
Biceps skinfold (mm) 5.55 ±1.97 6.01 ± 2.0 0.001
Triceps skinfold (mm) 9.2 ± 2.7 9.9 ±2.8 <0.001
Subscapular skinfold (mm) 6.3 ± 2.0 7.2 ±2.3 <0.001
Suprailiac skinfold (mm) 5.2 ± 2.6 6.1 ± 2.7 <0.001
49-71 months Age group Boys Girls P Value
Mean age (months) 54.5 54.3
BMI (kgr/m" )^ 16.11 ± 1.7 16.16 ± 1.74 0.741
Weight (kgr) 19.80 ± 2.93 19.38 ±3.0 0.072
Height (m) 1.11 ±0.05 1.09 ±0.05 0.001
Arm circumference (cm) 16.95 ± 1.51 17.18 ±1.65 0.061
Waist circumference (cm) 53.38 ±4.26 53.69 ± 4.5 0.376
Hip circumference (cm) 58.1 ±4.9 59.05 ± 4.9 0.010
Biceps skinfold (mm) 5.28 ±1.86 6.4 ± 2.2 <0.001
Triceps skinfold (mm) 9.00 ± 2.5 10.6 ±2.9 <0.001
Subscapular skinfold (mm) 6.00 ±1.9 7.13 ±2.6 <0.001
Suprailiac skinfold (mm) 4.7 ± 2.2 6.11 ±3.4 <0.001
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3.3 Results
3.3.1 Prevalence and overweight of obesity
The prevalence of overweight and obesity in the present population showed an increasing 
tendency with age for both genders (from 5.5% to 11.9% in boys and from 10% to 13.6% 
in girls for obesity) (Table 3.1). The same tendency was observed when determining these 
rates based on the CDC 2000 growth charts (from 6.4% to 12.3% in boys and from 5.4% to 
13.9% in girls for overweight). Although, there were no significant differences in BMI 
between boys and girls for any of the age gi*oups (Table 3.2), obesity was more prevalent 
in girls than in boys in all age groups (for example, 13.6% of girls were obese at the age of 
4-5 years compared to 11.9% of boys). A summary of the results for the prevalence of 
overweight and obesity based on both UK1990 and CDC 2000 reference data is given in 
Table 3.1.
3.3.2 Greek versus British growth reference data
The mean SDS and SD for weight and height from the Greek population were found to be 
significantly different from the reference population for age groups 2-3, 3-4 and 4-6 years 
and both genders (Table 3.3 and 3.4). In particular, Greek children of both genders were 
found to be heavier and taller than the British counterparts (Table 3.3 and 3.4). These 
differences were more prominent with increasing age in both genders. Although heavier 
and taller for all age groups, the Greek children differ significantly in SDS for BMI from 
the British ones only at 4-6 year's of age. A summary of the mean SDS values and SD for 
BMI, weight and height and a graphical presentation of the differences between these 
values and the reference population for both genders are given in Tables 3.3, 3.4 and 
Figure 3.2 respectively.
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Table 3.3 Mean SDS, 95% CIs, and SD for Greek boys produced from the 1990 British 
Growth Reference Charts.
Measurement Age Group Mean SDS 95% Cl SD P value
1-2 years -0.15 (-0.38 to 0.08) 1.12 0.205
BMI 2-3 years -0.004 (-0.14 to 0.13) 1.06 0.9533-4 years 0.07 (-0.04 to 0.18) 1.20 0.223
4-5 years 0.23 (0.10 to 0.36) 1.21 0.001
1-2 years 0.56 (0.37 to 0.75) 0.91 <0.001
2-3 years 0.73 (0.61 to 0.85) 0.95 <0.001
T T 3-4 years 0.71 (0.61 to 0.81) 1.05 <0.001
4-5 years 0.83 (0.71 to 0.95) 1.06 <0.001
1-2 years 1.03 (0.72 to 1.34) 1.51 <0.001
2-3 years 1.09 (0.96 to 1.22) 1.01 <0.001
3-4 years 0.99 (0.89 to 1.09) 1.04 <0.001
4-5 years 1.02 (0.91 to 1.13) 0.99 <0.001
Table 3.4 Mean SDS, 95% CIs, and SD for Greek girls produced from the 1990 British Growth 
Reference Charts.
Measurement Age Group Mean SDS 95% Cl SD P value
1-2 years 0.05 (-0.18 to 0.28) 1.13 0.676
BMI 2-3 years 0.10 (-0.05 to 0.25) 1.09 0.1943-4 yeai's 0.20 (0.09 to 0.31) 1.10 <0.001
4-5 yeai's 0.27 (0.15 to 0.39) 1.11 <0.001
1-2 years 0.52 (0.31 to 0.73) 1.00 <0.001
2-3 years 0.76 (0.61 to 0.91) 1.09 <0.001T T  C l g i l L 3-4 years 0.78 (0.67 to 0.89) 1.07 <0.001
4-5 years 0.74 (0.63 to 0.85) 1.03 <0.001
1-2 years 0.70 (0.44 to 0.96) 1.26 <0.001
2-3 years 1.04 (0.88 to 1.20) 1.14 <0.001
3-4 years 1.06 (0.95 to 1.17) 1.09 <0.001
4-5 years 0.94 (0.82 to 1.06) 1.10 <0.001
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3.3.2 Greek versus US reference data
Comparison of anthropometric indices, such as arm and waist circumferences, as well as 
triceps and subscapular skinfolds between the present population and reference data from 
US children (NHANES m ) revealed similar patterns of development for both populations 
(Figure 3.3). In both Greek and US boys (2-6 years), the waist and arm circumference 
increase with age. Greek boys showed significantly higher waist circumference 
measurements compaied to their US counterparts at all ages; for example the mean waist 
circumference for Greek boys (3-4 yeai's) was 52.95 cm versus 51.4 cm in the US boys 
(P<0.001) (Figure 3.3). In contrast, US boys had significantly higher arm circumference 
compared to Greeks at ages 1-5 years (Figure 3.3). Although significant differences 
between the present cohort and the US population were observed in waist and arm 
circumferences, Greek boys did not differ significantly from the US boys in triceps and 
subscapular skinfolds at any ages (Figure 3.3), but showed similar patterns of adiposity 
development. In particular, triceps and subscapular skinfolds decrease with age in both 
Greek and US boys, with the former showing slightly higher (but not significantly) scores 
for these subphenotypes than the latter at most of the ages (Figure 3.3). However, the 
aforementioned decline in triceps skinfold was not obvious for the present population at 
the ages of 1-2 and 5-6 years, probably due to the smaller number of subjects at these age 
groups in the Greek (79 and 43 respectively) compared to the US population (644 and 492 
respectively).
In both Greek and US girls, waist and aim circumference increased with advancing age 
similarly to those in boys (Figure 3.3). Although Greek girls were found to have 
significantly higher waist circumference than their US counterparts at all ages, the former 
showed significantly lower arm circumference measurements than the latter at ages 1-2, 3- 
4 and 4-5. Although significant differences between the Greek and the US girls have been
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observed in waist and arm circumferences, they did not differ significantly in triceps and 
subscapulai' skinfolds at ages 2-5 (Figure 3.3). Both triceps and subscapulai" skinfolds 
increase with increasing age with Greek girls showing slightly (but not significantly) 
higher mean values at these ages (Figure 3,3). Significant differences in these skinfolds 
observed between Greek and US girls at the ages of 1-2 and 5-6 years may be again due to 
the smaller number of individuals in these groups in the Greek population (80 and 39 
respectively) compared to those in the US (625 and 554 respectively).
3.4 Discussion
In the present study (2102 children), although the prevalence of overweight was found to 
be similar for both genders (10.6% for boys and 10.3% for girls), the rates of obesity were 
higher in girls compared to that in boys (9.7% and 7.5% respectively) based on the 1990 
UK reference data (Table 3.1). These estimates were higher when based on the CDC 2000 
growth charts for both genders (10.6% of boys and 15.03% of girls being overweight, 
while 10.25% and 9.8% being obese) although the 85^ and 95^ ^^  percentiles, which 
correspond to similar BMI values between different national reference data (Reilly, 2002) 
were used in both cases (Table 3.1). In a larger subset of the GENESIS (Growth, Exercise 
and Nutrition Epidemiological Study In preSchoolers) cohort (2374 Greek children), the 
prevalence of overweight and obesity according to the CDC 2000 growth charts were 
found to be even higher (Manios, 2006) than those estimated in the present population 
(17.4% and 17.2% of boys being overweight and obese, respectively), possibly due to the 
inclusion of additional children with high BMI in the analysis. These differences between 
estimates of the UK 1990 and the CDC definition could suggest that the former 
underestimates overweight and obesity in the Greek population. When compared to 
findings from the Health Survey for England (2004) that assessed overweight and obesity
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rates in children aged 2-10 years (15% and 16% of boys, as well as 15% and 13% of girls 
were found to be overweight and obese respectively) based on the 1990 Growth reference 
dataset, Greek children showed lower prevalence of overweight and obesity in both 
genders (Figure 3.4). A higher prevalence of overweight and obesity, compared to those in 
the present population, was also observed in a representative US population of a similar 
age, where 27.3% and 15% of boys, as well as 25.2% and 12.6% of girls aged 2-5 years 
were found to be overweight and obese according to the CDC 2000 growth reference 
(Ogden et al., 2006) (Figure 3.5). When compared to the findings from other large and 
similarly aged populations from Europe, Australia, China and Mexico, Greek children of 
the present cohort show similai' alai'ming rates of overweight and obesity based on the 
lOFT cut-off points (Figure 3.6). Previous studies in Greek children, although limited, 
have also reported high rates of overweight and obesity in specific geographical regions 
(Krassas et al., 2001;Magkos et al., 2005), rather than in a representative sample of the 
population. The lowest prevalence rates were observed in a nationwide study in Greek 
children aged 11-16 years (13.4% overweight and 3.7% obese, CDC 2000 chaits), but 
these were based on self-reported data for weight and height, which can underestimate 
obesity (Kai’ayiannis et al., 2003). Dispaiities in these estimates may be due to several 
potential factors, such as the employment of different BMI cut-off points, the 
representativeness of the population (national or regional), the sample size, the age and sex 
of the subjects, as well as differences in measurement methods and time periods of data 
collection (Lissau et al., 2004).
Body composition undergoes marked changes in absolute amounts and relative proportions 
of water, protein, lipid and mineral mass during the first yeai's of life (Fomon et al., 1982). 
Growth of both fat mass index (FMI) and fat-free mass index (FFMI), which constitute the 
two main components of BMI, are influenced by age and gender; FFMI increases steadily
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with advancing age, whilst FMI decreases rapidly during childhood after reaching a peak 
in infancy and starts increasing again towards adulthood. These changes in BMI during 
early childhood for both genders are illustrated well in Figure 3.1 where BMI was 
observed to increase (adiposity rebound) after its developmental nadir. Children from the 
current study experience an early adiposity rebound (as defined between the 48^ to the 61®*^ 
month of age), reflecting along with other studies (Dorosty et al., 2000) a secular trend |  
towards earlier adiposity rebound possibly due to strong environmental influences. This 
increase in BMI after 48 months seems to be faster in girls than boys and especially in girls 
above the 75^ percentile (Figure 3.1). However, it is not clear whether this rebound in BMI 
is attributed to FM or FFM, since BMI does not distinguish lean or fat masses. 
Furthermore, skinfold thickness, although being reliable indices of regional fat and being 
highly correlated with arm circumference, they give no information on lean mass (Wells 
and Fewtrell, 2006). In the present study, biceps skinfold decrease, while arm 
circumference increase in boys suggesting that BMI rebound may be attributed to changes 
in FFMI (muscle and/or bone mass) rather than FMI. In girls, in contrast, arm, waist and 
hip circumferences, as well as biceps, triceps and suprailiac skinfolds are rising 
simultaneously during this period indicating that this is a genuine increase in FMI rather 
than FFMI (Figure 3.1), As for BMI, the increase in these indices seems to be faster in girls
above the 75^ percentile.
In the present study, the mean values for anthropometric measurements, such as BMI, 
weight, height and waist circumference were similar to those reported in other national 
surveys in Europe (Haschke and van't Hof, 2000;McCarthy et al., 2005;Savva et al., 2005) 
indicating a similar pattern of growth in preschoolers. There is also increased evidence that 
modern children are getting fatter faster than those in the past (Reilly, 2005). However, 
such secular trends in adiposity during early childhood are not always recognizable by
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changes solely in BMI, since quantitative changes in body composition (defined as the 
ratio between FFM and FM) do not always reflect a change in BMI (Hall and Cole, 2006).
Previous studies have shown that, although modern children had higher FMI than those in 
the past, these changes in body composition were not obvious by changes in BMI, since 
they were accompanied by a reduced FFMI. In the present population, children of both 
genders were found to be significantly taller and concomitantly heavier than their British 
counterparts (Tables 3.3 and 3.4, Figure 3.2). The observed increase in mean height in the 
present population could be an indicator of a secular trend for accelerated natural growth 
and improved nutritional status and could explain the absence of significant differences in 
the mean BMI between the Greek children in the present and the British children 2 decades 
ago, since BMI is independent of height (Freedman et al., 2001). Additionally, an early 
adiposity rebound observed in the Greek children could also be suggestive of a rapid 
gi'owth (Freedman et al., 2001). An age-related trend towaids higher BMI in the present 
population, when compared to the UK reference data, in association with the evolution of 
the growth curves (Figure 3.1) could further support the notion of a continuing secular 
trend to an increase in childhood fatness. Nevertheless, previous studies, in which the BMI 
of British toddlers (Stenhouse et al., 2004) and preschoolers (Reilly et al., 2006) were 
compared with the 1990 UK reference data, have shown that the excess BMI SDS was 
0.26 and 0.39 respectively. These values are very similar to the ones in the present 
population and could be indicative of increased fatness in modern children. Additionally, 
when compared to the US population, in which the onset of childhood obesity epidemic 
occurred a decade before that in other populations (Goran, 2001), Greek children showed a 
similar development of other anthropometric indices, as illustrated in Figure 3.3.
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Figure 3.3 Comparison of mean values for waist and arm circumferences, triceps and sub 
scapular skinfolds between NHANES III (1988-1994) data and Greek children (present study) 
for boys (top panel) and girls (bottom panel) at different ages. 95% CIs for these phenotypes 
are also shown, (t) indicates statistically significant differences (P<0.05).
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In conclusion, the present study, carried out on a large representative sample of toddlers 
and preschoolers from Greece, is the first cohort of toddlers and preschoolers that includes 
such a wide range of adiposity-related phenotypes. The present population had similar 
prevalence of obesity relative to other preschool populations. Compared to normative data 
from British children, Greek children were much taller and concomitantly heavier 
suggestive of improved nutritional status and accelerated growth and they showed a 
tendency for increasing BMI with advancing age. The excess BMI levels were similar to 
those found in modem preschoolers and most likely attributed to increased adiposity.
Rates of overweight and obesity based on UK 1990
□  % Overweight 
■  % Obesity
Current study Ireland (2003- UK (2004) 2-10 yrs 
(2003-2004) 1-6 yrs 2004) 5-12 yrs n=4000
n=2102 n=596
Location/Study
Figure 3.4 Prevalence of overweight and obesity based on the UK1990 reference data. Grey 
and black bars represent % of overweight and obesity respectively. The period during which 
each study was carried out, as well as the number and the age of subjects in each study are 
also given. Data were nationally representative for both Ireland ((O'Neill et al., 2007) and UK 
(Health Survey for England 2004).
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Rates of overweight and obesity based on CDC
□ Overweight 
■ Obesity
Current study Mexico (2000) Ireland (2003- China (2004) 2- US (2003-2004) 
(2003-2004) 1-6 10-17 yrs 2004) 5-12 yrs 18yrsn=21198 2-5 yrs n=818
yrs n=2102 n=16806 n=596
Location/Study
Figure 3.5 Prevalence of overweight and obesity based on the CDC 2000 reference data. 
Grey and black bars represent % of overweight and obesity respectively. The period during 
which each study was carried out, as well as the number and the age of subjects in each 
study are also given. Data were nationally representative for Mexico (Rio-Navarro et al., 
2004), Ireland (O'Neill et al., 2007) and US (Ogden et al., 2006)and regionally representative 
for Beijing China (Mi et al., 2006).
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Rates of overweight and obesity based on lOFT
20 
^ 1 8  
' i  16 '
0  14
1 12 4 
£  10 
f  8 4
I 6 -
6  4 4
^  2 
0
Location/Study
■  Current study (2003-2004) 1-6 yrs 
n=2102
□  Cyprus (2004) 2-6 yrs n=1412 
11 Australia (2004) 4-5 yrs n=4934
□  UK (1997) 4-18 yrs n=1836
□  Greece (1990-1991) 6-17 yrs n=6448
□  China (2004) 2-18 yrs n=21198
■  Ireland (2003-2004) 5-12 yrs n=596
■  Mexico (2000) 10-17 yrs n=16806
Figure 3.6 Prevalence of overweight and obesity based on the lOFT cut-off points. Group of 
bars on the left and on the right represents % of overweight and obesity respectively. The 
period during which each study was carried out, as well as the number and the age of 
subjects In each study are also given. Data were nationally representative for Cyprus (Savva 
et al., 2005), Australia (Wake et al., 2007), UK (Jebb et al., 2004), Greece (Georgladls and 
Nassis, 2007), Ireland (O'Neill et al., 2007) and Mexico (RIo-Navarro et al., 2004) and 
regionally representative for Beijing China (Ml et al., 2006).
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Chapter 4
Effect of ACE I/D polymorphism on adiposity- 
related phenotypes in Greek children
73
4.1 Introduction
The ACE gene, encodes a cai'boxypeptidase that is a key component of the RAS and 
converts angiotensin I into a biologically active hormone, angiotensin II (a potent 
vasoconstrictor) (Bernstein et al., 1989). ACE also has the ability to hydrolyze numerous 
other peptide substrates (Hooper and Turner, 2003). Although ACE gene is highly 
polymorphic, work is historically focused on the I/D polymorphism with alleles 
characterised by the presence (insertion, allele ‘F) or absence (deletion, allele ‘D’) of a 
287bp Alu repeat sequence in intron 16 (Rigat et al., 1990). Although ACE I/D is not the 
causative variant for serum ACE levels, a better candidate being rs4363 (a SNP at genomic 
nucleotide position 22982) (Zhu et al., 2000;Cox et al., 2002), I/D is a sufficiently good 
marker of circulating ACE activity in Caucasian populations, since it is in almost complete 
linkage disequilibrium with the functional rs4363 variant (Soubrier et al., 2002). Moreover, 
in a previous study in older Greek girls (11-18 years old), the ACE I/D polymorphism 
showed a stronger degree of association with obesity-related phenotypes that was not 
exceeded by other AC£ polymorphisms (Moran et al., 2005).
Previous studies, albeit in adults, have shown somewhat contradictory findings (Cooper et 
al., 1997;Strazzullo et al., 2003;Um et al., 2003;Riera-Fortimy et al., 2005). It is unclear 
whether ACE exerts an appreciable influence on adiposity, although hints of such an effect 
are beginning to outweigh the counterarguments. Difficulties have included differences in 
age and ethnicity between studies, as well a lack of statistical power. There are no data on 
ACE association with adiposity in young children. With these limitations in mind the 
present study aimed to assess whether associations between the I/D polymorphism and 
adiposity-related phenotypes exist in the large population of Greek toddlers and 
preschoolers from the GENESIS study (Manios, 2006).
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4.2 Methods
4.2.1 Subjects and phenotypes
The number of subjects that took part in the study, as well as information on the assessed 
adiposity-related phenotypes and the protocols used for anthropometry, are given in 
Chapter 2 (General Methods). The anthropometric measurements assessed in the current 
analysis included: BMI, ai'm, waist and hip circumferences, as well as sum of skinfolds.
4.2.2 DMA extraction and ACE I/D genotyping
The method used for DNA extraction from all buccal samples is given in Chapter 2 
(General Methods). Details on the set up of PCR reactions and digestions for ACE 1/D 
genotyping are also given in the same section.
4.2.3 Statistical analyses
Data and statistical analyses carried out are described in detail in Chapter 2 (General 
Methods).
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4.3 Results
4.3.1 Genotyping and phenotyping
2102 children (1095 boys and 1007 girls) were included in the phenotypic analyses and 
marked differences between boys and girls were found (Figure 3.1), a reflection of gender- 
specific differences in growth and development. Genotyping for the ACE ¥D 
polymorphism was successful in 2008 individuals (1037 boys and 971 girls). The 
population was found to be in HWE at this locus (x^df=i)=l-64, P=0.199) and the overall 
allele frequencies were/^/j=0.39 m d f(D)=0.61. Overall allele frequencies matched the 
frequencies (x^df=i)=0.007, P=0.936) observed in a Greek cohort of adolescents (Moran et 
al., 2005;Manios, 2006). There were no differences in genotype frequencies between boys 
and girls (x^df=2)=0.731, P=0.694).
4.3.2 GLM analysis for ACE I/D polymorphism
GLM analysis was carried out in the total population (boys and girls) to assess the main 
effect of the ACE I/D polymorphism on adiposity-related phenotypes and whether these 
genetic effects were influenced by gender and/or age. GLM analysis has shown that the 
ACE I/D individually had a significant main effect on BMI (P=0.019) and an almost 
significant effect on waist circumference (P=0.055). For the same polymorphism, 
significant interactions were observed between age and genotype for BMI (P-0.023) 
(Figure 4,1) and close to significance for waist circumference (P=0.074). Based on these 
findings, further ANOVA analysis was carried out stratified by single-year age groups but 
not gender. ANOVA analysis has revealed significant association between the I/D 
genotypes and BMI in 1-2 year old boys and girls (P=0.003) that explained 6.4% of the
76
phenotypic variation. In particular, boys and girls aged 1-2 years bearing the II genotype 
showed significantly higher BMI compared to those carrying the DD genotype (Figures 4.1 
and 4.2). Boys and girls aged 2-4 years carrying the II genotype had also higher (but not 
significantly) BMI compared to those with the DD genotype. (Figure 4.1) However, at the 
age o f 4 years, boys and girls with the DD rather than II genotype had higher, but not 
significantly, BMI indicating a change in the direction of I/D genotypic effect (Figure 4.1).
Mean BMI for ACE  I/D genotypes
CM
18.00 1
17.50 -
17.00 1
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Figure 4.1 Effects of ACE I/D genotypes on mean BMI in boys and girls In each age group.
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4.3.3 ACE I/D genotype associations with phenotypes
After performing the Dunn-Sidak correction for multiple testing for each age group, 
differences between the means of the 1/D genotypes for BMI (a value=0.014) in boys aged 
1-2 years (Figure 4.3), as well as for BMI, waist and arm circumferences (a value=0.022) 
in girls aged 4-6 years (Table 4.1) were found to be statistically significant. ANOVA tests 
revealed that boys 1-2 years old with the II genotype had significantly higher mean values 
for BMI (P=0.001) than did boys with either ID or DD genotypes (Figure 4.1). This 
finding was reflected in the main GLM analysis. At 4-6 years of age, girl carriers of the D 
allele had higher BMI (P=0.018), as well as higher arm (P=0.013) and waist (P=0.001) 
circumferences than girls with the other genotypes (Table 4.1). However, these isolated 
significant associations were not reflected in the GLM analysis. The mean values for all 
anthropometric parameters according to gender and ACE I/D genotypes aie shown in the 
Appendix 1 (Tables 1 and 2).
4.3.4 Determination of the type of genetic effect observed for 
associations with the I/D polymorphism
To determine the genetic mechanism for the significant associations, three genetic models 
(additive and dominance models) were tested using conelation analysis against model 
genotype scores. For the GLM analysis, a D-dominant model could explain 91% (P=0.001) 
of the genetic vai’iance observed for BMI in boys and girls aged 1-2 years. For the gender 
and age subgroup analysis, an additive model best explained the statistically significant 
associations observed between I/D genotype and BMI, waist and arm circumferences in 
girls 4-6 years accounting for 96% of the genetic vaiiance for BMI and 99% for both 
circumferences. For the same analysis, a D-dominant model could explain 98% of the 
genetic variance for BMI in boys aged 1-2 years.
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4.3.4 ACE I/D genotypic effects on the phenotypic distribution
As already mentioned, significant associations of the I/D polymorphism with adiposity- 
phenotypes could be due to a small number of extreme individuals influencing the 
ANOVA analysis, or to a distributed effect of the polymorphism on most of the population. 
For the GLM analysis, the influence of the genotype on the distribution of BMI in boys 
and girls 1-2 years was also assessed by calculating odds ratios and visualised by using 
probability plots. When tested by odds ratio, the DD homozygotes were underrepresented 
in both the lowest and highest quartiles for BMI, while the II homozygotes were almost 
significantly underrepresented and significantly overrepresented in the lowest and the 
highest quartiles, respectively (Table 4.2). The significant odds ratio in the whole range of 
the distribution could indicate a distributed effect of the I/D genotype on most of the 
population for BMI. This effect is also illustrated in Figure 4.4 where the cumulative 
frequency distribution of BMI within 1/D genotypes is plotted in a normal probability 
scale. For the age and gender subgroup analysis, when tested by odds ratios, II 
homozygotes (n=ll) were significantly underrepresented (0/11) in the lowest and 
overrepresented (9/11) in the highest quartiles for BMI, indicating that the effect of the I/D 
genotype was throughout the phenotypic range in boys aged 1-2 yeai's, while in girls 4-6 
years old DD homozygotes were significantly underrepresented in the lowest quartile for 
arm and waist circumferences and II homozygotes significantly overrepresented in the 
same quartile for arm and waist circumferences (Table 4.3). However, neither genotype 
(DD or II) was significantly over- or underrepresented in the highest quaitile for these 
phenotypes indicating that the effect of the I/D genotype was mainly in the thinner end of 
the population distribution.
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Table 4.1 Analysis of associations between I/D genotypes and adiposity-related phenotypes in girls 
4-6 years.
ACE I/D BMI Arm Circumference Waist Circumference
« ^  11=15.41 (15.01 to 15.84) 11=16.58 (16.20 to 16.99) 11=51.52 (50.45 to 52.67)
«  rf ID=15.89 (15.63 to 16.16) ID=16.93 (16.67 to 17.20) ID=52.93 (52.27 to 53.61)
a  ^  DD=16.16 (15.87 to 16.47) DD=17.32 (17.04 to 17.60) DD=53.97 (53.21 to 54.77).b V)O ^  V=2.5%,P=0.018 V=2.7%,P=0.013 V=4.0%, P=0.001
Summary of associations between I/D genotypes and particular adiposity-related parameters assessed  b% 
ANOVA in girls 4-6 years. For each test, mean values, 95% confidence intervals are given, as well ai 
percentage variance explained by ANOVA (V), probability (P), and the number (N) of individuals of II, ID ahc 
DD genotypes respectively. P values are given to three significant figures. Only age groups with at leas 
one significant association after Sidak correction are shown. I
Boys and girls (1-2 years)
BMI
Genotype N Mean ANOVA
II 24 17.65 P=0.003
ID 88 16.50 V=6.4%
DD 36 16.75 N=176
II
ID   O-
DD  -O-
O'
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Figure 4.2 ACE 1/D genotype differences in BMI for 1-2 year* old boys and girls after GLM 
analysis. P=probability, V=observed variance explained, N=number within group.
II
ID  O-
DD ....   "O......
Boys (1-2 years) 
BMI
O-
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Genotype N Mean ANOVA
II 11 18.41 P=0.001
ID 39 16.62 V=16.6%
DD 36 16.46 N=86
“ 1- - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1- - - - - - - - - - - - - - - - - - - - - - - - - - - - 1- - - - - - - - - - - - - - - - - - - - - - - - - - - - - T ”16.0 17.0 18.0 19.0
Figure 4.3 ACE I/D genotype differences in BMi and subscapuiar skinfold for 1-2 year old 
boys. P=probability, V=observed variance explained, N=number within group.
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4.4 Discussion
Obesity is a complex disorder caused by genetic and environmental factors and interactions 
between them (Prentice and Jebb, 1995). It is expected that the influence of genetics is 
mediated through the minor contributions of many individual susceptibility genes (Marti et 
al., 2004). Longitudinal twin studies have suggested that these genetic determinants have a 
greater influence on the development of obesity than environment in young populations 
(Maes et al., 1997). In this study, the effects of the ACE I/D polymoiphism on adiposity 
indices were investigated in a population of toddlers and preschoolers by two different 
approaches. GLM analysis on the total population has revealed a significant main effect of 
the I/D genotype on BMI (P=0.019) and a significant interaction between 1/D genotype and 
age for BMI (P=0.023) (Figure 4.1). Further ANOVA analysis stratsfied by age has 
revealed that children (boys and girls) aged 1-2 years with the II genotype had singificantly 
higher BMI than those with the DD genotype (Figure 4.2). Employing the second approach 
of analysis with gender and age sub grouping has also revealed that boys aged 1-2 years 
bearing the I-allele showed significantly higher BMI (P=0.001) that explained 17% of the 
phenotypic vaiiance (Figure 4.3). No previous studies have associated the ACE I allele 
with higher adiposity measurements and therefore these significant findings did not 
confirm hypothesis 1 (see Introduction). In contrast, age and gender subgrouping analysis 
has shown that the D-allele was significantly associated with higher BMI waist and arm 
circumferences in girls aged 4-6 years (Table 4.1), a finding consonant with hypothesis 1 
and with previous studies in teenagers (Moran et al., 2005) and adults (Strazzullo et al., 
2003;Riera-Fortuny et al., 2005). The observation that these significant findings in girls 4- 
6 years were not reflected in the GLM analysis could be an evidence that these associations 
are Type I errors. It is also possible though that gender and genotype do interact, but the 
study lacks the power to detect such an interaction.
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Although greater genetic effects aie likely to be found in younger populations due to 
absence of confounding environmental factors, as previously suggested (Maes et ah, 1997) 
and as shown in the current study, it is possible that ACE genotype only influences 
adiposity during a particular set of developmental windows, presumably because of other 
events and processes occurring at that time. As Figure 4.1 indicates, although subjects with 
the n  genotype show higher BMI than those with the DD genotype between the ages of 1-4 
years, children aged 4-6 yeai's signal in an opposite way with the DD rather than II 
genotype showing higher (but not significantly) BMI. However, by comparing the 4-6 age 
group of boys with the corresponding age group of girls (4-6 yeai’s), it is clear that 
although girls bearing the D allele show higher BMI than those with the I allele, the 
opposite is observed in boys (i.e. the I allele carriers shows higher BMI) (Appendix 1, 
Tables 1 and 2). In the population studied here, BMI decreased until the age of about 4 
years (48 months) (Figure 3.1), and then began to rise in both sexes. As Figure 3.1 
indicates, all the measured subphenotypes (arm and waist circumference and biceps 
skinfold) ai’e rising simultaneously during this period in girls, suggesting that this is a 
genuine increase in adiposity. In boys, in contrast, as BMI increases after 48 months, 
biceps skinfold decreases and levels off, while arm circumference increases (Figure 3.1), 
suggesting that BMI increase at this time may be as much related to an increase in 
muscularity and/or bone volume as to an increase in adipose tissue volume. The finding of 
significant associations in girls but not in boys at this time therefore suggests that its effect 
is mediated though adipose tissue metabolism and growth, rather than other growth 
processes. The fact that these isolated significant associations ai*e not reflected in the GLM 
analysis could not exclude the possibility that gender, as age, is also a significant factor in 
modifying genotype-phenotype interactions. However, the present study lack the power to 
detect such an interaction, since gender differences in the effects of I/D genotype on BMI 
were observed only in one age group (i.e. 4-6 years). Furthermore, in view of the
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apparently contrary results obtained with younger boys and girls (Figure 4.2) and the 
significant interaction observed between age and I/D genotypes, the finding of altered 
expression of different angiotensin receptor types during the first years of life may be 
significant (Viswanathan et al., 2000).
The influence of the ACE I/D polymorphism on adiposity was found to be relatively small 
(see percentage of phenotypic variance in Figure 4.2), as expected for a complex trait, and 
it is presumed that the effect is mediated possibly through interactions with other 
susceptibility genes and/or environmental factors. A distributed effect of the I/D genotypes 
over the whole phenotypic range, as shown by odds ratios (Table 4.2, Figure 4.4), also 
supports the fact that the ACE is a polygene quantitative trait locus. Environmental factors 
such as nutritional status and physical activity may also modulate the extent to which the 
I/D polymoiphism influences obesity, as previously suggested (Frederich, Jr. et al., 
1992;Moran et al., 2005). In particular, the previous study in Greek teenagers (Moran et 
al., 2005) revealed significant associations between the DD genotype and larger skinfold 
thickness in inactive females, but not in inactive males or active females. The young 
children in the GENESIS study showed an increased tendency for reduced physical activity 
and increased energy intake with advancing age (Manios, 2006). Specifically, children 
aged 4-5 yeais old tended to spend more time watching television and were less physically 
active than children in younger age groups (1-2, 2-3 and 3-4 years old). Similar trends have 
previously been reported in schoolchildren aged 5-6 years (Salmon et ah, 2006), although 
other studies in preschool children aged 3-4 years reported an increase in physical activity 
over a one-year period (Jackson et ah, 2003). Therefore, it is possible that inactivity even 
at this young age (e.g. girls aged 4-6 years in the present study) may interact with the ACE 
I/D polymorphism and in doing so influence body fat accumulation in a similar manner as 
previously reported in Greek teenaged girls (Moran et al., 2005).
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While the present study provides further support for the ACE I/D polymorphism being a 
good candidate gene for human obesity (Strazzullo et ah, 2003;Moran et ah, 2005;Riera- 
Fortuny et al., 2005), the precise mechanism by which ACE may produce this effect 
remains unclear. The primary role of ACE is to convert angiotensin I into angiotensin II (a 
potent vasoconstrictor) (Bernstein et al., 1989). The main components of the tissue RAS 
systems, which can generate angiotensin II and other active peptides independently of 
circulating RAS components, are expressed in both visceral and subcutaneous adipose 
tissue (Giacchetti et ah, 2002). While the exact role of angiotensin II in adipose tissue is 
not yet clear’, it has been shown to promote adipocyte growth and differentiation and can 
inhibit lipolysis by reducing skeletal and adipose-tissue blood flow leading to increased fat 
storage in normal-weight and obese subjects (Goossens et ah, 2004). Furthermore, 
angiotensin II has been shown to increase lipid synthesis and storage in adipose cells in 
vitro (Jones et al., 1997) and, thus, may play an important role in growth and 
differentiation of this tissue. The DD genotype is associated with higher circulating ACE 
levels than the other I/D genotypes (Rigat et al., 1990). In the context of obesity, the I/D 
polymorphism (or another polymorphism in strong linkage disequilibrium with it, if it 
turns out not to be the functional polymoiphism responsible for these associations) may 
modulate locally produced angiotensin II levels at particular times indevelopment, 
resulting in the significant associations found between the I/D polymorphism and 
adiposity-related phenotypes in this and other studies (Strazzullo et al., 2003;Moran et al., 
2005;Riera-Fortuny et al., 2005).
In summary, the data presented here revealed that the I/D polymorphism has a stronger 
influence on particular adiposity-related phenotypes in young Greek children than in adult 
populations. The I/D polymorphism, being a sufficiently good marker of circulating ACE
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levels, may be associated with developmental changes observed during the first stages of 
life. Environmental factors, such as dietary patterns and physical activity, could also 
mediate the age-specific effects of ACE I/D polymorphism in childhood obesity.
Table 4.2 Odds ratios for BMI in boys and girls aged 1-2 years.
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Genotype Phenotype Lowest quartile Highest quartile
c 1 II
0.35 (0.10-1.24) 
P=0.09
5.69 (2.30-14.07) 
P=<0.001CO </3
^  OûfS ID
BMI 1.50(0.77 to 2.95) 
P=0.233
0.37 (0.18 to 0.75) 
P=0.005
03 ^ DD 0.99 (0.49 to 1.98) P=0.974
0.99 (0.48 to 2.02) 
P=0.999
95% CIs are given in the parentheses. Chi-square tests were significant (P<0.05) for odds ratios 
and CIs indicated in bold and showed tendencies to significance in those indicated in italics. P 
values are given to three significant figures.
99
95
90
80
7060504030
20
10
5
1
-0.003-0.008 -0.007 -0.006 -0.005 -0.004-0.009
DD
ID
Transformed BMI (kg/m )
Figure 4.4 Normal probability plots for BMI (boys and girls 1-2 years) by ACE I/D genotype. 
Centiles were calculated for each genotype separately and plotted against the Box-Cox 
transformed data for each individual using the default method in Minitab 13.30. Higher centiles 
represent increased adiposity (i.e. higher adiposity measurements are further to the right).
Table 4.3 Odds ratios for phenotypes significant by ANOVA.
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Genotype Phenotype Lowest quartile Highest quartile
§ n
0.26 (0.03-2.17) 
P=0.045
24.00 (4.60-125.17) 
P=<0.001
pq ID
BMI 0.81 (0.30 to 2.15) P=0.835
0.40 (0.14 to 1.16) 
P^O.085
DD 1.92 (0.72 to 5.10) P=0.120
0.45 (0.16 to 1.31) 
P=0.137n 1.72 (0.91 to 3.27) P=0.094 0.61 (0.28 to 1.32) P=0.203
ID BMI 0.97 (0.59 to 1.60) P=0.896
1.02 (0.61 to 1.70) 
P=0.942
DD 0.74 (0.44 to 1.25) P=0.265
1.26 (0.75 to 2.10) 
P=0.383
§
n 1.90 (0.94 to 3.81) P=0.069 0.92 (0.43 to 1.95) P=0.822
ID Arm 1.44 (0.83 to 2.51) 0.74 (0.43 to 1.27)o  ^ circumference P=0.193 P=0.278
DD 0.44 (0.24 to 0.82) P=0.008
1.41 (0.83 to 2.40) 
P=0.205
n 2.80 (1.49 to 5.29) P=0.001 0.62 (0.29 to 1.34) P=0.223
ID Waistcircumference
1.0 (0.60 to 1.69) 
P=0.987
0.92 (0.55 to 1.53) 
P=0.739
DD 0.50 (0.28 to 0.88) P=0.014
1.39 (0.83 to 2.32) 
P=0.213
95% CIs are given in the parentheses. Chi-square tests were significant (P<0.05) for odds ratios 
and CIs indicated in bold and showed tendencies to significance in those indicated in italics. P 
values are given to three significant figures.
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Chapter 5
Effects of ADRB gene polymorphisms on 
adiposity-related phenotypes in Greek children
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5.1 Introduction
ADRBl, ADRB2 mAADRBS genes, which encode for GPCRs (G-protein coupled receptor) 
in the plasma membrane, represent attractive candidate genes for obesity. Expression of 
these genes in adipose tissue promotes lipolysis and thermogenesis by mediating the 
stimulation by catecholamines (adrenaline and noradrenaline) of adenylyl cyclase 
(Lafontan and Berlan, 1993). Functional SNPs within the coding region of ADRB genes 
have been suggested to contribute to the development of several pathophysiologies, such as 
asthma, congestive heart disease and obesity (Small et al., 2003;Leineweber et al., 2004). 
Conflicting results have been published, so fai’, as to whether specific ADRB variants at 
different loci are associated with obesity or not. Most of these association studies have 
been focused mainly on adult populations and on polymorphisms within a single ADRB 
gene rather than considering haplotypes. Genotyping of the ADRBl Gly49Ser (rs 1801252) 
and Ai’g389Gly (rs 1801253) variants allows the inference of three haplotypes that 
represent the majority of variation along the complete length of gene. In ADRBl gene, 
genotyping of the Glyl6Arg (rs 1042713) and Glu27Gln (rs 1042714) variants reveals the 
occurrence of three haplotypes that account for 95% of the genetic variance observed in 
ADRBl gene in Caucasian populations (Drysdale et al., 2000).
To obviate the limitations of previous studies, the present study aimed to investigate the 
effects of variations in all thiee ADRB genes on adiposity-related phenotypes in a large 
population of toddlers and preschoolers using both genotype and haplotype-based 
approaches. Young cohorts may be the study group of choice when characterising the 
genetic influences on complex diseases like obesity, as the environment has less time to 
take effect (Maes et al., 1997).
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5.2 Methods
5.2.1 Subjects and phenotypes
The number of subjects that took pai*t in the study, as well as information on the assessed 
adiposity-related phenotypes and the protocols used for anthropometry, are given in 
Chapter 2 (General Methods). The anthropometric measurements assessed in the current 
analysis included: BMI, arm, waist and hip circumferences, as well as sum of skinfolds.
5.2.2 DNA extraction, genotyping and haplotype inference
The method used for DNA extraction from all buccal samples is given in Chapter 2 
(General Methods). Details on the set up of PCR reactions, digestions fox ADRBl (C49 and 
C389), ADRBl (C l6 and C27) and ADRB3 (C64) genotyping, as well as ADRBl and 
ADRBl haplotype inference are also given in the same section.
5.2.5 Statistical analyses
Data and statistical analysis carried out are described in detail in Chapter 2 (General 
Methods).
92
5.3 Results
5-3.1 Genotyping and phenotyping
2102 children (1095 boys and 1007 girls) were phenotyped. Genotyping for ADRBl gene 
was successful in 1929 individuals at the C49 polymorphism and 1856 individuals at the 
C389 polymorphism. The overall allele frequencies f(Giy49)"0.09 mA f(Ser49f=^^^  ^ for
Gly49Ser polymorphism and /fA/gJSP)=0.67, f(Giy389)~ -^' '^  ^ for Arg389Gly polymorphism 
and the population was found to be in HWE for both C49 (%^ (df=i)=0.22, P=0.638) and 
C389 (x (^df=i)=0.45, P=0.503) loci. Diplotypes (haplotype allelic combinations) were 
inferred in 1795 individuals; haplotype frequencies were f(Ser49Arg389)=^ -'^ ^^  
f ( S e r 4 9 G l y 3 8 9 ) ~ ^ - 5 9  and f(Giy49Arg389)=^ ‘^ ^- Genotyping was successful in 1999 children for 
ADRBl C16 polymorphism and in 2027 subjects for ADRBl C27 polymorphism. The 
overall allele frequencies were f(Giyi6)=^’^ '  ^ and ^Arg7^;=0.37 for Glyl6Arg and 
f(Giu27)=^‘^ '  ^ and/('g/„27j=0.63 for Glu27Gln polymorphism. The population was found to
be in HWE for both C16 (jc%c=i)=2.36, P=0.124) and C27 (xV=i)=l-99. P=0.158) loci. 
Diplotypes were inferred based on published literature (Drysdale et ah, 2000) in 2008 
individuals; haplotype frequencies were f(Argl6Gln27)~ '^'^l, f(Glyl6Gln27)'= -^'^^  and 
f(Giyi6 Giu2 7 )=^-'^l■ Finally, for Arg64Trp polymorphism in ADRB3, genotyping was 
successful in 2032 individuals and the overall allele frequencies were f(Arg64)-^-^^ and 
f(Trp64)=^-^^- The population was found to be in HWE for this polymorphism (x^(df=i)=l-03, 
P=0.311). There were no significant differences between boys and girls for any of the 
aforementioned polymorphisms (data not shown). None of the individuals above showed 
evidence of rare recombinant haplotypes. The population was found to be in HWE for both 
ADRBl m à ADRBl haplotypes (Table 5.1)
Table 5.1 Haplotypes frequencies for ADRBl and ADRB2 genes.
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Gene Haplotype HaplotypeFrequency
HWE for 
haplotypes
Gly49Arg389 0.09 xV=5)=3.80,
AD RBl
Gly49Gly389
Ser49Arg389
Ser49Gly389
0
0.59
0.33
P=0.578
Glyl6Glu27 0.37 X (df=5)=5.68,
ADRB2
Glyl6Gln27
Argl6Glu27
Argl6Glii27
0.26
0
0.37
P=0.339
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B-3.2 GLM analysis for ADRB polymorphisms
GLM analysis was carried out in the total population to assess the main effects of the 
ADRBl, ADRBl and ADRB3 polymoiphisms of interest on adiposity-related phenotypes 
and whether these genetic effects were influenced by gender and/or age. GLM analysis on 
the total population has shown that the ADRBl C16 polymorphism individually had a 
significant effect on waist (P=0.041) and hip (P=0.004) circumferences. For the same 
polymorphism, significant interactions were found between age and C l6 genotype for 
waist (P=0.042) (Figure 5.1) and hip (P=0.008) (Figure 5.2) circumferences and between 
gender and C16 genotype for BMI (P=0.025) and aim circumference (P=0.041) (Table 
5.2). Furthermore, GLM on the total population for Glu27Gln polymorphism has revealed 
that ADRBl C27 genotypes had a significant main effect on hip circumference (P=0.006), 
as well as total skinfolds (P=0.025). Significant interactions between age and C27 
genotypes (P=0.012), as well as gender and C27 genotypes (P=0.019) were observed for 
hip circumference (Figure 5.3). For ADRBl C49 and C389, as well as ADRB3 C64 
polymorphisms, GLM analysis on the total population has shown no significant main 
genotypic effects or interactions with age and/or gender.
Based on these findings from the GLM analysis, futher ANOVA analysis was carried out 
stratisfied by age but not gender to assess associations between ADi?52 C l6 genotypes and 
waist and hip circumferences. ANOVA analysis revealed that although boys and girls 
carrying the Argl6 allele genotype had higher (but not significantly) waist (Figure 5.1) and 
hip (Figure 5.2) circumference measures between the ages of 1 to 4 yeai’s compared to 
those with the Glyl6 variant, in the 4-6 yeai’s age group boys and girls homozygotes for 
the Glyl6 allele rather than those homozygotes for the Ai'gl6 allele had significantly 
higher waist (P=0.026) (Figures 5.2 and 5.3) and higher (but not significantly) hip
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(P=0.129) (Figure 5.2) circumferences. Further ANOVA analysis stratisfied by gender was 
also carried out to assess possible associations between ADRBl C16 genotypes and BMI 
and arm circumference. This analysis revealed no significant associations between ADRBl 
C16 genotypes and BMI or arm circumference in total boys or total girls (Table 5.2). 
However, boys carrying the Argl6 allele showed higher measures for both BMI and arm 
circumference than those with the Glyl6 allele, whereas girls carrying the Glyl6 rather 
than Aigl6 variant had higher (but not singificantly) measures for the same phenotypes 
(Table 5.2). As far as GLM analysis on the total population for ADRBl C27 effects on 
adiposity is concerned, further ANOVA analysis stratisfied by age and gender for hip 
circumference revealed that boys aged 2-3 years bearing the Gln27 (C) allele had 
significantly higher hip circumference (P=0,001) than those with the Glu27 (G) allele 
(Figure 5.4).
5.3.3 ADRB genotype associations with phenotypes after age and 
gender subgrouping
5.3.3.1 ADRB2 Cl 6 and 027 genotype associations with phenotypes
After performing Dunn-Sidak correction for multiple testing for each age group, 
differences between the means of the C16 genotypes for BMI in boys (3-4 years) (a 
value=0.020) (Appendix 1, Table 7), as well as the means of the C27 genotypes for hip 
circumference in boys (2-3 years) (P=0.001) (a value=0.017) were statistically significant 
(Figure 5.4). In particular’, boys with the Argl6 allele had significantly higher BMI 
(P=0.020) than those carrying the Glyl6 allele. This isolated significant finding was also 
reflacted in the main GLM analysis (Table 5.2) where total boys carrying the Argl6 allele 
had higher BMI than those with the Glyl6 variant. The mean values of all anthropometric
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parameters according to gender and ADRBl C l6 and C27 genotypes are shown in 
Appendix 1 (Tables 7 to 10).
S.3.3.2 ADRBl C49 and C389 genotype associations with phenotypes
ANOVA tests for ADRBl Gly49Ser polymorphism revealed no significant differences in 
boys or girls for any adiposity-related trait (shown in Appendix 1, Tables 3 and 4). This 
was also reflected in the GLM analysis where no main effects of C49 genotypes on 
phenotypes or genotype and/or gender interactions were observed (data not shown). For 
the Arg389Gly polymorphism, after adjusting the P value for significance within each 
gender and age group using the Dunn-Sidak correction for multiple testing, differences 
between the means of C389 genotypes for hip circumference (P=0.004) in girls aged 2-3 
years (a value=0.018) were found to be statistically significant (Appendix 1, Table 6). 
However, this isolated significant association was not reflected in the GLM analysis on the 
total population. Also, due to the fact that this association was best explained by an 
overdominant model as correlation analysis showed (data not shown), this finding should 
be interpreted with caution and seems to be a Type I error. Such genetic models (under- or 
over-dominance) are difficult to be explained mechanistically and were most likely caused 
by lack of power or by outliers shifting the Arg389Gly mean higher than both the 
homozygote means. The mean values of all anthropometric pai*ameters according to gender 
and ADRBl C49 and C389 genotypes aie shown in Appendix 1 (Tables 3 to 6)
5 3.3.3 ADRB3 C64 genotype associations with phenotypes
For ADRB3 Arg64Trp polymorphism, no statistically significant differences where 
observed for any adiposity-related trait tested after Sidak correction for repeated tests. This 
was also reflected in the GLM analysis where no main effects of C64 genotypes on
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phenotypes or genotype and/or gender interactions were observed (data not shown). The 
Arg64 allele was found to be relatively raie in the Greek population (/(Arg64)=0.05), as 
shown also in previous studies (Corella et ah, 2001) and thus, only heterozygotes at this 
site were identified in some age groups for both genders. The mean values of all 
anthropometric parameters according to gender and ADRB3 C64 genotypes are shown in 
Appendix 1 (Tables 11 and 12).
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Mean waist circumference for ADRB2 C16 
genotypes
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Figure 5.1 Effects of ADRB2 C l6 genotypes on mean waist circumference in boys and girls 
in each age group.
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Figure 5.2 Effects of ADRB2 016 genotypes on mean hip circumference in boys and girls in 
each age group.
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Table 5.2 Analysis of associations between ADRB2 C16 polymorphism and adiposity- 
related phenotypes in total boys and total girls.
Total boys
ADRB2 C16 
GG=407, GA=485, 
AA=140
BMI
GG= 16.05 (15.91 to 16.20) 
GA= 16.06 (15.92 to 16.20) 
AA=16.33 (16.08 to 16.59) 
V=0.4%, P=0.139
Arm Circumference
GG=16.24 (16.11 to 16.37) 
GA=16.28 (16.16 to 16.40) 
AA=16.43 (16.21 to 16.66) 
V=0.2%, P=0.350
Total girls
ADRBl C27 
GG=368, GA=480, 
AA=119
BMI
GG=16.10 (15.93 to 16.27) 
GA=16.10 (15.97 tol6.23) 
AA=15.81 (15.54 to 16.09) 
V=0.4%, P=0.153
Arm Circumference
GG=16.52 (16.35 to 16.68) 
GA= 16.41 (16.27 to 16.54) 
AA= 16.27 (16.01 to 16.53) 
V=0.3%, P=0.267
Associations between ADRB2 C16 genotypes and adiposity-reiated parameters assessed by 
ANOVA in total boys and girls. For each test, mean values, 95% Cis are given, as well as 
percentage variance explained by ANOVA (V), probability (P). P values are given to three 
significant figures.
100
Boys and girls (4-6 years) 
Waist, circumference
Genotype______ N_________Mean_______ANOVA
AA 83 52.70 P=0.026
AG 302 53.44 V=1.2%
GG 239 53.83 N=624
J_____________ I_____________ I_____________ I
O-
GG  O'
AA
AG  O
n  I I52.0 52.8 53.6 54.4
Figure 5.3 ADRB2 C l6 genotype differences in waist circumference for boys and girls aged 
4-6 years. P=probability, V=observed variance explained, N=number within group.
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Boys (2-3 years) 
Hip circumference
Genotype N Mean ANOVA
GG 29 50.94 P=0.001
GC 115 52.47 V=6.0%
CC 97 53.46 N=241
O'
cc  -o-
GG
GC  O
50.5 51.5 52.5 53.5
Figure 5.4 ADRB2 C27 genotype differences in hip circumference for 2-3 years boys. 
P=probability, V=observed variance explained, N=number within group.
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5.3.4 Determination of the type of genetic effect observed for 
associations with the ADRB gene poiymorphisms
Three genetic models were used (additive, dominance and recessive models) to determine 
the genetic mechanism for the observed significant associations using correlation analysis. 
Under-/over-dominant models were also tested. In boys and girls aged 4-6 years, an 
additive model best explained the significant association between C16 and waist 
circumference accounting for 87% of the genetic variance (Figure 5.3). In boys aged 2-3 
years, an additive genetic model best explained the statistically significant association 
observed between Glu27Gln genotype and hip circumference of age accounting for 97% of 
the genetic variance, while Glu-dominant and Glu-recessive models accounted for 63% 
and 0% of the genetic vaiiance respectively (Figure 5.4). Finally, under/overdominance 
models accounted for 6% of the variance. In boys (3-4 yeai's), a dominant genetic model, 
with the Glyl6 allele completely dominant over the Argl6 allele, could explain the 
statistically significant associations between Glyl6Arg genotypes and BMI accounting for 
99% of the genetic variance (Appendix 1, Table 7).
5.3.4 Genotypic effect of ADRBl and ADRB2 variants on the 
phenotypic distribution
The influence of genotype on the distribution of the measured adiposity-related phenotype 
was assessed by calculating odds ratios and visualised by using probability plots. The odds 
ratios (Table 5.3) were generally in agreement with the phenotypic means given by 
ANOVA and the genetic models by correlation analysis. In boys and girls aged 4-6 years, 
calculation of odds ratios for waist circumference has shown that homozygotes for the 
Argl6 allele were significantly overrepresented in the lowest quartile and underrepresented
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(but not significantly) in the highest quartile, whereas homozygotes for the Glyl6 allele 
were significantly underrepresented in the lowest quailile and overrepresented (but not 
significantly) in the highest (Table 5.3). This could suggest that the Glyl6Ai*g 
polymorphism exerts a lai'ger effect on the thinner end of the distribution. In boys (2-3 
years), the difference between the means of the three ADRBl C27 genotypes for hip 
circumference is not uniform throughout the distribution, as illustrated by the normal 
probability plot and this difference becomes more pronounced in the fatter end of the 
distribution (Figure 5.5). This uneven effect of the Glu27Gln polymorphism throughout the 
phenotypic range is also highlighted by the odds ratios for individuals of different C27 
genotypes falling into the low or high quartiles (Table 5.3). According to these odds ratios, 
Glu27 homozygotes (n=29) were significantly overrepresented in the lowest quartile 
(14/29) and significantly underrepresented in the highest quartile (0/29) for hip 
circumference, whereas Gln27 homozygotes (n=97) were significantly underrepresented 
(9/97), but not significantly overrepresented (23/97) in the highest quartile, suggesting that 
the Gln27Glu polymorphism exerts a larger effect on the leaner end of the distribution 
(Table 5.3).
5.3.5 ADRB2 diplotypes association with phenotypes
Significant associations by ANOVA were further assessed by haplotype-based analysis for 
the ADRBl gene. The extra portion of the phenotypic variance accounted for by using 
ADRBl diplotypes instead of the individual C l6 or C27 genotypes was not significantly 
larger for any of the measured phenotypes. However, in boys 2-3 years old, the 
Argl6Gln27/Glyl6Gln27 and Glyl6Gln27/Glyl6Gln27 diplotypes were associated with 
higher hip circumference measurements compared to the Glyl6Glu27/Glyl6Glu27 
diplotype (Figure 5.6). Correlation analysis for possible genetic models underlying these 
associations in boys revealed that a Gly 16-dominant model could explain the data best
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when assessing the effect of the ADRBl C16 genotypes on adiposity, in the absence of 
vai'iation in C27 (a fixed Gln27 allele at this locus), while a Glu27-recessive model could 
best predict the phenotype when assessing the effect of the ADRBl C27 genotypes on 
adiposity, in the absence of variation in C l6 (a fixed Gly 16 allele at this locus) (Figure
5.6). The mean values of all anthropometric parameters according ADRBl diplotypes for 
both genders aie shown in Appendix 2 (Tables 1 and 2).
Table 5.3 ADRB2 C16 and C27genotype odds ratios for phenotypes significant by ANOVA.
Genotype Phenotype Lowest quartile Highest quartile
AA 1.86 (1.14-3.04) 0.96 (0.55-1.68)P=0.011 P=0.889a 4  g VO AG Waist 1.13(0.78-1.62) 0.95 (0.65-1.39)circumference P=0.517 P=0.806pq bo GG 0.62 (0.42-0.91) 1.07 (0.72-1.58)P=0.015 P=0.727
GG 3.67 (1.65 to 8.18)g P=0.001 P=0.005
GC Hip 1.88 (1.03 to 3.44) 1.60 (0.84 to 3.04)pq CO O circumference P=0.039 P-0.150<N CC 0.20 (0.09 to 0.44) 1.48 (0.78 to 2.80)P=<0.001 P=0.226
95% Cis are given in the parentheses. Chi-square tests that were significant (P<0.05) for odds 
ratios and Cis are indicated in bold. P values are given to three significant figures. Note that in the 
highest quartile, no individuals with the GG genotype falling into the highest quartile for hip 
circumference were identified, so calculation of odds ratio was not possible.
105
gU
99
95
90
80
70605040
30
20
10
5
1
- 3.4 - 2.9 - 2.4
cc
GC
GG
Transformed hip circumference (cm)
Figure 5.5 Normal probability plots for bip circumference by Glu27Gln genotype in boys 2-3 years. 
Gentiles were calculated for each genotype separately and plotted against the Box-Cox 
transformed data for each individual using the default method in Minitab 13.30. Higher centiles 
represent increased adiposity (i.e. higher adiposity measurements are further to the right).
106
5.4 Discussion
In the present study (GENESIS), variation within the ADRB2 (C l6 and C27) was 
significantly associated with specific adiposity-related phenotypes. The GEM analysis on 
the total population has revealed a significant main effect of ADRB2 C l6 genotypes on 
waist (P=0.041) (Figure 5.1) and hip (P=0.004) (Figure 5.2) circumferences, as well as 
significant interactions between age and C16 genotype for waist (P=0.042) and hip 
(P=0.008) circumferences and between gender and C l6 genotypes for BMI (P=0.025) and 
arm circumference (P=0.041). Further ANOVA analysis stratisfied by age for waist and 
hip circumference has revealed that boys and girls with the Glyl6 allele had significantly 
higher waist circumference (P=0.026) than those with the Argl6 allele (Figures 5.1 and
5.3), This was in agreement with hypothesis 2 according which homozygotes for the Glyl6 
allele would be expected to show higher adiposity than those with the Argl6 allele. 
Previous studies, albeit in adolescents and adults, on the effect of the Glyl6Arg 
polymoiphism on adiposity are in agreement or in contrast to the present findings. For 
example, a strong association was observed in Greek adolescents between C16 and BMI, 
as well as skinfold thickness with homozygotes for the Glyl6 allele showing higher 
adiposity (unpublished data). Furthermore, the Glyl6 variant was associated with lower 
BMI in French-Canadian men (Ukkola et al., 2000) and Japanese women but no 
association was found in Japanese men (Ishiyama-Shigemoto et al., 1999). Based on the 
GEM analysis for the Glu27Gln polymorphism, a significant main effect of this variant on 
hip circumference and significant interactions between both age and gender with the same 
phenotype were observed. Boys 2-3 yeais bearing the Gln27 allele showed significantly 
higher hip circumference measures (P=0.001) than those with the Glu27 allele (Figure 5.4). 
These findings are consistent with a previous published report where the Gln27 allele was 
associated with higher scores for adiposity-related phenotypes in French men, but not in
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women (Meirhaeghe et al., 2000b). Furthermore, the Glu27 variant frequency was found to 
be significantly lower in obese Swedish males but not females (Hellstrom et al., 1999), 
while the Glu27 allele was associated with increased adiposity in Swedish women (Large 
et al., 1997) and reduced lipolysis in Spanish women (Macho-Azcarate et al., 2002). These 
discrepancies in the findings could suggest that ethnicity, age (Ellsworth et al., 2002) and 
gender differences (Hellstrom et al., 1999;Meirhaeghe et al., 2000b;Gonzalez Sanchez et 
al., 2003), as well as environmental factors, such as physical activity (Meirhaeghe et al.,
1999) and diet (Ukkola et al., 2001) can modify the possible effects of ADRB genotypes on 
adiposity.
Haplotypes have been advocated to be a more powerful tool for detecting associations 
between genetic variation and phenotypes than single SNPs in complex traits (Stephens et 
al., 2001), since SNPs predispose to a disease in combination with other variants. In the 
present study, genotyping of ADRBl (rsl801252 and rsl801253) and AD/?j52 (rsl042713 
and rs 1042714) polymorphisms that help define the major haplotypes in European 
populations (current study for ADRBl and (Drysdale et al., 2000)study fot ADRBl) did not 
produce phenotypic associations stronger than those with the individual SNPs (Appendix 
2, Tables 1 and 2) and the proportion of variance explained by haplotypes, although 
generally larger (due to increased degrees of freedom, after splitting the data into more 
groups), was not significantly greater than that explained by C49 or C389 and C l6 or C27 
genotypes analysed alone. This could suggest that most of the genetic effect observed is 
accounted for either by the individual SNPs or by variants, which are in strong linkage 
disequilibrium with them. However, this is not a proof against the higher analytical power 
and robustness of the haplotypes over the single markers. Nevertheless, by using 
haplotype-based tests in the present study, hi boys 2-3 years old, the 
Argl6Gln27/Glyl6Gln27 and Gly 16Gln27/Gly 16Gln27 diplotypes were associated with
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higher hip circumference measurements compared to the Glyl6Glu27/Glyl6Glu27 (Figure
5.6), which could suggest a dominant effect of the Glu27Gln polymorphism on the 
function of the receptor.
Although previous work has mainly focused on cai'diovascular diseases (Drysdale et al., 
2000;Small et al., 2003), a few studies have attempted to associate ADRBl polymorphisms 
with obesity with somewhat conflicting results (Ryden et al., 2001;Dionne et al., 2002). In 
the present study, no significant associations were identified between Gly49Ser genotypes 
and adiposity-related phenotypes (Appendix 1, Tables 3 and 4) Furthermore, no significant 
associations were observed between ADRB3 C64 genotypes for any of the adiposity- 
related phenotypes for either gender (Appendix 1, Tables 11 and 12). It is known that 
ADRB3 expression is largely confined to adipose tissue, where it regulates noradrenaline- 
induced changes in energy metabolism (white adipose tissue) and thermogenesis (brown 
adipose tissue) (Leineweber et al., 2004). The Trp64Arg polymorphism has been studied 
mainly in obese subjects from several populations, such as Prima Indians (Walston et al., 
1995), Finns (Widen et al., 1995), French Caucasians (Clement et al., 1995), as well as 
Japanese subjects (Kim-Motoyama et al., 1997) with different allelic frequencies being 
reported reflecting ethnic variability. In the present study, the low prevalence of the Gly49 
(f(Giy49)~^^^^) and the Arg64 ( f(Arg64)=0.05) alleles coupled to the small number of 
subjects may have influenced the accurate assessment of any small effects of this 
polymorphism on adiposity. However, the little significance of these variants to the Greek 
population does not preclude them from having significant effects in other populations 
where they are more common (Kawamura et al., 2001).
Although the study of younger populations may be a more powerful approach to 
investigate complex traits than adult populations, since the environmental influence is less 
(Maes et al., 1997), the effect of ADRB genes in the present population of toddlers and
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preschoolers (Figures 5.3 and 5.4) was not generally stronger than that observed in 
adolescents for the Glyl6Arg polymoiphism (unpublished data) and in adults for the 
Glu27Gln polymorphism (Meirhaeghe et al., 2000b). These results, as well as the 
significant interactions between age and both C l6 and C27 could suggest that the effects of 
ADRBl polymorphisms on adiposity are possibly age-dependent. This notion is also 
supported by a previous longitudinal study, which has shown that, although children (4-9 
years) with the Glyl6Gly genotype had higher adiposity-related measures than those with 
the other Glyl6Arg genotypes, these differences became more pronounced with age and 
reached statistical significance by the age of 20 (Ellsworth et al., 2002). Furthermore, 
given the fact that plasma catecholamine levels increase with advancing age 
(approximately 10-15% per decade in adults) (Seals and Esler, 2000) and they have been 
shown to have no or little effect on lipolysis during the first years of life due to a prominent 
antilipolytic effect of a2A-adrenoceptor (Arner, 2005), the effects of variation in the ADRB 
genes ai*e expected to be larger in adult populations.
The modest effects of ADRB genes on adiposity observed in the present study are the ones 
expected for the development of complex trait, such as obesity and are manifested possible 
through interactions with other variants of functional significance and/or environmental 
factors, such as physical activity (Meirhaeghe et al., 1999) and diet (Ukkola et al., 2001). 
For example, in Greek adolescents (unpublished data), the association of Glyl6Gly 
genotype with larger triceps skinfold was stronger in active (P=0.005, V=2.7%) than in 
inactive males (P=0.986, V=0%), while physically inactive French men with the Gln27Gln 
genotype had increased BMI compared to inactive carriers of the Glu27 allele or active 
men of any genotype (Meirhaeghe et al., 1999). Children in the GENESIS study showed an 
increased tendency for reduced physical activity with advancing age (Manios, 2006). 
Given the fact that the adrenergic system responds to physical activity by increasing
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plasma catecholamines (Strobel et al., 1999), it is possible that different alleles of ADRB 
genes will respond differently to this catecholamine activation. Therefore, it is possible that 
inactivity even at a very young age can modify or mask the possible effects of ADRB 
variants on fat accumulation.
In summary, variants of the ADRBl gene were associated with subtle influences on 
adiposity-related phenotypes in early childhood and these effects were manifested in a 
gender-specific and age-related manner. Although haplotype-based analysis did not reveal 
stronger associations compared to individual SNPs, Glyl6Gln27/Glyl6Gln27 and 
Argl6Gln27/Glyl6Gln27 diplotypes were associated with higher hip circumference 
measurements compared to the Gly 16Glu27/Gly 16Glu27 suggesting a possible dominant 
effect of the ADRBl Glu27Gln polymorphism on the receptor’s function.
Boys 2-3 years
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Hip Circumference
AD RBl Diplotypes N Mean ANOVA
AC/AC 37 52.92
AC/GC 44 53.64 P=0.011
AC/GG 61 52.21 V=6.3%
GC/GC 14 53.41 N=232
GG/GC 50 52.77
GG/GG 26 51.15
AC/AC : : ,
Ac/Gc
....................... Î.*........................ ) GC/GC
( _____ * ______ ) GG/GC
( _________ * ________ ) GG/GG
51.0 52.5 54.0
Figure 5.6 ADRB2 diplotype differences in hip circumference for 2-3 year old boys. P=probability, 
V=observed variance explained, N=number within group. For haplotypes, AC=Arg16Gln27, 
GC=Gly16Gln27 and GG=Gly16Glu27.
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Chapter 6
Effects of PPARy polymorphisms on adiposity- 
related phenotypes in Greek children
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6.1 Introduction
The nuclear receptor, PPARy, which is abundantly expressed in adipose tissue, has a 
pivotal role in adipose tissue differentiation, fatty acid metabolism and insulin 
sensitization, as well as in the regulation of transcription of several adipocyte genes 
(Martin et al., 1998;Gurnell, 2005). The most frequently occurring PPARy polymorphism, 
the Prol2Ala, has been extensively studied in association with obesity, insulin resistance 
and type 2 diabetes with inconsistent results being reported (Martin et al., 
1998;Meirhaeghe and Amouyel, 2004). Conflicting findings have prompted a meta­
analysis based on data from 30 independent studies, which has shown that the Ala 12 allele 
was significantly associated with higher BMI than the Pro 12 variant in obese but not in 
lean subjects (Masud and Ye, 2003). The next commonest PPARy polymorphism, the 
C1431T, has been studied in relation to glucose intolerance and obesity (Meirhaeghe et al., 
1998;Valve et al., 1999;Poulsen et al., 2003). Although not in the promoter region and 
being a synonymous polymorphism, the C l43IT has been shown to interact with the 
Pro 12Ala polymorphism, resulting in opposing associations with body weight (Valve et al., 
1999;Doney et al., 2002) and highlighting the complex nature of these polymorphisms in 
vivo.
In view of the contradictory associations between the PPARy polymoiphisms and obesity, 
the aim of this study was to clarify the situation by cairying out an association analysis 
using a large population of toddlers and preschoolers. Assessing associations between 
Prol2Ala and C143IT polymorphisms and adiposity-related phenotypes using genotype- 
and haplotype-based methods in a younger population may reveal stronger genotype- 
phenotype associations than in older populations, since the amount of opportunity for 
environmental influence is reduced.
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6.2 Methods
6.2.1 Subjects and phenotypes
The number of subjects that took part in the study, as well as information on the assessed 
adiposity-related phenotypes and the protocols used for anthropometry, aie given in 
Chapter 2 (General Methods). The anthropometric measurements assessed in the current 
analysis included: BMI, arm, waist and hip circumferences, as well as biceps, triceps, 
subscapulai" and suprailiac thickness.
6.2.2 DNA extraction, genotyping and hapiotype inference
The method used for DNA extraction from all buccal samples is given in Chapter 2 
(General Methods). Details on the set up of PCR reactions, digestions for Pro 12Ala and 
C1431T genotyping, as well as PPARy hapiotype inference are also given in the same 
section.
6.2.3 Statisticai anaiyses
Data and statistical analysis carried out are described in detail in Chapter 2 (General 
Methods).
115
6.3 Results
6.3.1 Genotyping
2102 children (1095 boys and 1007 girls) were included in the final analysis after 
excluding subjects with missing phenotypic data or DNA sample. Genotyping for PPARy 
Pro 12Ala and C1431T polymorphisms was successful in 1888 (981 boys and 907 girls) 
and 1956 (1019 boys and 937 girls) individuals, respectively. Allele frequencies and the 
observed genotype frequencies for Pro 12Ala and C143 IT ai'e given in Table 6.1. The 
population was found to be in HWE at both Prol2Ala (x^df=i)=2.29, P=0.129) and C1431T 
(X^ (df=i)=3.34, P=0.068) loci. The frequency of the Alal2 was 0.07, which was lower than 
that reported for French (0.11) (Valve et al., 1999;Doney et al., 2002;Meirhaeghe et al., 
2005b)and Finnish (0.12) (Deeb et al., 1998) cohorts and for Danish twins (MZ 0.14 and 
DZ 0.12) (Poulsen et al., 2003), but the same as the one reported in school-aged chidren 
from Greece (0.07) (Dedoussis et al., 2007) and in adults from Southern Europe (0.07) 
(Poirier et al., 2000). Similarly, the frequency of the T1431 valiant was 0.09, which was 
also lower than that reported for the French cohort (0.13) (Meirhaeghe et al., 2005b) and 
Danish twins (MZ 0.14 and DZ 0.12) (Poulsen et al., 2003). There were no significant 
differences in genotype frequencies between boys and girls for both Pro 12Ala 
(X^df=2)=0.706, P=0.706) and C1431T (xVf=2)=0.831, P=0.660) polymorphisms (data not 
shown). The Prol2Ala and C143 IT polymorphisms were found to be in LD, as it has 
previously demonstrated (Valve et al., 1999;Doney et al., 2002)(Table 6.2).
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6.3.2 GLM and one-way ANOVA analysis for PPARy Pro12Aia and 
C l 431T polymorphisms
GLM analysis was carried out in the total population to assess the main effects of the 
PPARy Prol2Ala and C1431T polymorphisms on adiposity-related phenotypes and 
whether these genetic effects were influenced by gender and/or age. GLM analysis on the 
total population has shown no significant main effects of the Pro 12Ala and C1431T 
genotypes on adiposity were observed. In addition to that, no interactions between age 
PPARy genotypes and age and/or gender were revealed.
6.3.3 PPARy genotypes and associations with obesity-reiated 
phenotypes after age and gender subgrouping
After performing the Dunn-Sidak correction for multiple testing for each age group in each 
gender, differences between the means of the Pro 12Ala genotypes for mid-upper aim 
(P=0.010) and hip (P=0.005) circumferences, as well as sum of skinfolds (P=0.011) (a 
value=0.020) in girls aged 3-4 years were found to be statistically significant and these 
associations accounted for 2.0%, 3.7% and 1.9% of the variance respectively (Appendix 1, 
Table 14). In particular, girls carrying the A lai2 allele had significantly higher mean 
values for aim (P=0.010) and hip (P=0.005) circumferences, as well as sum of skinfolds 
(P=0.011) at the age of 3-4 years (Appendix 1, Table 14) than those carrying the Pro 12 
allele. For C1431T polymoiphism, girls bearing the T1431 allele showed significantly 
higher waist circumference (P=0.018) (a value=0.020) than those carrying the C1431 
variant and this association explained 1.6% of the phenotypic variance (Appendix 1, Table 
16). However, these isolated significant findings were not reflected in the GLM analysis 
on the total population and as such they might be cases of Type I errors. The mean values
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of all anthropometric parameters for PPARy genotypes are shown in the Appendix 1 
(Tables 13 to 16).
Table 6.1 Observed PPARy genotype and allele frequencies
Polymorphism Prol2Ala C1431T
Pro/Pro 1628 C/C 1616
Observed
Genotypes
Pro/Ala 255 C/T 331
Ala/Ala 5 T/T 9
Total 1888 1956
Allele
frequencies
Prol2
Alal2
0.930
0.070
C1431
T1431
0.911
0.089
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Table 6.2 Frequencies of combined PPARy genotypes and estimated haplotypes.
Diplotypes DiplotypeDistribution Hapiotype
Hapiotype
Distribution
Hapiotype
Frequencies
Pro-C/Pro-C 1396
Pro-C/Pro-T 168
Pro-T/Pro-T 3 Pro-C 3203 0.88
Pro-C/Ala-C 105 Pro-T 179 0.05
Pro-C/Ala-T 138 Ala-C 110 0.03
Pro-T/Ala-T 5 Ala-T 148 0.04
Ala-C/Ala-C 1
Ala-C/Ala-T 3 D’=0.529
Ala-T/Ala-T 1
Total 1820
Individuals with the Pro-C/Pro-C diplotype are homozygotes for the Pro-C hapiotype. Invididuals 
with the Pro-C/Pro-T and Pro-T/Pro-T diplotypes are heterozygotes and homozygotes for the Pro-T 
hapiotype respectively, while those with the Pro-C/Ala-C and Ala-C/Ala-C are heterozygotes and 
homozygotes for the Ala-C hapiotype respectively. The Ala-T hapiotype group includes individuals 
with Pro-C/Ala-T, Pro-T/Ala-T, Ala-C/Ala-T, Ala-T/Ala-T diplotypes. The level of LD between the 
two polymorphisms is also shown.
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6.3.3 PPARy interactions with ADRB3 Arg64Trp poiymorphism
Interactive effects of the PPARy Pro 12Ala polymorphism with the ADRB3 Arg64Trp 
variant were assessed on the total population by ANOVA analysis. However, no significant 
interactions between these two polymorphisms were observed (data not shown).
6.3.4 Moduiating effect of BMi on PPARy genetic influence
Subjects of both genders were classified as overweight/obese if their BMI was more than 
the 85^  ^percentile based on the UK reference data. Separate ANOVA analysis for lean and 
obese boys and girls has revealed that BMI had no significant modulating effect on the 
influence of PPARy Pro 12Ala polymorphism on adiposity (data not shown)
6.3.5 Associations of PPARy diplotypes with adiposity-related 
phenotypes
Haplotype-based analysis for the PPARy polymorphisms did not reveal stronger 
associations than genotype-based analysis and the portion of variance explained by the 
diplotypes, although generally higher than that explained by individual genotypes (based 
on the increase in the sum of squares and as a result of the increased degrees of freedom) 
(data not shown), was not significantly larger, suggesting that most of the genetic effect 
observed is accounted for either by the individual SNPs or by variants which are in strong 
LD with these SNPs.
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6.4 Discussion
In the present study, no significant main effects of the PPARy Prol2Ala and C1431T 
polymorphisms on adiposity-related phenotypes were observed in the total population. A 
significant interactive effect of the PPARy genotypes with age and/or gender was not 
shown by GLM analysis. Previous reports mainly in adults A lai2 cairiers showed 
increased adiposity (Beamer et al., 1998;Valve et al., 1999;Poirier et al., 2000;Meirhaeghe 
et al., 2000a) are in accordance with hypothesis 4, whereas others where the Ala 12 allele 
was associated with lower BMI (Deeb et al., 1998;Ek et al., 1999) are contradictory. 
Previous studies, albeit in overweight subjects, have also reported significant associations 
between the T1431 allele and higher adiposity-related traits (Valve et al., 1999;Doney et 
al., 2002) and as such they are in agreement with hypothesis 4.
Haplotype-based analysis did not reveal stronger associations than genotype-based analysis 
and the proportion of variance explained by the diplotypes, although generally higher than 
that explained by individual genotypes (based on the increase in the sum of squares and as 
a result of the increased degrees of freedom) (data not shown), was not larger than tha= 
expected by random sampling, suggesting that most of the genetic effect observed was 
accounted for either by the individual SNPs or by variants in strong LD with them. Further 
splitting of the data according to PPARy diplotypes might have reduced the statistical 
power to detect any significant, though modest, influence of the PPARy variants on 
adiposity in the Greek population.
The frequency of the Ala 12 allele in the present study was 0.07 (Table 6.1), which is lower 
than that reported for French (0.11) and Danish twins (MZ 0.14 and DZ 0.12) (Poulsen et 
al., 2003;Meirhaeghe et al., 2005b), but similar to other Caucasian populations. Similarly, 
the T1431 allele was 0.09 (Table 6.1), which is lower than that reported for French (0.13)
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and Danish twins (MZ 0.13 and DZ 0.09). These results, however, are consistent with a 
previous study involving 11 European countries that reported an apparent north-to-south 
gradient in the Alal2 allele frequency through Europe, decreasing from 0.21 in Baltic 
countries to 0.07 in Mediterranean countries (Poirier et ah, 2000). However, the hypothesis 
for that the prevalence of the Pro 12Ala, ranging between 0.02 to 0.23 in different ethnic 
groups, (Altshuler et al., 2000;Poirier et al., 2000;Stumvoll and Haring, 2002) might affect 
the statistical power of comparisons, could not explain the inconsistent results. Similai’ 
frequencies for the rare Ala 12 allele were reported in British and French populations yet 
contrasting associations were found with BMI (Doney et al., 2002;Meirhaeghe et al., 
2005b). Similai' associations were reported with BMI in Chinese and Indian populations, 
although they possessed different Alal2 allele frequencies (Tai et al., 2004). Similarly, 
comparable T1431 allele frequencies in British and French populations found opposing 
associations with BMI (Meirhaeghe et al., 1998;Doney et al., 2002).
Although genetic influences on adiposity-related phenotypes are easier to detect and 
measure in young individuals, as the environment has less time to exert its confounding 
effects that at later ages (Maes et al., 1997), in the present study, the Pro 12Ala seemed to 
have no significant effect on adiposity-related phenotypes in early childhood, whereas in 
adults variation in PPARy was significantly associated with changes in adiposity (Masud 
and Ye, 2003). A previous study in children (4-10 years old) has also revealed that this 
polymorphism had smaller effects on BMI in younger ages compared to adult populations 
(Cecil et al. 2005), whereas Prol2Ala variant was found not to contribute significantly to 
early onset obesity in a German population (Hamann et al., 1999). These modest effects of 
genes on the development of obesity ai’e possibly attributed to gene-gene or gene- 
environment interactions. This notion is supported by two studies reporting an interaction 
effect of the Prol2Ala polymoiphism with the Tip64Ai'g variant in ADRB3 gene (which
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individually was not associated with higher body weight) (Hsueh et ah, 2001;0choa et ah, 
2004). In the present study, ANOVA tests for assessing the synergistic effect of Prol2Ala 
and Trp64Arg polymorphisms on adiposity-related phenotypes revealed no significant 
associations (data not shown). Furthermore, an interaction between nutrient and Pro 12Ala 
polymorphism on BMI has been observed with carriers of the Ala 12 allele showing higher 
BMI when the dietary polyunsaturated fat-to-saturated fat (PUFA/SFA) ratio was low and 
lower BMI when PUFA/SFA was high (Luan et al., 2001). Based on these findings, it is 
possible that in early childhood dietaiy composition is not similar to that in adults and 
especially differences in fat intake can mask potential significant effects of the PPARy 
gene on adiposity at young ages. Previous reports have also shown that weight has a 
modulating effect on the genetic influence of PPARy (Meirhaeghe et al., 1998;Ek et al., 
1999;Valve et al., 1999), with the A lai2 allele being associated with higher BMI only in 
obese subjects. In the present study, separate ANOVA analysis for lean and 
overweight/obese boys and girls (defined as a BMI for age more than the 85^  ^ percentile 
based on the UK 1990 reference data) (Chapter 3) revealed no stronger associations 
between the Ala 12 variant and BMI in overweight/obese compared to those in lean 
subjects (data not shown) and this could be attributed to BMI being a less direct 
measurement of adiposity in childhood.
In conclusion, the present study revealed that Prol2Ala and C l43IT polymoiphisms in 
PPARy had no effect on adiposity and showed no interaction with age or gender in early 
childhood. An interactive effect of the Prol2Ala and Arg64Trp polymorphisms, as well as 
a modulating influence of BMI was not confirmed. Variation in the PPARy seems not to 
contribute significantly to the high prevalence of early-onset obesity.
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Chapter 7
General Discussion
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The main objective of these series of experiments was to assess whether variation in 
selected candidate genes had an effect on adiposity-related phenotypes. In particular, the 
possible effects of polymorphic alleles in ACE, ADRBl, ADRBl, ADRB3 and PPARy on 
specific adiposity-related traits were investigated in a large, representative and genetically 
homogeneous population of toddlers and preschoolers by using genotype- and haplotype- 
based approaches. Although more than 600 genes, markers and chromosomal regions have 
been associated with adiposity-related traits (Ek et al., 1999;Rankinen et al., 2006), the 
aforementioned genes in the present study were selected because of their biological 
significance in metabolic pathways. Previous studies on these variants have been focused 
mainly in adult populations, which were selected in most of the cases on the basis of 
specific phenotypic characteristics. Reported findings on the effects of these genetic 
variants on obesity are not, however, consistent and these disparities may be attributed to 
gender, age and ethnicity differences, insufficient power, genotyping errors, as well as 
unconsidered multiple testing effects and regional variations in allele frequencies. Limited 
or no data on genes association with adiposity is available in young children, although 
there is evidence that genetic influences may be stronger in young individuals, as the 
environment has had less time to exert the confounding effects. Therefore, the series of the 
SNP-based association studies described in Chapters 4-6 aie one of the first to investigate 
such associations and to assess the effect of these variants on early childhood development. 
In the current chapter, findings from these series of experiments are described and 
conclusions are discussed along with the strengths and limitations of the present study.
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7.1 Growth and adiposity in Greek chiidren: a comparison 
with British norms
The prevalence of overweight and obesity was found to be high in the Greek children; 
13.6% and 10% of children were ovei'weight and obese respectively (Table 3.1). The rates 
of overweight and obesity were comparable to those reported in similarly aged populations 
throughout the world (Figures 3.5 and 3.6), but lower than those reported in UK or US 
(Figures 3.4 and 3.5). These results were in agreement with previously studies where 
increasing rates of obesity were recorded in Greek children and adolescents (Ek et al., 
1999;Krassas et al., 2001;Lissau et al., 2004;Magkos et al., 2005;Rankinen et al., 2006). 
Furthermore, children of the present study, irrespective of gender, were found to be 
significantly taller and heavier than their British counterparts, with these differences being 
more prominent with advancing age (Table 3.3 and 3.4). Compared to anthropometric data 
from similarly aged children from the USA, Greek children showed similar growth 
patterns (Figure 3.3). Sex-specific differences in the evolution of anthropometric indices 
were observed in both the Greek and US populations.
Due to scarcity of studies on similarly aged-children in Greece, the explanation for the 
present high rates of overweight and obesity becomes somewhat troublesome. 
Environmental factors are likely to account for the observed differences between the 
present and the reference population of a generation ago. Previous studies have indicated 
that Greek families tend to overfeed or force-feed their children, while increased adiposity 
in school-aged Greek children was attributed to reduced physical activity and increased 
sedentary behaviours rather than increased energy intake (Mamalakis et al., 2000). 
Furthermore, the fact that the average age of adiposity rebound in the present population is 
around the 4^  ^year- of age for both genders and much lower than those reported in studies
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initiated several decades ago (Rolland-Cachera et al., 1984) could suggest that modem 
environmental factors, such as TV and video games, are major contributors to the 
development of obesity. Nevertheless, (Manios, 2006) has reported for the present 
population that the mean daily intake of energy and macronutrients was found to be 
increasing with advancing age but was similar to those reported for Greek children of a 
decade ago. On the other hand, Greek children showed an increased tendency with 
advancing age for sedentary lifestyles, further supporting previous suggestions of an 
association between overweight and reduced physical activity during preschool yeais 
(Trost et al., 2003). In light of the alarming rates of overweight and obesity in toddlers and 
preschoolers of the present cohort, the significant differences in the mean values of BMI 
observed at 4-6 years of age relative to the British normative data (Table 3.3, Table 3.4) 
could be reflective of an increased adiposity, as the excess BMI SDS was comparable to 
that reported on the specific age group in previous studies (Stenhouse et al., 2004;Reilly et 
al., 2006).
7.2 Effects of polymorphisms in the selected candidate 
genes on adiposity-related phenotypes in Greek toddlers 
and preschoolers
7.2.1 ACE I/D polymorphism and adiposity-related phenotypes
According to the findings in Chapter 4, a significant main effect of the ACE I/D 
polymorphism on BMI and significant interactions between I/D genotype and age for the 
same phenotype were revealed (Figure 4.1). The ACE I-allele, being associated with lower 
circulating ACE levels, was significantly associated with higher BMI in boys and girls 1-2 
years (Figure 4.2). The findings in boys and girls aged 1-2 years are not in agreement with
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therefore, variation in these genes can have functional consequences that influence 
adiposity. In recombinant cells, the ADRB2 Glyl6 allele was found to undergo enhanced 
agonist-promoted down-regulation compared to the Argl6 allele and hence reduced 
receptor efficiency and lower lipolysis, whereas the Glu27 allele was found to undergo 
very little agonist-promoted down-regulation as compared to the Gln27 allele (Green et al., 
1994;Bachman et al., 2002). This effect of Glyl6 allele on adiposity is consistent with the 
present finding in boys and girls 4-6 years where the Glyl6 allele was associated with 
higher waist circumference (Figure 5.3). Furthermore, based on the observation that in 1-2, 
2-3 and 3-4 year's age groups, boys and girls with the Aigl6 rather than Glyl6 variant had 
higher hip circumference, it could be postulated that changes in the environment at the 4^  ^
year of age may be responsible for the altered effect of the C l6 polymorphism at older 
children (4-6 years age group). According to hypothesis 3, individuals with different alleles 
will respond differently to environmental stimuli, such as exercise and feeding For 
example, homozygotes for the Glyl6 allele will lose less weight during physical activity 
since they will respond less to the presence of catecholamines than those homozygotes for 
the Argl6 allele. Furthermore, inactivity may influence the effect of Glu27Gln 
polymorphism on adiposity in the present population. As such, although according to 
hypothesis 2 (based on in vitro studies) individuals with the Gln27 variant will be 
expected to show lower adiposity, the opposite effect observed in boys 2-3 years (Figure
5.4) (i.e. boys bearing the Gln27 allele had higher hip circumference) and in a previous 
study in adults (Meirhaeghe et al. 1999) could suggest that physical activity may be a 
significant factor in modifying genotype-phenotype relationships reported here.
In the present study no apparent effect of the ADRBl Ser49Gly and Arg389Gly 
polymorphisms and inferred haplotypes, as well as ADRB3 Trp64Arg polymorphism on 
adiposity was observed. In recombinant cells, the ADRBl Arg389 allele has been
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hypothesis 1 which was based on previous studies albeit in adolescents or adults. 
However, at 4-6 year's of age, subjects bearing the ACE D-allele (associated with higher 
circulating ACE levels) rather than I-allele had higher (but not significantly) BMI. This 
change in the direction of effect of I/D polymorphism was apparent mainly in girls (Table 
4.1) and was in accordance with previous studies in teenagers and adults that have reported 
increased adiposity in DD individuals compared to those with the II or ID genotypes 
(Hypothesis 1). The age, at which this alteration in the effect of ACE I/D polymorphism 
on adiposity was observed, coincided with the age at which BMI increased after its 
developmental nadir. These results suggested that the ACE I/D polymorphism is associated 
with developmental changes in adiposity during eat'ly childhood with age and possibly 
gender being important factors in modifying genotype-phenotype relationships.
There is evidence that a local angiotensin II generating system independent of circulating 
RAS components exists in several tissues, such as heart, brain, kidney, pancreas and 
adipose tissue (Lavoie and Sigmund, 2003), where production of this potent 
vasoconstrictor results in decreased blood flow locally (Goossens et al., 2003). Although 
an increase in local blood flow due to angiotensin II remains controversial (Goossens et al., 
2004), such an effect would be in contrast with the present finding of the I-allele being 
associated with higher adiposity, as higher levels of circulating ACE (associated with the 
D-allele) would result in an excess secretion of angiotensin II, which will decrease 
adipose-tissue blood flow and consequently lead to increased lipogenesis and fat storage in 
adipocytes (Jones et al., 1997). Furthermore, it is known that angiotensin II induces the 
release of noradrenaline (Goossens et al., 2004), which stimulates the a2-adrenergic 
receptors that inhibit lipolytic action (Lafontan and Berlan, 1993). Increased bradykinin 
inactivation could also play a role in adipocyte metabolism. This finding in very young 
boys supports the notion of a possible lipolytic action of angiotensin II, which is based on
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the fact that stimulation of ATI receptor by angiotensin II leads to increased levels of 
cellular calcium concentrations associated in adipocytes with increased lipolysis 
(Strazzullo and Galletti, 2004). However, the hypothesis of a putative role of angiotensin II 
in lipolysis has not yet been confirmed in humans (Townsend, 2001). Furthermore, it has 
been shown that the two angiotensin II receptor subtypes (ATI and AT2) are differentially 
expressed in renal and vascular tissues during the first 2 years of life (Viswanathan et ah,
2000) and that AT2 is a natural antagonist for ATI (Danser, 2003). Therefore, it could be 
postulated that overexpression of AT2, which results in downregulation of ATI 
expression, could induce vasodilation and concomitantly have an effect in fat 
accumulation. This notion could explain in part the association of the I-allele (lower levels 
of ACE) with increased adiposity in very young boys and girls in the present study, since 
the actions of ATI, through which angiotensin II exerts its effects, may be counteracted by 
AT2 receptor.
The ACE I/D polymorphism has been associated in an additive manner with almost half of 
the variance in semm ACE activity (Rigat et al., 1990) in Caucasian populations (Tiret et 
al., 1992). The majority of the genetic effects observed in the present study are accounted 
for either by the I/D polymorphism or a variant in strong LD with it (Tiret et al., 1992). 
Two previous studies (Zhu et ah, 2000;Cox et ah, 2002) have suggested that such a 
functional polymorphism is the rs4363 (A22982G). This variant has been shown to be a 
better candidate for circulating ACE levels than the I/D polymorphism in African 
populations, where it was found not to be in complete LD with the I/D polymorphism. In 
Caucasian populations, though, the FD polymorphism is in almost complete LD with this 
functional variant (Soubrier et al., 2002) and as such, is a sufficiently good marker of 
circulating ACE activity. A previous study on Greek teenagers has also shown the degree
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of association between the ACE FD polymorphism and adiposity-related phenotypes, was 
not exceeded by other ACE polymoiphisms (Moran et ah, 2005).
7.2.2 ADRB polymorphisms and adiposity-related phenotypes
The results of the experiments described in Chapter 5 indicated a significant main effect of 
the ADRBl Glyl6Arg polymorphism on waist and hip circumferences and a significant 
interaction of the C l6 genotypes with age for the same phenotypes. The ADRBl Gly 16 
allele (the receptor with this allele showing enhanced agonist-promoted downregulation) 
was associated with significantly higher waist circumference at the age of 4 years in boys 
and girls (Figures 5.1 and 5.3) and this finding was in accordance with hypothesis 2 and 
with previous studies in adolescents and adults. Furthermore, a significant main effect of 
ADRBl Glu27Gln polymorphism on hip circumference and significant interactions with 
both age and gender for the same phenotype were revealed. In boys aged 2-3 years, the 
Gln27 allele was significantly associated with higher hip circumference (Figure 5.4); 
however this association was not in agreement with hypothesis 2, which was based on in 
vitro studies and previous association studies in adults. These results suggested that the 
effects of ADRBl C l6 and C27 polymorphisms are influenced by age and gender, while 
variation in ADRBl C49 and C389, as well as in ADRB3 C64 has no effect on adiposity- 
related phenotypes in early childhood.
The biological mechanisms through which variation in the ADRB genes influence adiposity 
have yet to be elucidated. Catecholamines effects are mediated by binding to lipolytic beta- 
adrenoceptors and anti-lipolytic alpha2-adrenoceptors of white adipose cells (Lafontan and 
Berlan, 1993). Stimulation of ADRBs in adipose tissue leads to activation of the adenylyl 
cyclase and subsequent increase in cAMP, which promotes lipolysis and thermogenesis 
(Bachman et al., 2002;Gonzalez Sanchez et al., 2003;Lowell and Bachman, 2003) and
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associated with increased adenylyl cyclase activity and intracellular concentration of 
cAMP due to enhanced receptor-Gs interaction compared to the Gly389 receptor (Maqbool 
et al., 1999;Mason et al., 1999). Despite the reported effects in cell systems, this 
polymorphism has not been associated with obesity (Ryden et al., 2001;Tafel et al., 
2004;Ellsworth et al., 2005), consistent with the present findings, and had no apparent 
effect on catecholamine-induced lipolysis (Ryden et al., 2001). Furthermore, the ADRB3 
Trp64Arg polymorphism is located either in the first transmembrane domain or the first 
intracellular loop of the ADRB3 receptor (Small et al., 2003), where aminoacids residues 
are thought not to be important for the trafficking of the receptor to the cell surface or its 
coupling to Gs proteins (Strosberg, 1997). In addition to that, in vitro studies have shown 
conflicting results regarding the effects of this polymorphism on the pharmacological and 
functional properties of the receptor raising arguments for or against the involvement of 
the Arg64 receptor in obesity (Candelore et al., 1996;Pietri-Rouxel et al., 1997). Finally, it 
is known that adipocytes from normal children have a higher content of alpha2- 
adrenoceptors than adipocytes from adults (Lafontan and Berlan, 1993) and therefore, a 
preferential stimulation of these anti-lipolytic receptors rather than ADRBs can inhibit 
lipolysis and mask the possible effects of ADRBs on adiposity in early childhood.
7,2.3 PPARy polymorphisms and adiposity-related phenotypes
According to the findings in Chapter 6, no significant effects of PPARy Pro 12Ala and 
C1431T polymorphisms (i.e. Alal2 and T1431) on adiposity or significant interactions 
with age and/or gender were revealed in the total population. These findings were 
consistent with previous studies in children (Hamann et al., 1999;Cecil et al., 2006), where 
these polymorphisms had smaller or no effect on adiposity and contradictory to other 
studies, mainly in adult populations, where the Ala 12 and/or the T4131 alleles were 
associated with increased adiposity (Beamer et al., 1998;Valve et al., 1999;Meirhaeghe et
132
al., 2000a;Doney et al., 2002). Furthermore, a previously reported modulating effect of 
weight on Pro 12Ala polymorphism (Meirhaeghe et al., 1998;Ek et al., 1999;Valve et al., 
1999) or an interactive effect of this polymorphism with the ADRBS Arg64Trp variant was 
not cofirmed in the present population. These findings collectively could indicate that 
variation in PPARy does not contribute to increased adiposity observed in early childhood 
but it is possible that the impact of these variants on adiposity-related phenotypes becomes 
more apparent later in life.
Although functional differences between the Pro 12 and Alai 2 PPARy receptors (Deeb et 
al., 1998) could suggest that the Pro 12Ala polymorphism is the causative variant, the 
observed effects of this polymorphism on adiposity in the present and previous studies may 
be due to a variant in LD with it. A polymorphism in the promoter of PPARy2, which has 
been previously tested along with the Pro 12Ala polymorphism by haplotype-analysis for 
significant associations with obesity (Deeb et al., 1998;Meirhaeghe et al., 2005b) and 
metabolic syndrome (Meirhaeghe et al., 2005a), was found to be in almost complete LD 
with the Pro 12Ala in a Caucasian population (Meirhaeghe et al., 2005b). hi the same 
population, the synonymous C143 IT polymorphism was in LD at 66-69% with the PPARyz 
promoter and Pro 12Ala polymorphisms (Meirhaeghe et al., 2005b). The PPARy2  promoter 
and Pro 12Ala polymorphisms were associated with increased risk for metabolic syndrome 
only in the presence of a C1431 allele in the haplotype (Meirhaeghe et al., 2005a). 
Furthermore, C143 IT was found to be a better predictor of fasting insulin levels and 
insulin sensitivity than the Pro 12Ala polymorphism (Moffett et al., 2005), while an 
opposing interaction of these two polymorphisms with BMI has been observed in adults 
(Doney et al., 2002). Collectively these findings could suggest that the non-functional 
C l43IT polymoiphism may in tight LD with a functional variant in the PPARy or in a 
linked gene. In the present study, haplotype analysis revealed no interaction between the
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Pro 12Ala and C l43IT polymorphisms with any of the adiposity-related phenotypes. 
Nevertheless, a systematic screening of 70 diabetic individuals did not reveal any 
additional missense mutations in the PPARy gene suggesting that a functional variant may 
be in a nearby gene (Altshuler et al., 2000).
7.2A Common findings for the effects of variants in the seiected 
candidate genes on adiposity-reiated phenotypes
The series of experiments described in Chapters 4-6 assessed the effect of individual 
polymorphisms in selected candidate genes on a number of adiposity-related phenotypes. 
A large number of familial and twin studies have shown that there is a strong contribution 
of heredity in obesity (Bouchai’d and Perusse, 1988), which is likely to be the result of a 
number of predisposing alleles, each conferring a small increase in the risk to the 
individual but a significant cumulative contribution to the development of obesity (Marti et 
al., 2004;Rankinen et al., 2006). In the present study, genetic variations in the selected 
candidate genes accounted for 1-6% (for example Figures 4.2 and 5.3) of the observed 
variance in the adiposity-related phenotypes for significant gene associations (as 
determined by ANONA). Thus, the influence of these polymorphisms on adiposity was 
found to be relatively small, as expected for a complex disease and such a polygenic effect 
was also reflected by the distributed effect of the genotypes on the whole phenotypic range 
(for example Tables 4.2 and 4.4). In the present study, a cohort of toddlers and 
preschoolers was chosen in an attempt to characterise the genetic influence on adiposity, 
since longitudinal twin studies have shown that this influence is easier to detect and 
measure in younger populations, as the environment has less time to exert confounding 
effects than at later ages (Maes et al., 1997). Findings of the present study further 
supported the notion of a more pronounced genetic effect on adiposity in young children.
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For example, the ACE I/D polymorphism explained a larger proportion of variance for 
BMI in the younger boys and girls (Figure 4.2; ACE FD genotype explaining 6.4% of 
phenotypic variance) than in Greek adolescents (the proportion of variance explained in 
that study was 0.8% for BMI) (Moran et al., 2005). However, a stronger effect of 
polymoiphisms in ADRB and PPARy in the present young cohort compared to that in adult 
populations was not observed, offering support to previous suggestions that the effect of 
these genes may be age-specific and dependent on their age-related variability in exposure 
to environmental factors that predispose to their expression (Maes et al., 1997).
Previous reports have revealed gender-specific effects of the selected variants on adiposity 
(Beamer et al., 1998;ODonnell et al., 1998;Meirhaeghe et al., 2000b) and maiked 
differences in body composition during the first years of life (Fomon et al., 1982). The 
present study attempted to assess possible interactions of the genotypes of interest with 
gender by carrying out GLM analyses in the whole series of experiments. Gender-specific 
effects were demonstrated mainly for the ADRBl C l6 and C27 polymorphisms assessed in 
the present population. Gender-specific effects may be the result of the dependency of 
certain genetic determinants on other cofactors such as hormones or other genes for their 
function and the influence of these cofactors may become detectable only later in life. 
Nevertheless, previous studies have shown that there are gender-specific differences in 
sympatho-adienal activity in preschool children, with boys excreting higher levels of both 
catecholamines than girls (Lundberg, 1983) and these differences could account for the 
gender-specific effects of the ADRB variants in adiposity regulation.
Haplotype-based analysis did not reveal stronger associations than genotype-based analysis 
and the portion of variance explained by the diplotypes, although generally higher than that 
explained by individual genotypes (based on the increase in the sum of squares and as a 
result of the increased degrees of freedom) (data not shown), was not significantly larger.
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This could suggest that the haplotypes mediate the majority, if not all, of any effect they 
have through the individual SNPs and that if the haplotypes have a significantly increased 
effect on the phenotypes of interest it is small enough that this study did not have the 
statistical power to identify, after splitting in many genetic sub-groupings. Several studies 
have advocated that genotyping of more than one polymorphism in a gene allows the 
inference of haplotypes that represent the majority of variation along the complete length 
of gene and they are better tools for assessing genetic effects on the development of 
complex traits (Akey et al., 2001). The present study did not provide further evidence for 
the greater analytical power of haplotypes. However, the present findings did suggest a 
dependency of haplotype-based approaches on sample size that is proportional to the 
strength of the effect under investigation.
7.3 Strengths and weaknesses of the study
Validity is the “degree to which the inference drawn from a study is warranted when 
account is taken of the study methods, the representativeness of the study sample and the 
nature of the population from which it is drawn”. Minimizing bias and accounting for 
confounding factors are crucial for the validity of association studies (Akey et al., 
2001;Zaccai, 2004).
7.3.1 Selection of sample and reiiabiiity of the measurements
7.3.1.1 Measurement error
Measurement bias can affect validity and can arise from the choice of the instruments used 
for this purpose, as well as the assessor’s experience and the subject’s cooperation. In the 
present study, all study sites used the same measuring equipment and procedures.
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Measurements were taken by two well-trained members, which were referred as leading 
and assisting observer, respectively. The role of the assisting observer was to help position 
the child correctly, while the leading observer recorded the measurements (Manios, 2006). 
In that way, measurements errors due to lack of experience of the assessor and incorrect 
position of the subject were limited. Furthermore, the measuring equipment used was 
highly accurate to avoid the systematic error arising from inaccurate measurement of the 
different subphenotypes of interest and reduce the contribution of noise to variability (i.e. 
increase the fraction of variation explained by genetic factors). In the present population, 
children were found to be significantly taller compared to British counterparts (Tables 3.3 
and 3.4, Figure 3.2). Although it could be argued that there was a systematic error in the 
measurement of this subphenotype in the present cohort, comparison of the mean height 
values in Greek children with those reported in a representative sample of preschool 
children (2-6 years) from Cyprus (Akey et al., 2001;Savva et al., 2005) revealed no 
differences in height between these two populations. Furthermore, the similarities in the 
evolution of anthropometric indices (waist and arm circumferences, as well as triceps and 
subscapular skinfolds) between Greek children of the present study and US children 
(Figure 3.3) could provide more evidence for the plausibility of these measurements.
7.3.1.2 Choice of study population
Selection of subjects is known to have an impact on the conclusions of a study (Zaccai,
2004). In the present study, subjects were sampled from randomly selected public and 
private nursery schools, as well as day-care centers within five counties in Greece (Manios, 
2006). Given the fact that these counties are widely distributed across Greece and their 
overall local population comprises 70% of the total Greek population (Manios, 2006), the 
present cohort could be considered as a representative sample of Greek toddlers and 
preschoolers. However, not all Greek children attend nursery or day-care centers at that
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age and as such children included in the study aie likely to differ from non-participants 
(children that do not attend nursery) in a number of important ways, such as levels of 
physical activity (organized activities in the school), as well as differences in the health 
knowledge and practices between parents and caregivers that exert an increased control in 
food intake at that age. Therefore, it is possible that the sample of the present study is 
representative of the nursery/carecentre preschoolers rather than the total Greek population 
of this age. Furthermore, the higher rates (95%) of participation for rural areas compared to 
those in urban areas in the present study may have also introduced bias. However, a 
previous study in preschoolers (2-6 years) has shown that area of residence or parental 
education level was not significantly associated with obesity status at that age (Savva et al.,
2005). Finally, the population studied here is genetically homogeneous (by ethnicity) and 
as such pitfalls due to population stratification ai*e diminished.
7.3.2 GLM analysis on total population versus gender- and age- 
stratified ANOVA analysis: power of the study
Previous studies have shown effects of gender and/or age on the association of ACE FD, 
ADRBl C16 and C27, as well as PPARy Pro 12Ala and C1431T polymorphisms on 
adiposity-related phenotypes. For example, Ellsworth et al. (2002) has used gender and 
age-stratified analysis to account for growth and developmental effects in the investigation 
of the effects of the ADRBl gene on childhood obesity. In the present study, GLM 
analysis has been carried out initially in the total population (boys and girls together) to 
assess possible associations between genetic variants and adiposity-related phenotypes and 
to test for possible interactions between gender and/or gender and genotypic effects on 
phenotype. Results from this GLM ANOVA analysis were compared to those found in the 
one-way ANOVA analysis for each gender and age group.
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A key determinant in the quality of an association study is sample size. Studies should be 
powered to detect the small effects of common variants involved in complex traits, such as 
obesity (Hattersley and McCarthy, 2005). Based on this fact, GLM ANOVA analysis was 
caiTied out in the total population (2102 children) and provided evidence of genotype 
interactions with age and/ or gender which could indicate that carrying out ANOVA 
analysis in the total population can mask potential significant genotype-phenotype 
interactions. For example, GLM analysis has shown that the C27 genotypes interact with 
both age and gender for hip circumference and, as such, dividing the population in boys 
and girls, as well as age groups becomes essential. As such, significant associations 
between C27 genotype and hip circumference were observed only in boys aged 2-3 years 
rather than the total population. Therefore, although examining the total population 
increases the power of the study, sub-grouping is necessary when age and/or gender are 
shown to be significant factors in modifying the genotype-phenotype associations. On the 
other hand, when no significant interactions between gender and/or age aie found by 
GLM-ANOVA analysis, dividing the population in genders and age groups for further 
analysis may lead to false positive genotype-phenotype associations. For example, 
although no significant interactions were found between age and/or gender and PPARy 
C1431T variants, further one-way ANOVA analysis stratified by gender and age revealed 
significant associations between the T1431 allele and higher adiposity measurements only 
in girls 3-4 years suggesting that these may be the result of a Type I error. In some cases, 
however, it may be that two variables do interact, but the study lacks the power to detect an 
interaction. For example, it has been shown that the ACE FD polymoiphism has a gender 
effect on the influence of genotype in children 11-18 years (Moran et al., 2005). In the 
present study, GLM analysis has shown an interaction between age and FD genotype but 
no interaction between gender and genotype. This could suggest that either the relationship
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between gender and FD genotype is truly insignificant or that the present study failed to
detect the significance of gender (a Type II error).
Association studies should take into consideration possible age and/or age effects that can 
influence genetic effects on phenotypes. Furthermore, subdividing a cohort by gender or 
age could easily mask the small effects of genes on the phenotype in question and the 
presence of such effects may have contributed to the shortcomings of previous 
investigations. Although gene association studies require, by design, large sample sizes for 
genuine findings (Clayton and McKeigue, 2001), analyzing the total population instead of 
gender and/or age subgroups can increase the likelihood of type II errors so that real 
associations are missed.
Despite the limitations mainly associated with the design of the study, association studies 
based on candidate-gene approaches offer a potentially powerful tool in identifying genetic 
variants that influence susceptibility to obesity (Risch, 2000). According to the human 
Obesity Map, the number of studies reporting associations between genetic variants in 
specific genes and obesity-related phenotypes increases each year with 358 findings of 
positive associations with 113 candidate genes being reported in the 2004 update (Pemsse 
et ai., 2005) and 429 findings of associations with 127 candidate genes in the 2005 update 
(Rankinen et al., 2006). Studying the impact of these genetic variants on phenotypic 
outcomes of interest enhances the evidence of causality, while knowledge of the 
functionally significant variants may also aid in prediction and prognosis, as well as in 
designing drug therapies and intervention. Results from candidate-gene based approaches 
complemented by analyses quantifying protein expression in several tissues under different 
environmental influences can provide new insights into the understanding of energy 
homeostasis and management of obesity.
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7.4 General conclusions
From the findings of the aforementioned experiments the following conclusions can be 
made:
I. From the results of the study assessing the developmental changes in adiposity in a 
large, representative sample of Greek toddlers and preschoolers, as described in 
Chapter 3, the following conclusions can be made:
a. The present study was carried out on a large cohort of toddlers and
preschoolers from Greece and a wide range of adiposity-related phenotypes 
were included in the analyses. As such, this is the first study with such a 
wide range of adiposity-related phenotypes available on toddlers and 
preschoolers.
b. The rates of overweight in the present population were found to be 
comparable to the high rates reported in other studies conducted in 
representative populations worldwide. Considering overweight and obesity 
prevalence, the present population had comparable rates with those in other 
European and Australian preschool children, but still lower than those 
reported in UK and the USA. Relative to normative data from British
children of two decades ago, Greek childien were much taller and
concomitantly heavier suggestive of improved nutritional status and 
accelerated growth and they showed a tendency for increasing BMI with 
advancing age. The excess BMI levels were similar to those found in 
modern preschoolers and most likely attributed to increased adiposity.
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c. Greek children of the present population were characterised by an early 
adiposity rebound possibly attributed to increased body fat in girls and 
increased bone and/or muscle mass in boys. The age- and gender- related 
differences in the evolution of several adiposity-related phenotypes were 
similai" to those observed in similarly aged US children, suggesting similar 
growth patterns among preschoolers.
n. From the series of experiments assessing the influence of variation in ACE, ADRB and 
PPARy genes on adiposity-related phenotypes, as described in Chapters 4-6, the 
following conclusions can be made:
a. The present findings advocated a stronger effect of the ACE FD
polymorphism in Greek toddlers and preschoolers than that reported in 
adolescent and adult populations. The ACE I-allele was significantly 
associated with higher scores for BMI in younger boys and girls in contrast to 
hypothesis 1, but with lower measures at the age of 4 confirming the 
significant interaction between I/D genotypes and age. The I/D
polymorphism, being a sufficiently good marker of circulating ACE activity, 
was associated with developmental changes observed during early childhood. 
The age- and possibly gender- related significant associations suggested that 
the effect of ACE FD polymorphism on adiposity is possibly modulated by 
gene-environment interactions.
b. The effects of ADRBl variants on adiposity were modest and manifested in a
gender- and age-specific manner, whereas polymorphic variants of ADRBl
and ADRBS genes were found to have no influence on adiposity-related 
phenotypes or to interact with age/gender in early childhood. A significant
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interaction between C16 genotypes and age was observed with Glyl6 carriers 
showing higher adiposity. This effect was in accordance with hypothesis 2. A 
significant interaction was also revealed between C27 genotypes and age, as 
well as gender with the Gln27 allele being associated with higher adiposity 
only in boys 2-3 years. This effect was in contrast to hypothesis 2, but it could 
be explained by hypothesis 3, which supports an age-related variability to 
environmental stimuli important for the function of ADRB2 receptor. 
Although haplotype-based analysis did not reveal stronger associations 
compared to individual SNPs, Gly 16Gln27/Gly 16Gln27 and 
Argl6Gln27/Glyl6Gln27 diplotypes were associated with higher adiposity 
compared to the Gly 16Glu27/Gly 16Glu27 suggesting a possible dominant 
effect of the ADRBl Glu27Gln polymorphism on the receptor’s function.
c. Polymorphic variants of the PPARy gene had no significant effect on 
adiposity in eai'ly childhood. A synergistic effect of PPARy Pro 12Ala and 
ADRBS Arg64Trp polymorphisms or a modulating effect of BMI on the 
genetic influence of the Pro 12Ala on adiposity-related phenotypes was not 
confirmed. Haplotype-based analysis revealed no stronger associations 
compared to individual genotypes. Variation in PPARy is not a significant 
contributor to childhood obesity. The lack of significant associations in 
children, but not in adults, could be attributed to age-related differences in fat 
intake, since fatty acids derived from nutrition are the main governors of 
PPARy activity.
d. Findings from the present study further supported previous suggestions of a 
more pronounced genetic effect on adiposity in young children than adults. 
This effect was only observed for ACE I/D polymorphism, but not for ADRB
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and PPARy variants indicating that genetic influence can be age-specific and 
expression of these genes may be dependent on the age-related variability in 
exposure to environmental factors. The observed gender-specific effects of 
the selected genetic variants on adiposity may also reflect gender-specificity 
in gene expression that results in differences in adipose tissue metabolism 
between boys and girls.
e. Haplotype-based analysis did not produce markedly stronger associations 
relative to individual SNPs and the proportion of variance explained by 
haplotypes, although generally larger, was not significantly greater than that 
expected by random-sampling effects, suggesting that most of the genetic 
effect observed accounted for either by the individual SNPs or by variants in 
strong LD with them. This is not, however, against the robustness of 
haplotypes in analysing complex traits and it could indicate that the present 
population was probably not large enough to assess the modest genetic effects 
on phenotypes when so many different genetic subgroups were created, 
suggesting a dependency of haplotype-based approaches on sample size.
f. Association studies can lead to misleading results, if not designed well. Bias 
and confounding factors should be taken into consideration for maximizing 
the study’s validity. Dividing the population in many subgroups when not 
necessary can increase the risk of Type I errors, while examining the total 
population without taking into consideration confounding factors, such as age 
and gender can result in missing genuine associations. Discussing significant 
associations with respect to their biological plausibility, as well as reporting 
any potential impact of limitations on the findings is in keeping with good
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scientific practice and can help assess the validity or bias of significant 
findings.
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List of appendices
Appendix 1
ANOVA analysis for associations between adiposity- 
related phenotypes and variants of the ACE, ADRBl, 
ADRBl, ADRBS and PPARy gene polymorphisms in 
different age groups for boys and girls.
ANOVA analysis for associations between adiposity- 
Appendix 2 related phenotypes and ADRBl and PPARy diplotypes in
different age groups for boys and girls.
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Appendix 1: ANOVA anaiysis for associations between 
adiposity-reiated phenotypes and variants of the A C E ,  
A D R B l ,  A D R B 2 ,  A D R B 3  and P P A R y  gene polymorphisms 
in different age groups for boys and giris.
Mean values and 95% CIs ai'e given for the measured parameters for each genotype at 
different ages in boys and girls. Associations between the genotypes and the adiposity- 
related phenotypes in different age groups were analysed by ANOVA. Data have been 
normalised, then analysed, then back-transformed to values appropriate for each age group. 
For each test, the percentage of variance explained by ANOVA (V) and the probability (P) 
are given. P values are given to three significant figures. Tests significant before (P<0.05), 
but not after Sidak correction are indicated in italics; tests that remained significant after 
Sidak correction for each age group are indicated in bold. N values indicate group sizes for 
the individual genotypes.
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Table 1 Associations of adiposity-related phenotypes with ACE I/D polymorphism in boys.
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BMI
11=18.41 (17 .51 to 19 .50)  
1 0 = 1 6 .6 2 (1 6 .2 5  to 17 .02) 
0 0 = 1 6 .4 6  (16 .10  to  16 .85) 
V = 1 6 .6 % , P =0 .001  
Sum of Skinfolds 
11=29.80 (25 .72  to 34 .14)  
1 0 = 2 5 .5 9  (24.01 to 27 .22)  
0 0 = 2 6 .1 4  (24 .24  to 28 .11)  
V = 0 % ,P = 0 .1 0 9  
BMI
n = 1 6 .3 4  (15 .76  to 16.95) 
1 0 = 1 6 .4 3  (16 .16  to 16.69) 
0 0 = 1 6 .2 7  (16 .02  to 16.53) 
V =0,3% , P =0 .725  
Sum of Skinfolds
11=25.39 (22.91 to 26 .31)  
10= 2 5 .6 1  (24 .55 to 26 .76) 
0 0 = 2 5 .8 8  (24.81 to 27 .05)  
V =0% , P =0.487
Arm Circumference
U = 15 .90  (15 .08  to 16 .64) 
1 0 = 1 5 .5 7  (15 .3 0  to 15 .84 )  
0 0 = 1 5 .5 9  (15 .23  to 15.94) 
V = 1 .1 % ,P = 0 .6 2 7
Waist Circumference
n = 4 7 .5 0  (46 .02  to 48 .9 9 )  
1 0 = 4 6 .5 2  (45 .47 to 47 .58 ) 
0 0 = 4 6 .7 4  (45 .98  to 47 .51 ) 
V = 1 .2 % ,P = 0 .6 1 2
Hip Circumference
11=50.51 (49 .26  to 51 .75) 
1 0 = 4 9 .3 1  (48 .19  to 50 .42)  
0 0 = 4 9 .0 9  (48 .33  to 49 ,85 )  
V =2.4% , P =0 .368
Arm Circumference
n =  16.00  (15 .62  to 16.41) 
1 0 = 1 6 .0 3  (1 5 .8 2  to 16.24) 
0 0 = 1 5 .9 3  (15.71 to 16 .16) 
V =0.2% , P =0.821
Waist Circumference
n = 4 9 .8 9 (4 8 ‘.66  to 51 .19)  
1 0 = 4 9 .7 0  (49 .13  to 50 .29)  
0 0 = 4 9 .2 2  (48 .65 to 49 .80 )  
V =0.8% , P =0.415
BMI
11=15.88 (15 .55  to 16.23) 
1 0 = 1 6 .0 2  (15 ,94  to 16.24) 
0 0 = 1 5 .9 7  (15 .74  to 16.21) 
V =0.1% , P = 0 .777  
Sum of Skinfolds
11=23.43 (22 .10  to 24 .89 )  
10= 25 .21  (24 .85 to 26 .14)  
0 0 = 2 4 .7 9  (23 .95  to 25 .68)  
V=0% , P = 0 .084
Arm Circumference
11=16.30 (15 .99  to 16.64) 
1 0 = 1 6 .4 1  (16 .33  to 16.61) 
0 0 = 1 6 .2 6  (16 .05  to 16.47) 
V =0.3% , P = 0 .587
Waist Circumference
11=51.06 (50 .23  to 51 .93)  
1 0 = 5 1 .4 4  (51 .22  to 51 .98 )  
0 0 = 5 1 .0 4 (5 0 .5 1  to 51 .59)  
V =0.3% , P =0.556
BMI
11=15.98 (15 .59  to 16.40) 
1 0 = 1 5 .9 0  (15 .65  to 16.16) 
0 0 = 1 5 .9 0  (15 .62  to 16.19) 
V=0% , P =0.948  
Sum of Skinfolds
11=23.76 (22 .32  to 25 .39 )  
1 0 = 2 3 .4 6  (22 .60  to 24 .38)  
0 0 = 2 3 .5 5  (22 .53 to 24 .65)  
V =0% , P = 0 .9 4 7 _________
Arm Circumference
11=16.79 (16 .38  to 17.23) 
1 0 = 1 6 .6 5  (16 .43  to 16.89) 
0 0 = 1 6 .8 3  (16.61 to 17.07) 
V =0.4% , P =0.553
Waist Circumference
11=53.27 (52 .21 to 54 .40) 
1 0 = 5 2 .9 6  (52.31 to 53 .64)  
0 0 = 5 2 .8 2  (52 .09  to 53 .58)  
V = 0 .1 % ,P = 0 .8 0 4
Hip Circumference
n=53.21 (52.19 to 54.27) 
10=52.87 (52.24 to 53.53) 
00=52.45 (51.85 to 53.06) 
V=0.7%, P=0.446
Hip Circumference
11=54.89 (54 .08  to 55 .73)  
1 0 = 5 5 .1 8  (54 .95  to 55 .75)  
0 0 = 5 4 .6 7  (54 .06  to 55 .30)  
V =0.3% , P = 0 .484
Hip Circumference
11=57.58 (56 .27  to 58 .98) 
1 0 = 5 7 .2 9  (56 .58  to 58 .03) 
0 0 = 5 7 .4 5  (56.71 to 58 .23 ) 
V =0.1% , P=0.911
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Table 2 Associations of adiposity-related phenotypes with ACE I/D polymorphism in girls.
II
BMI
11=17.04 (16.31 to 17.87) 
1 0 = 1 6 .4 0 (1 6 .0 2  to 16.80) 
0 0 = 1 7 .0 8  (16 .54  to 17.67) 
V =5.4% , P = 0 .092  
Sum of Skinfolds 
11=25.24 (22 .93 to 27 .85) 
1 0 = 2 5 .6 2  (23 .95  to 27 .43) 
0 0 = 2 4 .6 6  (22 .85  to 26 .64)  
V =0.3% , P=0.771
Arm Circumference
11=15.38 (14 .83  to 15.92) 
1 0 = 1 5 .3 8  (15 .05  to 15.70) 
0 0 = 1 5 .2 9  (14 .68  to 15.88) 
V = 0.1 % ,P = 0 .9 5 1
Waist Circumference
11=47.05 (45 .35 to 48 .91 )  
10= 4 5 .7 3  (44 .87  to 46 .62 )  
0 0 = 4 6 .1 4  (44 .86  to 47 .5 1 )  
V =1.8% , P = 0 .444
Hip Circumference
11=48.28 (45.71 to 50 .95)  
1 0 = 4 9 .2 9  (4 8 .2 2  to 50 .39 )  
0 0 = 4 9 .0 0  (47.61 to 50 .42)  
V =0.8% , P = 0 .715
k g
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BMI
11=16.27 (15 .75  to 16.81) 
1 0 = 1 6 .3 6  (16 .03 to 16 .70)  
0 0 = 1 5 .9 6  (15 .69  to 16.25) 
V =1.6% , P = 0 .204  
Sum of Skinfolds
11=28.87 (26 .00  to 31 .98)  
1 0 = 2 6 .5 0  (25 .16  to 27 .94)  
0 0 = 2 7 .3 2  (26 .00  to 28 .74)  
V =0% , P =0.286
Arm Circumference
11=16.32 (15 .78 to 16 .89) 
1 0 = 1 5 .9 4  (1 5 .6 4  to 16 .25) 
0 0 = 1 6 .0 6  (1 5 .8 0  to 16.32) 
V =0.9% , P = 0 .424
Waist Circumference
11=50.14 (48 .74  to 51 .56)  
1 0 = 4 9 .3 5  (48 .53 to 50 .17)  
0 0 = 4 9 .5 1  (48 .84  to 50 .18)  
V =0.6% , P =0.578
g
3 1
I ® 'o
Îo
BMI
11=16.39 (16 .03 to 16.76) 
1 0 = 1 5 .9 9  (15 .77  to 16.22) 
0 0 = 1 5 .8 3  (15 .58  to 16.09) 
V =1.5% , P = 0 .064  
Sum of Skinfolds
n = 2 8 .8 2  (27 .02  to 30 .79) 
10= 2 7 .9 1  (26 .85  to 29 .03)  
0 0 = 2 7 .2 0  (26 .18  to 28 .27) 
V =0.6% , P =0.295  
BMI
n=15.41 (15.01 to 15.84) 
10=15.89 (15.63 to 16.16) 
00=16.16 (15.87 to 16.47) 
V=2.5%, P=0.018 
Sum of Skinfolds 
11=26.21 (24 .88  to 27 .07)  
10= 2 8 .0 1  (26 .86  to 29 .26)  
0 0 = 2 9 .0 0  (27.56 to 30 .58)  
V =1.7% , P = 0 .069
Arm Circumference
11=16.72 (16 .36  to 17.09) 
1 0 = 1 6 .4 0  (16 .18  to 16.61) 
0 0 = 1 6 .3 0  (16 .07  to 16.52) 
V = 1 .0 % ,P = 0 .1 4 7
Waist Circumference
11=52.34 (51 .25  to 53 .47)  
1 0 = 5 1 .4 8  (50 .87  to 52 .11)  
0 0 = 5 1 .0 3  (50 .36  to 51 .71)  
V = 1.1 % ,P = 0 .1 2 5
Arm Circumference 
n=16.58 (16.20 to 16.99) 
10=16.93 (16.67 to 17.20) 
00=17.32 (17.04 to 17.60) 
V=2.7%, P=0.013
Waist Circumference 
n=51.52 (50.45 to 52.67) 
10=52.93 (52.27 to 53.61) 
00=53.97 (53.21 to 54.77) 
V=4.0%, P=0.001
Hip Circumference
11=53.02 (51 .55  to 54 .62)  
1 0 = 5 3 .1 9  (52 .4 0  to 54 .01)  
0 0 = 5 2 .6 6  (52 .06  to 53 .2 8 )  
V =0.5% , P = 0 .622
Hip Circumference
11=56.73 (55 .56  to 57 .97)  
1 0 = 5 5 .2 5  (54 .68  to 55 .84)  
0 0 = 5 5 .6 3  (55.01 to 56 .26)  
V = 1 .6 % ,P = 0 .0 5 6
Hip Circumference
11=57.47 (56.36 to 58.64) 
ID=58.25 (57.50 to 59.03} 
DD=59.26 (58.42 to 60.14) 
V=I.9%, P=0.046
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Table 3 Associations of adiposity-related phenotypes with ADRBl C49 polymorphism in
boys.
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BMI
(G G = 16.62  (16 .62  to i 6 .62)) 
G G + G A =16.94  (15 .67  to
18.46)
A A = 16 .75  (16 .42  to 17.10) 
V =0.1% , P =0.749
Sum of Skinfolds
(G G = 27.00  (27 .00  to 27 .00))  
G G + G A =25.12  (24 .19  to
26 .25 )
A A = 2 5 .6 4  (25 .29  to 26 .01)  
V = 1 .0 %, P =0.349
BMI
Arm Circumference
(G G =15.69 (15 .69  to 15.69)) 
G G +G A =15.21 (14 .27 to 
16.09)
A A = 15 .51  (15 .27 to 15.74) 
V =0.7% , P =0463
Waist Circumference
(G G =48.00 (4 8 .0 0  to 4 8 .00 ))  
G G + G A =48.52 (46 .67  to 
50.38)
A A = 46 .55  (45.91 to 47 .20 )  
V =4.1% , P =0.067
Hip Circumference
(G G =50.98 (50 .98  to 50 .98))  
G G +G A =50.31 (46 .38  to 
53.81)
A A = 4 9 .2 9  (4 8 .6 6  to 49 .92 )  
V =1.0% , P = 0 .3 7 6
G A = 16 .40  (16 .00  to 16.82) 
A A = 1 6 .4 2  (16.21 to 16.62) 
V =0% , P=0.995  
Sum of Skinfolds
G A = 25 .36  (24 .89  to 25 .87) 
A A = 2 5 .4 9  (25 .25 t o  25 .73) 
V = 0.1% ,P = 0 .731
Arm Circumference
G A = 15 .89  (15 .53  to 16 .29) 
A A = 16 .03  (15 .87  to 16 .19) 
V =0.2% , P = 0 .524
Waist Circumference
G A = 49.59  (49 .59  to 49 .59 ) 
A A = 49 .59  (49 .59  to 49 .59 ) 
V =0% , P = 0 .997
Hip Circumference
G A = 52.71 (51 .73  to 53 .72)  
A A = 5 2 .8 4  (52 .37  to 53 .31)  
V =0% , P =0.818
1
CO Ç
I Spq
1
isPQ voi
BMI
(G G = 14.32  (14 .32  to 14.32)) 
G G +G A =15.91 (15 .58  to
16.26)
A A = 1 6 .0 0  (1 5 .8 4  to 16.16) 
V =0.1% , P =0.627  
Sum of Skinfolds
(G G =25.01 (25.01 to 25 .01)) 
G G + G A =25.19 (24 .85 to
2 5 .56 )
A A = 25 .23  (25 .05 to 25 .42)
V =0% , P = 0 .837
BMI
(G G =17.28 (15 .39 to 19.87)) 
G G + G A =15.98 (15.61 to
16.37)
A A = 1 5 .8 7  (15 .68  to 16.06) 
V =0.1% , P =0 .625  
Sum of Skinfolds
(G G =26.07 (24 .20  to 29 .66))  
G G + G A =25.00  (24 .60  to
2 5 .4 6 )
A A = 2 4 .7 6  (24 .59  to 24 .95)  
V =0.4% , P =0 .297
Arm Circumference
(G G = 14.49  (14 .49  to 14.49)) 
G G + G A =16.28  (15 .97  to
16.60)
A A = 1 6 .3 4  (16 .19  to 16 .49) 
V =0% , P = 0 .708
Waist Circumference
(G G =45.04 (45 .04  to 4 5 .04 ))  
G G + G A =51.04 (50 .28  to  
5 1 .90)
A A = 51 .29  (5 0 .9 0  to 51 .70)  
V = 0 .1 % ,P = 0 .6 2 9
Hip Circumference
(G G = 52.99  (52 .99  to 52 .99))  
G G + G A =55.10  (54 .20  to
56 .04)
A A = 54 .83  (54.41 to 55 .25)  
V =0.1% , P =0 .575
Arm Circumference
(G G = 17.44  (15 .82  to 19.82)) 
G G + G A = 16 .74  (16 .38  to 
17.14)
A A = 1 6 .7 2  (16 .55  to 16 .89)  
V =0% , P = 0 .890
Waist Circumference
(G G =56.03 (50 .36  to 64 .20))  
G G +G A =53.37 (52 .18 to 
54.64)
A A = 52 .77  (52 .29  to 53 .27)  
V =0.3% , P =0 .345
Hip Circumference
(G G =58.71 (53 .57  to 65 .90))  
G G + G A =58.08  (56 .93  to
59 .30)
A A = 57 .11  (56 .58  to 57 .6 7 ) : 
V =0.7% , P =0.163
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Table 4 Associations of adiposity-related phenotypes with ADRBl C49 polymorphism in
girls.
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BMI
G A = 17.03  (16 .22  to 17.96) 
A A = 16 .63  (16.31 to 16.97) 
V =0.7% , P = 0 .432
Sum of Skinfolds
G A = 24 .86  (23 .65  to 26 .25)  
A A = 25 .29  (24 .95 to 25 .64)  
V =0.8% , P = 0 .430
Arm Circumference W aist Circumference Hip Circumference
G A = 15 .32  (14 .33  to 16 .26) 
A A = 1 5 .3 2  (15 .0 4  to 16.60) 
V =0% , P = 0 .992
G A = 46.54  (44 .94  to 48 .27 )  
A A = 46 .03  (45 .30  to 46 .78)  
V =0.2% , P = 0 .646
G A = 49 .82  (48 .14  to 
51 .5 3 )
A A = 49 .01  (48 .08  to
49 .94 )
V =0.4% , P = 0 .552
7
3 ?%.la OO o '
If î(T) If
I  s“I
BMI
G A = 16 .12  (15 .6 0  to 16.67) 
A A = 1 6 .2 2  (15 .99 to 16 .45) 
I V = 0 .1 % ,P = 0 .7 4 0
Arm Circumference W aist Circumference Hip Circumference
G A = 15 .73  (15 .29  to 16.19) 
A A = 16 .11  (15 .9 0  to 16.33) 
V = 1 .1 % ,P = 0 .1 4 7
G A = 48.88  (47 .53 to 50 .24)  
A A = 49 .65  (49 .10  to 50 .20)  
V =0.6% , P = 0 .274
Sum of Skinfolds
G A = 25 .72  (25.21 to 26 .27) 
A A = 2 5 .6 9  (2 5 .4 0  to 25 .99) 
V =0% , P =0.929
BMI
(G G =18.06 (18 .06  to
18.06))
G G + G A =16.12  (15 .75  to 
16.51)
A A = 15 .93  (15 .77  to 16.10) 
V =0.2% , P =0.368  
Sum of Skinfolds
(G G = 31.50  (31 .50  to 
3 1 .50 ))
G G + G A =25.56  (25 .12  to
26 .04 )
A A = 2 5 .6 4  (25 .44  to 25 .85)  
V =0% , P =0.763
Arm Circumference
(G G =17.93 (17 .93  to 17.93)) 
G G + G A = 16 .34  (16.01 to 
16.68)
A A = 1 6 .3 9  (16 .23  to 16.54) 
V =0% , P =0.798
W aist Circumference
(G G =55.05 (55 .05  to 55 .05))  
G G +G A =51.09  (50 .16  to
52 .05)
A A = 51 .43  (50 .96  to 51 .90)  
V =0.1% , P = 0 .562
I
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BMI
(G G =15.11 (14 .46  to 
15.84))
G A = 15 .72  (15 .36  to 16.10) 
A A = 1 5 .9 5  (15 .75  to 16.16) 
V = 0 .3 % ,P = 0 .3 1 9
Sum of Skinfolds
(G G =26.11 (25 .28  to 
2 7 .08 ))
G A = 25.91 (25 .46  to 26 .40)  
A A = 25 .91  (25 .66  to 26 .18)  
V =0% , P = 0 .929
Arm Circumference
(G G = 16.49  (15 .91  to 17.12)) 
G A = 17 .02  (16 .63  to 17.42) 
A A = 1 6 .9 8  (16 .79  to 17 .18) 
V =0% , P = 0 .864
W aist Circumference
(G G =52.35 (50 .18  to 53 .69))  
G A = 52 .34  (51 .38  to 53 .36)  
A A = 53 .15  (5 2 .6 4  to 53 .69)  
V =0.6% , P = 0 .172
G A = 52 .28  (5 0 .9 2 x 0  
53 .77)
A A = 5 3 .0 6  (52 .53  to
53 .60 )
V =0.7% , P =0.263
Hip Circumference
(G G =58.95 (58 .95  to 
58 .9 5 )) G G +G A =55.21  
(54.31 to 56 .14 )  
A A = 5 5 .6 5  (5 5 .2 0  to
56 .11)
V =0.2% , P = 0 .417
Hip Circumference
(G G =55.88 (53 .22  to
58 .94 ))
G A = 58 .12  (56 .95  to
59 .37 )
A A = 5 8 .6 4  (58 .07  to 
59 .22 )
V =0.2% , P = 0 .447
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Table 5 Associations of adiposity-related phenotypes with ADRBl C389 polymorphism in
boys.
i
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u
BMI
C C = 16.84  (16 .37  to 17.35) 
C G =16.61 (16 .12  to 17.14) 
G G = 17.06  (16 .26  to 17 .96)  
V =0.9% , P =0.707
Sum of Skinfolds
C C = 28.82  (27 .02  to 30 .79)  
C G =27.91 (26 .85 to 29 .03) 
G G = 27.20  (26 .18 to 28 .27)  
V =3.2% , P =0.265
Arm Circnmference
C C =15.68 (15.41 to 15.94) 
C G =15.13 (14.71 to 15 .54) 
G G =15.58 (14 .69  to 16.40) 
V =5.7% , P = 0 .094
Waist Circumference
C C =47.39 (46 .62  to 48 .67 )  
C G = 46.22 (45 .07 to 47 .3 8 )  
G G = 45.74  (44 .09  to 4 7 .4 2 )  
V = 5 .3 % ,P = 0 .1 1 2
Hip Circumference
CC=50.11 (49.30 to 50.89) 
CG=48.31 (47.00 to 49.57) 
GG=48.82 (47.24 to 50.31) 
V=7.7%, P=0.040
BMI
C C =16.51 (16 .24  to 16.78) 
C G = 16.40  (16.11 to 16.69) 
G G =16.58 (16 .13 to 17 .05)  
V =0.2% , P =0.794
Sum of Skinfolds
C C = 28 .82  (27 .02  to 30 .79)  
C G =28.91 (26 .85 to 29 .03)  
G G = 27.20  (26 .18  to 28 .27)  
V =1.2% , P =0.259__________
Arm Circumference
C C =16.01 (15 .80  to 16.23) 
C G =15.93 (15 .70  to 16 .18) 
G G =16.37 (15 .98  to 16.80) 
V =1.2% , P = 0 .286
Waist Circumference Hip Circumference
C C =49.64 (49 .05  to 50 .2 4 )  
C G =49.52 (48 .88 to 50 .18 )  
G G =49.82 (48 .76  to 50 .95)  
V =0.1% , P = 0 .905
0 0 = 5 2 .4 2 (5 1 .7 7  to 53 .08)  
O G =53.03 (52 .33 to 53 .75)  
G G =52.75 (51 .40  to 54 .17)  
V =0.7% , P =0.463
I
II
ÿ
BMI
0 0 = 1 5 .9 8  (15 .77  to 16.21) 
0 0 = 1 6 .0 7  (15 .84  to 16.30) 
G G = 16.00  (15 .54  to 16.50) 
V =0.1% , P =0.869
Sum of Skinfolds
0 0 = 2 5 .3 5  (22.91 to 26 .31)  
0 0 = 2 5 .5 1  (24 .55  to 26 .76)  
0 0 = 2 5 .9 7  (24.81 to 27 .05)  
V =0.4% , P =0.436
Arm Circumference
0 0 = 1 6 .2 6  (16 .07  to 16.46) 
0 0 = 1 6 .4 2  (16 .19  to 16.65) 
0 0 = 1 6 .4 7  (16 .13  to 16.83) 
V =0.4% , P = 0 .500
Waist Circumference
0 0 = 5 0 .9 2  (50 .40  to 51 .46)  
0 0 = 5 1 .6 8  (51 .13  to 52 .25)  
0 0 = 5 1 .5 3  (50 .55  to 52 .57)  
V = 1 .1 % ,P = 0 .1 3 4
Hip Circumference
0 0 = 5 4 .7 2  (5 4 .2 0  to 55 .25)  
0 0 = 5 5 .2 1  (54 .59  to 55 .85 )  
0 0 = 5 4 .9 8  (5 3 .8 2  to 56 .20 )  
V =0.4% , P = 0 .500
l i  
§
PQ
BMI
0 0 = 1 6 .0 0 (1 5 .7 4  to 16.27) 
0 0 = 1 5 .8 3  (15.53 to 16.14) 
0 0 = 1 5 .5 5  (15 .04  to 15.81) 
V =0.9% , P =0.323
Sum of Skinfolds
0 0 = 2 8 .9 8  (26 .85 to 29 .03)  
0 0 = 2 8 .8 2  (27 .02  to 30 .79)  
0 0 = 2 7 .1 9  (26 .18 to 28 .27)  
V = 1 .1 % ,P = 0 .2 4 2
Arm Circumference
0 0 = 1 6 .6 7  (16 .43  to 16 .92) 
0 0 = 1 6 .6 8  (16 .43 to 16.95) 
0 0 = 1 6 .9 8  (16 .61 to 17 .17) 
V =0.5% , P = 0 .544
Waist Circumference
0 0 = 5 3 .1 6  (52 .47  to 53 .87)  
0 0 = 5 2 .5 9  (51 .79  to 53 .43 )  
0 0 = 5 2 .7 9  (5 1 .5 0  to 53 .45)  
V=0.4% , P = 0 .574
Hip Circumference
0 0 = 5 7 .4 4  (56 .68  to 58 .22)  
0 0 = 5 7 .0 0  (56 .19  to 57 .85)  
0 0 = 5 6 .6 9  (55 .25  to 57 .43)  
V =0.4% , P=0.611
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Table 6 Associations of adiposity-related phenotypes with ADRBl C389 polymorphism in
girls.
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C C =16.71 (16 .28 to 17.18) 
C G =16 .9 0  (16 .43  to 17.42) 
0 0 = 1 5 .7 0  (15 .19  to 16.27) 
V =5.4% , P = 0 .102
Sum of Skinfolds
0 0 = 2 4 .3 5  (22.91 to 26 .31) 
0 0 = 2 5 .2 3  (24 .55 to 26 .76)  
0 0 = 2 5 .8 2  (24.81 to 27 .05) 
V = 2 .1 % ,P = 0 .3 8 7
Arm Circumference
0 0 = 1 5 .1 3  (14 .77  to 15.48) 
0 0 = 1 5 .5 9  (15 .1 4  to 16.04) 
0 0 = 1 4 .6 5  (1 4 .1 4  to 15.15) 
V = 5 .2 % ,P = 0 .1 1 0
Waist Circumference
0 0 = 4 5 .5 0  (44 .56  to 46 .4 9 )  
0 0 = 4 6 .3 9  (45 .37  to 47 .47 )  
0 0 = 4 6 .1 3  (44 .23 to 48 .22 ) 
V =1.8% , P = 0 .466
BMI
0 0 = 1 6 .0 8  (15 .79  to 16.38) 
0 0 = 1 6 .3 7  (16 .03  to 16.72) 
0 0 = 1 6 .1 3  (15 .64  to 16.63) 
V =0.9% , P = 0 .432
Sum of Skinfolds
0 0 = 2 5 .1 9  (22.93 to 27 .85) 
0 0 = 2 5 .5 9  (23 .95  to 27 .43) 
0 0 = 2 4 .3 7  (22 .85  to 26 .64)  
V =0.2% , P =0.783
Arm Circumference
0 0 = 1 5 .9 0  (15 .62  to 16.18) 
0 0 = 1 6 .2 8  (15 .99  to 16.59) 
0 0 = 1 5 .6 8  (15 .04  to 16.36) 
V =2.7% , P =0 .088
Waist Circumference
0 0 = 4 9 .4 0  (48 .75  to 50 .0 5 )  
0 0 = 4 9 .9 3  (49 .09  to 50 .78)  
0 0 = 4 9 .2 7  (47 .56  to 51 .01) 
V =0.6% , P =0 .566
BMI
0 0 = 1 5 .9 6  (1 5 .7 4  to 16 .20) 
0 0 = 1 5 .9 4  (15 .70  to 16.18) 
0 0 = 1 6 .2 6  (15 .74  to 16.82) 
V =0.5% , P =0 .456
Sum of Skinfolds
0 0 = 2 4 .2 9  (22 .95  to 26 .24)  
0 0 = 2 5 .2 1  (24 .55  to 26 .75)  
0 0 = 2 5 .7 0  (24.81 to 27 .00)  
V =0.5% , P =0.419
Arm Circumference
0 0 = 1 6 .3 3  (1 6 .1 2  to 16 .55) 
0 0 = 1 6 .3 7  (16 .15  to 16.59) 
0 0 = 1 6 .6 5  (16.21 to 17.10) 
V =0.5% , P = 0 .412
Waist Circumference
0 0 = 5 1 .3 8  (50 .75  to 52 .01) 
0 0 = 5 1 .1 9 (5 0 .5 4  to 51 .85)  
0 0 = 5 2 .1 1  (50 .86  to 53 .41) 
V =0.5% , P=0.421
BMI
0 0 = 1 6 .0 6  (15 .77  to 16.36) 
0 0 = 1 5 .8 8  (1 5 .6 2  to 16 .16) 
0 0 = 1 5 .9 1  (15 .43  to 16.44) 
V =0.3% , P =0 .678
Sum of Skinfolds
0 0 = 2 5 .2 4  (22 .93  to 27 .85)  
0 0 = 2 5 .6 2  (23 .95  to 27 .43)  
0 0 = 2 4 .6 6  (22 .85  to 26 .64) 
V =0.2% , P =0.688
Arm Circumference
0 0 = 1 7 .2 1  (16 .93  to 17.50) 
0 0 = 1 6 .9 0  (1 6 .6 4  to 17.17) 
0 0 = 1 6 .7 4  (16 .26  to 17.27) 
V =1.2% , P = 0 .170
Waist Circumference
0 0 = 5 3 .3 9  (52 .67  to 54 .15)  
0 0 = 5 2 .8 5  (52 .14  to 53 .59)  
0 0 = 5 3 .0 3  (51 .56  to 54 .67 )  
V =0.3% , P = 0 .604
Hip Circumference
0 0 = 4 8 .9 1  (47 .69  to 50 .15) 
0 0 = 4 9 .3 1  (47 .96  to 50 .68)  
0 0 = 4 7 .8 1  (46 .63 to 49 .02 )  
V = 1 .1 % ,P = 0 .6 4 7
Hip Circumference
00=52.42 (51.75 to 53.12) 
00=53.91 (53.13 to 54.73) 
00=51.60 (50.13 to 53.21) 
V=5.8%, P=0.006
Hip Circumference
0 0 = 5 5 .3 6  (54 .7 4  to 56 .00)  
0 0 = 5 5 .5 9  (54 .96  to 56 .24)  
0 0 = 5 6 .2 0  (5 5 .1 0  to 57 .37)  
V =0.4% , P =0.465
Hip Circumference
0 0 = 5 9 .0 5  (58.21 to 59 .92)  
0 0 = 5 8 .0 4  (57 .28  to 58 .82)  
0 0 = 5 8 .3 5  (56 .78  to 60 .03)  
V=1.G%, P = 0 .223
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Table 7 Associations of adiposity-related phenotypes with ADRB2 C16 polymorphism in
boys.
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BMI
0 0 = 1 6 .6 6  (16 .26  to 17.08) 
O A = 17 .10  (16 .57 to 17 .68)  
A A = 1 6 .6 6 (1 5 .8 7  to 17 .53)  
V =3.7% , P =0.202
Sum of Skinfolds
0 0 = 2 5 .9 8  (24 .85  to 26 .03)  
O A = 25 .52  (26 .02  to 26 .79)  
A A = 2 5 .1 9  (24 .18 to 26 .27) 
V =4.8% , P = 0 .110
Arm Circumference
0 0 = 1 5 .3 1  (14 .99 to 15.62) 
O A = 15 .70  (15 .35  to 16.04) 
A A = 1 5 .6 6 (1 5 .0 9  to 16.21)  
V =3.3% , P =0.237
Waist Circumference Hip Circumference
0 0 = 4 6 .3 8  (45 .48  to 47 .2 9 )  
O A =47.11 (46 .25 to 47 .9 8 )  
A A = 47 .37  (45.41 to 4 9 .3 6 )  
V =2.0% , P = 0 .430
0 0 = 4 8 .6 1  (49 .58  to 49 .58 )  
O A =50.01 (50 .87  to 50 .87) 
A A = 50 .03  (47.71 to 52 .19) 
V =5.5% , P = 0 .1 0 4
BMI
0 0 = 1 6 .2 1  (15 .93  to 16.48) 
O A = 16 .42  (16 .15  to 16.69) 
A A = 16 .53  (16 .09  to 16.98) 
V =0.8% , P = 0 .396  
Sum of Skinfolds
0 0 = 2 4 .6 6  (22 .85  to 26 .64) 
O A = 25 .62  (23 .95  to 27 .43) 
A A = 2 5 .2 4  (22 .93 to 27 .85) 
V =0.2% , P =0.625
BMI
00=15.93(15.17 to 18.29) 
OA=15.87 (14.54 to 17.57) 
AA=16.55(16.13 to 16.99) 
V=1.9%, P=0.020 
Sum of Skinfolds
0 0 = 2 5 .0 5  (24 .79  to 25 .33)  
O A = 25 .26  (25 .05  to 25 .49)  
A A = 25 .41  (24 .93  to 25.94) 
V =0.3% , P =0.619
BMI
0 0 = 1 5 .9 6  (15 .69  to 16.23) 
O A = 15.81 (15 .57  to 16.06) 
A A = 1 5 .9 1 (1 5 .4 5  to 16 .39) 
V =0.2% , P=0.721  
Sum of Skinfolds
0 0 = 2 4 .8 3  (24 .59  to 25 .10) 
O A = 24.88  (24 .65  to 25 .13) 
A A = 2 4 .6 2  (24 .23  to 25 .07) 
V =0.4% , P =0 .555
Arm Circumference
0 0 = 1 5 .9 5  (1 5 .7 4  to 16.18) 
O A = 15 .96  (15 .75  to 16.19) 
A A = 16 .03  (15 .69  to 16 .41) 
V =0% , P =0.933
Arm Circumference
0 0 = 1 6 .2 8  (16 .06  to 16.49) 
G A = 16 .30  (16.11 to 16 .50) 
A A = 1 6 .6 9  (16 .3 4  to 17.06) 
V =0.9% , P =0 .175
Arm Circumference
0 0 = 1 6 .7 7  (1 6 .5 4  to 17.02) 
G A = 16 .67  (16 .46  to 16.88) 
A A = 1 6 .6 3 (1 6 .1 9  to 17.12) 
V =0.2% , P = 0 .756
Waist Circumference
0 0 = 4 9 .3 9  (48 .77  to 50 .03) 
O A =49.61 (49 .03 to 50 .2 1 )  
A A = 49.65  (48 .87  to 50 .4 5 )  
V =0.1% , P =0.844
Hip Circumference
0 0 = 5 2 .3 9  (51 .77  to 53 .02)  
O A = 52 .92  (52 .27  to 53 .59)  
A A = 5 2 .9 2 (5 1 .8 9  to 53 .99 ) 
V =0.6% , P = 0 .475
Waist Circumference
0 0 = 5 1 .2 1  (50 .68  to 51 .76) 
O A = 51 .09  (50 .58 to 51 .61) 
A A = 5 2 .0 7 (5 1 .0 2  to 53 .1 8 )  
V =0.7% , P =0.243
Hip Circumference
0 0 = 5 4 .7 7  (5 4 .2 0  to 55 .37)  
G A = 54 .76  (5 4 .2 2  to 55 .31)  
A A = 5 6 .1 1 (5 5 .0 5  to 57 .23 ) 
V =1.2% , P = 0 .0 8 0
Waist Circumference
0 0 = 5 3 .1 2  (52.51 to 53 .76) 
O A = 52.87  (52 .26  to 53 .51) 
A A = 5 1 .9 3 (5 0 .4 7  to 55 .53 )  
V = 1 .0 % ,P = 0 .2 1 5
Hip Circumference
0 0 = 5 7 .6 3  (56 .88 to 58 .41)  
O A = 5 7 .15 (56 .48 to 57 .86)  
A A = 56 .77  (55 .45 to 58 .19)  
V =0.5% , P =0.461
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Table 8 Associations of adiposity-related phenotypes with ADRB2 C l6 polymorphism in
girls.
g
BMI
G G =16.68 (16 .23 to 17.17) 
G A = 16 .72  (16 .30  to 17.18) 
A A = 1 6 .1 9  (15 .40  to 17 .10) 
V =0.9% , P -0 .6 8 7
Sum of Skinfolds
G G = 25.34  (23 .90  to 26 .71)  
G A =25.31 (24 .87  to 25 .77)  
A A = 2 5 .2 0  (23 .90  to 26 .71) 
V =0% , P = 0 .980
Arm Circumference
G G = 15.57  (15 .18  to 15.95) 
G A = 15 .14  (14 .76  to 15.51) 
A A = 1 5 .2 3  (13 .73  to 16.63) 
V=2.6%, P = 0 .322
Waist Circumference
G G =45.88 (44 .78  to 47 .05 ) 
G A = 46.16  (45 .27  to 47 .08) 
A A = 44 .69  (42 .95  to 46 .62 ) 
V =1.3% , P =0.563
Hip Circumference
G G =49.11 (4 7 .7 2  TO 50.53)  
G A = 48 .96  (47 .82  TO 50 .13)  
A A = 4 8 .7 7  (46 .97  t o  5 0 .61)  
V =0.1% , P = 0 .974
â
S i
BMI
G G = 16.06  (15 .75  to 16.36) 
G A = 16 .39  (16 .07  to 16.71) 
A A = 1 5 .7 7  (15 .36  to 16.20) 
V =2.3% , P =0 .073  
Sum of Skinfolds
G G = 25.56  (24 .63  to 26 .33 ) 
G A =25.81 (25 .47 to 26 .16) 
A A = 25 .43  (24 .63 to 26 .33) 
V =0.6% , P =0.383
Arm Circumference
G G = 16.07  (15 .79  to 16.36) 
G A = 16 .07  (15 .79  to 16.36) 
A A = 1 5 .6 4  (15 .16  to 16 .15) 
V =1.2% , P = 0 .236
Waist Circumference Hip Circumference
G G =49.21 (48 .38  to 50 .04 )  
G A = 49 .99  (49 .26  to 50 .73)  
A A = 48 .68  (47 .72  to 49 .6 5 )  
V = 1 .8 % ,P = 0 .1 3 2
G G =52.53 (51.81 to 53 .29)  
G A = 53 .52  (52 .77  to 54 .30)  
A A = 5 1 .8 7  (51 .05  to 52 .74 )  
V = 3 .1 % ,P = 0 .0 5 ]
T f  7-4I
BMI
G G =15.99 (15 .70  to 16.30) 
G A = 16.03 (15 .84  to 16.22) 
A A = 15 .95  (15 .55  to 16.38) 
V =0.1% , P =0.945  
Sum of Skinfolds
G G =25.66 (25 .35  to 25 .98)  
G A = 25 .84  (25 .56  to 26 .12)  
A A = 25 .18  (24 .77  to 25 .62)  
V =1.5% , P = 0 .062
Arm Circumference
G G = 16 .44  (1 6 .2 0  to 16.71) 
G A = 16 .45  (16 .25  to 16.64) 
A A = 16 .21  (15 .89  to 16.56) 
V=0.3%, P =0.573
Waist Circumference
G G = 51.43 (50 .63 to 52 .54)  
G A = 51.44  (50 .90  to 52 .00)  
A A = 51 .59  (50 .67  to 52 .54)  
V =0% , P=0.971
Hip Circumference
G G =55.53 (54 .84  to 56 .25) 
G A = 55 .80  (55 .25  to 56 .36) 
A A = 5 5 .5 2  (54 .42  to 56 .66) 
V = 0 .1 % ,P = 0 .8 1 0
§
3
BMI
G G =16.09 (15 .79  to 16.40) 
G A = 15 .90  (1 5 .6 6  to 16 .14) 
A A = 15 .61  (15 .07  to 16 .20) 
V =0.9% , P =0.253  
Sum of Skinfolds
G G = 26.24  (25 .85  to 26 .65 )  
G A = 25 .76  (25 .46  to 26 .08 )  
A A = 25 .85  (25 .33 to 26 .43 )  
V = 1 .2 % ,P = 0 .1 4 2
Arm Circumference
G G =17.25 (16 .95  to 17.56) 
G A = 1 6 .9 4  (1 6 .7 2  to 17.18) 
A A = 1 6 .8 7  (16.41 to 17 .36) 
V = 0.8  %, P = 0 .217
Waist Circumference
G G =53.63 (52 .88 to 54 .42)  
G A = 53 .05  (52 .4 4  to 53 .69)  
A A = 52 .05  (5 0 .6 2  to 53 .62)  
V = 1 .4 % ,P = 0 .1 0 9
Hip Circumference
G G =59.18 (58 .33  to 60 .06) 
G A = 58.35  (57 .65  to 59 .06)  
A A = 5 7 .9 2  (5 6 .5 0  to 59 .4 3 )  
V =1.0% , P =0.213
g
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Table 9 Associations of adiposity-related phenotypes with ADRB2 C27 polymorphism in
boys.
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G G =16.33 (15 .67  to 17.05) 
G C = 16.86  (16 .37  to 17.40) 
C C =16.88 (16 .42 to 17 .37) 
V =2.1% , P = 0 .414
Sum of Skinfolds
G G = 25.02  (24.41 to 25 .73) 
G C = 25 .75  (25 .26  to 26 .30)  
C C = 25.43  (24.93 to 25 .99)  
V =3.0% , P = 0 .229
Arm Circumference
GG=15.03 (14.35 to 15.67) 
GC=15.81 (15.48 to 16.14) 
CC=15.48 (15.19 to 15.76) 
V=7.2%, P^O.042
Waist Circumference
G G =45.82 (44 .5 2  to 47 .12 )  
G C = 47.24  (46 .36  to 48 .1 3 )  
C C =46.81 (45 .8 4  to 47 .78 )  
V =3.3% , P = 0 .240
Hip Circumference
GG=47.60 (45.65 to 49.43) 
GC=49.78 (48.93 to 50.61) 
€0=49.80 (48.80 to 50.77) 
V=7.7%. P=0.039
BMI
G G =16.08 (15 .69  to 16 .49)  
G C = 16.29 (16.03 to 16 .55) 
C C =16.53 (16 .26  to 16.80) 
V =1.2% , P =0.223
Sum of Skinfolds
G G = 25.76  (25 .35  to 26 .20)  
G C= 2 5 .43  (25 .14  to 25 .73)  
C C =25.61 (25 .26  to 25 .97 )  
V =0.5% , P =0 .524
Arm Circumference
G G = 15.74  (15 .43  to 16.08)  
G C = 15.87  (15 .67  to 16.08) 
C C = 16.19  (15 .98  to 16.41) 
V =2.5% , P = 0 .0 5 2
Waist Circumference
GG=48.84 (48.11 to 49.58) 
GC=49.19 (48.60 to 49.80) 
00=50.08 (49.53 to 50.64) 
V=2.6%, P=0.043
Hip Circumference 
GG=S0.94 (50.16 to 51.75) 
GC=52.47 (51.83 to 53.12) 
CC=53.46 (52.85 to 54.07) 
V=6.0%, P=0.001
BMI
G G =16.11 (15 .66 to 16 .61)  
G C = 15.89  (15 .70  to 16.08) 
C C =16.10  (15 .87  to 16.34) 
V =0.5% , P =0.325
Sum of Skinfolds
G G = 25.06 (24 .53  to 25 .66 )  
G C =25.28 (25 .0 7  to 25 .51)  
C C =25.21 (24 .96  to 25 .47)  
V =0.2% , P = 0 .652
Arm Circumference
G G = 16.24  (1 5 .8 6  to 16.66) 
G C = 16.39  (16.21 to 16.58) 
C C = 16.32  (16 .1 2  to 16 .54)  
V =0.1% , P = 0 .759
Waist Circumference
G G =50.94 (49 .97  to 51 .97)  
G C =51.09 (50 .82  to 51 .81)  
C C =51.34 (50 .78 to 51 .93 )  
V =0.1% , P =0 .777
Hip Circumference
G G = 54.66  (53.51 to 55 .8 7 )  
G C = 54 .82  (54 .30  to 55 .36)  
C C = 55 .20  (54 .63 to 55 .78)  
V =0.3% , P = 0 .564
BMI
G G = 15.98  (15 .53 to 16.47) 
G C =15.83 (15 .60  to 16 .08) 
C C = 15.92  (15 .65 to 16.20) 
V =0.1% , P =0.814
Sum of Skinfolds
G G =24.83 (24 .48  to 25 .23 )  
G C = 25.03 (24 .79  to 25 .28 )  
C C = 24.62  (24 .37  to 24 .90)  
V =1.7% , P = 0 .064
Arm Circumference
G G = 16.82  (16 .46  to 17.20) 
G C = 16.73 (1 6 .5 2  to 16.95) 
C C = 16.66  (1 6 .4 2  to 16.92) 
V =0.1% , P = 0 .8 0 0
Waist Circumference
G G =53.23 (52 .34  to 54 .16)  
G C =52.95 (52 .32  to 53 .60)  
C C =52.66 (51.91 to 53 .44)  
V =0.2% , P =0.693
Hip Circumference
G G =58.05 (56 .88  to 59 .29)  
G C = 57.14  (5 6 .4 4  to 57 .88)  
C C =57.27 (56 .5 4  to 58 .02)  
V =0.5% , P =0.483
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Table 10 Associations of adiposity-related phenotypes with ADRB2 C27 polymorphism In
girls.
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BMI
G G =16.73 (15 .98 to 17.58) 
G C = 16.78 (16 .38  to 17.20) 
C C = 16.56  (16 .07  to 17.10) 
V =0.5% , P =0.809
Sum of Skinfolds
G G = 25.10  (24 .15  to 26 .16)  
G C = 25.26  (24 .86  to 25 .67)  
C C = 25.35 (24 .79  to 25 .95)  
V =0.3% , P = 0 .856
Arm Circumference
G G = 15.76  (15 .28  to 16.23) 
G C = 15.25 (14 .85  to 15.64) 
C C = 15.23 (14 .75  to 15.69) 
V =2.5% , P =0 .333
BMI
G G = 16.02  (15 .48  to 16.58) 
G C =16.15 (15 .85  to 16 .47) 
C C = 16.25 (15 .93 to 16.58) 
V =0.3% , P = 0 .639
Sum of Skinfolds
G G = 25.70  (24 .9 4  to 26 .56)
G C = 2 5 .7 4  (25 .38 to
2 6 .1 1 )
C C = 25.60  (25.21 to 26 .00) 
V = 0 .1 % ,P = 0 .8 3 2
Arm Circumference
G G =15.89 (15 .3 2  to 16.49) 
G C = 16.16  (15 .9 0  to 16 .43)  
C C = 15 .92  (1 5 .6 2  to 16.24) 
V =0.8% , P = 0 .394
BMI
G G = 16.06 (15 .53 to 16.64) 
G C =15.91 (15.71 to 16.13) 
C C =16.07 (15 .84  to 16 .30)  
V =0.3% , P =0 .616
Sum of Skinfolds
G G = 25.80  (25.21 to 26 .45)  
G C = 25.80 (25 .53 to 26 .07) 
C C =25.55 (25 .28 to 25 .85)  
V =0.4% , P = 0 .439
Arm Circumference
G G =16.61 (16 .15  to 17.08) 
G C = 16.43 (16 .2 4  to 16.63) 
C C = 16 .34  (16 .13  to 16 .57) 
V =0.3% , P = 0 .5 3 4
Waist Circumference
G G =46.63 (44 .95 to 48 .48 )  
G C = 46.36 (45 .49  to 4 7 .2 7 )  
C C =45.35 (44 .24  to 46 .5 4 )  
V =2.8% , P = 0 .290
Hip Circumference
G G =48.91 (47 .15  to 50 .71)  
G C = 49.57  (48 .39  to 50 .76 )  
C C =48.58 (47 .14  to 50 .05)  
V = 1.3% ,P = 0 .571
Waist Circumference
G G =49.39 (48 .04  to 50 .76 )  
G C =49.78 (49 .04  to 50 .50)  
C C =49.39 (48 .58 to 50 .21 )  
V =0.7% , P = 0 .392
Waist Circumference
G G =51.30 (49 .87  to 52 .78)  
G C =51.51 (50.91 to 52 .12)  
C C = 51.44  (50 .83 to 52 .05)  
V=0% , P = 0 .950
BMI
G G = 16.06  (15.53 to 16.64) 
G C = 15.98 (15 .72  to 16.25) 
C C = 15 .84  (15 .58 to 16.12) 
V =0.2% , P=0.691
Sum of Skinfolds
G G =26.17 (25 .56  to 26 .87)  
G C = 25.92  (25.61 to 26 .26)  
C C =25.93 (25 .57  to 26 .31)  
V =0.1% , P = 0 .782
Arm Circumference
G G =17.23 (16 .67  to 17.82) 
G C = 17.03  (16 .78  to 17.29) 
C C =17.05 (16.81 to 17.31)  
V = 0 .1 % ,P = 0 .7 9 2
Waist Circumference
G G =53.39 (52 .13 to 54 .77 )  
G C = 53.44 (52 .78 to 54 .13 )  
C C = 52.72  (52 .00  to 53 .48)  
V =0.7% , P =0.345
Hip Circumference
G G = 52.76  (51 .39  to 54 .26 )  
G C = 53.09  (52.41 to 53 .83)  
C C =52.71 (5 1 .9 4  to 53 .52)  
V =0.3% , P =0.738
Hip Circumference
G G =56.01 (5 4 .8 2  to 57 .26)  
G C = 55.69  (55 .1 2  to 56 .28)  
C C = 55.46  (5 4 .8 4  to 56 .10)  
V =0.2% , P = 0 .700
Hip Circumference
G G =58.65 (57 .28  to 60 .12)  
G C =58.89 (58 .15  to 59 .66)  
C C = 5 8 .18 (57 .29  to 59 .10)  
V =0.5% , P = 0 .438
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Table 11 Associations of adiposity-related phenotypes with ADRB3 C64 polymorphism in
boys.
I
BMI
(C C =17.71 (17.71 to 17.71)) 
C T +C C =17.31 (16 .19  to
18.61)
T T = 16 .70  (16 .38 to 17.02  
V =1.5% , P =0.262
Sum of Skinfolds
(C C = 24.00  (24 .00  to 24 .00)) 
C T +C C =25.16 (24 .25 to
2 6 .27 )
T T = 25.52  (25 .14  to 26 .20)  
V =0.5% , P =0.482
Arm Circumference Waist Circumference
(C C = 15.49 (15 .49  to 15.49)) 
C T + C C = 15.54 (14 .82  to 16.21) 
T T = 15.49  (15 .26  to 15.72) 
V =0% , P = 0 .904
(C C =44.50 (44 .50  to 4 4 .50 ))  
C T +C C =46.38 (44 .56  to 48 .21) 
T T =46.75 (46 .13  to 47 .37)  
V =0.2% , P = 0 .710
I B
PP cT
BMI
C T =16.13 (15 .65  to 16.62) 
T T = 16.39  (16.21 to 16.58) 
V =0.3% , P=0.421
Sum of Skinfolds
C T =25.87 (25 .17 to 26 .67) 
T T = 25.47  (25 .26  to 25 .69) 
V =0.4% , P =0.329
Arm Circumference
CT=15.45 (15.01 to 15.98) 
TT=16.02 (15.88 to 16.17) 
V=2.1%, P=0.027
Waist Circumference
C T =49.03 (48.01 to 50 .09)  
T T =49.57 (49 .17  to 49 .9 9 )  
V =0.2% , P =0 .448
IIIm II
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BMI
(C C = 14.79 (14 .79 to 14.79)) 
C T +C C =15.93 (15 .58 to
16.30)
T T =15.98 (15 .98  to 15.98) 
V =0% , P =0.829  
Sum of Skinfolds
(C C =24.01 (24.01 to 24 .01))  
C T +C C =25.19 (24 .74  to  
2 5 .7 0 )
T T =25.21 (25 .05 to 25 .38) 
V=Q%, P = 0 .982  
BMI
(C C =16.27 (16 .27  to 16.27)) 
C T +C C =16.46 (15 .83 to 
17.16)
T T =15.85 (15 .68  to 16.03) 
V =1.2% , P =0.059
Sum of Skinfolds
(C C = 24.00  (24 .00  to 24 .00))  
C T +C C =24.83 (24 .23 to 
2 5 .57)
T T = 24.85  (24 .68 to 25 .02) 
V =0% , P^O.958_____________
Arm Circumference
(C C = 15.49  (15 .49  to 15.49)) 
C T +C C =16.46 (16 .12  to 16.82) 
T T = 16 .32  (16 .18  to 16 .46) 
V = 0.1% ,P = 0 .511
Arm Circumference
(C C =17.01 (17 .01  to 17.01)) 
C T + C C = 16.92  (16 .30  to 17.63) 
T T = 16 .72  (16 .57  to 16.87) 
V =0.2% , P = 0 .472
Waist Circumference
(CC=53.05 (53.05 to 53.05)) 
CT+CC=54.88 (53.30 to
56.62)
T T = 52.74  (52 .29  to 53 .21)  
V=2.0%, P=0.013
Hip Circumference
(C C =52.98 (52 .98  to 52.98)] 
C T +C C =50.49 (48 .38  to
5 2 .46)
T T = 49.17  (48 .49  to 49 .83 ) 
V = 1 .8 % ,P = 0 .2 1 6
Waist Circumference
(C C =49.04 (4 9 .0 4  to 49 .04 ))  
C T +C C =50.97 (49 .93 to 52 .08) 
T T =51.28 (50.91 to 51 .65)  
V = 0.1% ,P = 0 .585
Hip Circumference
C T = 51.97  (50 .47  to 53 .55), 
T T =52.73 (52 .29  to 53 .17)  
V = 0.4% ,P = 0 .331
Hip Circumference t
(C C = 51.99 (51 .99  to 5 1 .9 9 ))  
C T + C C = 54.82 (53 .76  to I  
55 .89 ) I
T P = 54 .93  (54 .53 to 55 .33 ) ; 
V =0% , P =0.827  Î
Hip Circumference
(CC=59.97 (59.97 to 59.97)) 
CT+CC=59.38 (57.56 to
61.40)
T P = 57 .19  (56 .7 0  to 57 .69)  
V=1.7%, P=0.022
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Table 12 Associations of adiposity-related phenotypes with ADRB3 C64 polymorphism in
girls.
BMI Arm Circumference Waist Circumference Hip Circumference
I C T = 16.64  (16 .19  to 17.12) CT= 14.58 (13 .95  to 15.20) Cr=43.54 (41.38 to 45.99) CT=46.14 (44.26 to 48.07)M H T r = 1 6 .6 8  (16 .36  to 17.02) T T = 15 .42  (1 5 .1 4  to 15.70) TT=46.20 (45.51 to 46.90) TT=49.32 (48.45 to 50.21)V=0%, P = 0 .946 V = 3 .2 % ,P = 0 .1 0 1 V=6.0%, P=0.026 V=5.1%, P=0.039
U Sum of Skinfoldss “o® C T =24.61 (23 .74  to 25 .57)
T T = 25.40  (25 .05  to 25 .75)u V =2.0% , P =0.178
g BMI Arm Circumference Waist Circumference Hip Circumference
II* H C T =16.57 (15 .75 to 17.43) C T = 16.44  (15 .79  to 17.12) C T =50.83 (49 .03 to 52 .66) C T = 53.64  (51 .98 to 55 .47)
T T = 16.14  (15 .93 to 16.35) T T = 15.99  (15 .79  to 16.19) T T =49.38 (48 .86  to 49 .90 ) T T = 52 .84  (52 .33  to 53 .35)rc t-T V=0.7%, P =0.263 V=0.8%, P =0.209 V =1.3% , P =0.117 V =0.4% , P = 0 .387
Sum of Skinfolds.fa Oo ^A C T = 26.22  (25 .17 to 27 .43)CJu 1 T = 2 5 .6 4  (25 .38  to 25 .91)V =0.7% , P =0.287
BMI Arm Circumference Waist Circumference Hip Circumference
(C C =16.47 (16 .47  to (C C =17.93 (17 .93  to 17.93)) (C C =53.05 (53 .05 to 53 .05)) (C C =51.95 (51 .95  to
a 16.47)) C T + C C = 16.14 (1 5 .7 6  to C T +C C =50.56 (4 9 .4 0  to 51 .95))
'n C T +C C =15.70 (15 .67  to 16.54) 51.76) C T +C C =55.22 (54 .07  to% H 15.68) T T = 16.45  (1 6 .3 0  to 16 .60) (T T = 51.52 (51 .07  to 51 .97) 5 6 .42 )k H T T = 16.02  (15 .86  to 16.18) V =0.4% , P =0 .228 V =0.4% , P =0.203 T T =55.63 (55 .27  to 56 .14)
?  cT V =0.4% , P = 0 .244 V = 0 .1 % ,P = 0 .4 5 0cn 1, Sum of SkinfoldsIS (C C = 28.00  (2 8 .0 0  to
2 8 .00))
II C T +C C =25.46 (24 .80  toy 2 6 .21)T T = 25.70  (25.51 to 
2 5 .89 ))
V =0.1% , P =0.453
BMI Arm Circumference Waist Circumference Hip Circumference
(C C =16.71 (15 .34  to (C C = 18.30  (17 .04  to 19 .78)) (C C =58.89 (53 .10  to 67 .71)) (C C =65.08 (62 .67  tog 18.43)) C T +C C =17.28 (16 .77  to C T +C C =54.03 (52 .65 to 6 7 .76 ))2 C T +C C =15.84 (15.31 to 17.83) 55.55) C T + C C = 59.46 (5 8 .0 0  to
16.42) T T =17.01 (16 .83  to 17.19) T T = 53.00  (52 .53  to 53 .49) 61 .03)
r r = 1 5 .9 3  (15 .75  to 16.12) V =0.3% , P = 0 .346 V =0.5% , P =0 .187 T T = 58.43  (5 7 .9 0  to 58 .97 )\o  o V =0% , P =0.753 V =0.4% , P = 0 .259
a  H Sum of Skinfolds.fa U (C C =26.65 (24 .48  to
3 0 .04 ))
C T +C C =25.77 (25 .16  too 2 6 .46)
T T = 25.96  (25 .73  to 26 .20 ) 
V = 0 .1 % ,P = 0 .6 3 8
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Table 13 Associations of adiposity-reiated phenotypes with PPARy Pro12Ala polymorphism 
in boys.
ilA OIIuu
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BMI
C C = 16.69  (16 .37  to 17.03) 
C G = 17.65 (1 6 .6 4  to 18.77)
V =2.9% , P = 0 .123
Sum of Skinfolds
C C = 25.47  (25 .13  to 25 .83)  
C G = 26.55 (2 5 .4 4  to 27 .89)
V = 3 .1 % ,P = 0 .1 0 9
Arm Circumference
C C =15.43 (15 .19  to 15.67) 
C G = 15.97  (15.31 to 16.61)
V =2.0% , P = 0 .1 9 4
Waist Circumference
C C =46.47 (45 .85 to 47 .09 )  
C G = 48.02 (46 .29  to 49 .7 7 )
V = 2 .5 % ,P = 0 .1 5 4
Hip Circumference
C C =49.08 (48 .39  to 49 .76 )  
C G =49.97 (47 .85  to 52 .00)
V=0.7% , P =0.458
BMI
C C = 16 .4 5 (1 6 .2 4  to 16.65) 
C G + G G =16.17 (15 .76  to
16.60)
(G G = 16.04  (13 .59  to 18.94)) 
V =0.5% , P =0.273
Sum of Skinfolds
C C =25.53 (25 .30  to 25 .78)  
C G +G G =25.21 (24 .82  to
25 .62)
(G G = 24.00  (24 .00  to 2 4 .00 ))  
V =0.6% , P =0.235
Arm Circumference Waist Circumference Hip Circumference
C C = 16.00  (1 5 .8 4  to 16.16) 
C G +G G =15.81 (15 .47  to
16.19)
(G G = 15.47  (14 .58  to
16.56))
V =0.8% , P =0 .319
C C = 49.40 (48 .96  to 49 .8 5 )  
C G +G G =49.37 (48 .43 to
50.34)
(G G =46.94 (46 .94  to 4 6 .94 ))  
V =0% , P = 0 .9 5 4
C C = 52.90  (52 .45  to 53 .36)  
C G + G G =52.44 (51 .32  to
5 3 .61)
(G G =52.99 (51 .09  to 5 5 .01 ))  
V =0.3% , P = 0 .425
BMI
C C = 15.99  (15 .83 to 16.16) 
C G +G G =16.04  (15 .70  to
16.40)
(G G = 1 8 .1 6 to  18.16) 
V =0% , P =0.829
Sum of Skinfolds
C C =25.23 (25 .06  to 25 .42)  
C G +G G =25.17 (24 .78 to
25 .60)
(G G =27.01 to 27 .01) 
V =0% , P = 0 .786
Arm Circumference
C C = 16.36  (16.21 to 16 .51) 
C G +G G =16.35 (15 .99  to
16.73)
(G G = 17.49  to 17 .49) 
V =0% , P = 0 .9 5 4
Waist Circumference
C C = 51.24 (50 .8 4  to 51 .65) 
C G +G G =51.09 (50 .27  to
51.95)
(G G =54.46 to 54 .46)  
V=0% , P =0.779
Hip Circumference
C C =54.95 (54 .54  to 55 .38) 
C G +G G =54.97 (53 .97  to 
56.03)
(G G =59.07 to 59 .07)  
V =0% , P = 0 .974
BMI
C C =15.93 (15 .75  to 16.11) 
C G = 15.80  (15.31 to 16 .32)
V =0.1% , P =0 .583
Sum of Skinfolds
C C =24.85 (24 .68  to 25 .04)  
C G = 24.92  (24 .54  to 25 .35)
V =0% , P =0 .737
Arm Circumference
C C = 16.70  (16 .53  to 16.87) 
C G = 16 .84  (1 6 .4 6  to 17.25)
V =0.1% , P = 0 .549
Waist Circumference
C C =52.83 (52 .33  to 53 .34) 
C G =52.74 (51.71 to 53 .82)
V =0% , P =0 .887
Hip Circumference
C C = 57.34  (5 6 .8 0  to 57 .89) 
C G = 57.32  (5 6 .0 4  to 58 .70)
V =0% , P = 0 .986
161
Table 14 Associations of adiposity-related phenotypes with PPARy Pro12Ala polymorphism 
in girls.
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BMI
C C =16.67 (16.31 to 17.05) 
C G = 16.80 (16.11 to 17.55)
V =0.1% , P =0.805
Sum of Skinfolds
C C = 25.26  (24 .88 to 25 .66)  
C G = 25.12  (24 .08  toc26 .26)
V =0.1% , P = 0 .734
BMI
C C =16.11 (15 .90  to 16.34) 
C G =16.38 (15 .74  to 17.04)
V=0.3% , P =0.454  
Sum of Skinfolds
C C =25.68 (25 .40  to 25 .96)  
C G = 25.70 (24 .92  to 26 .56)
V =0% , P =0.962
BMI
C C =15.88 (15 .72  to 16.04) 
C G = 16.25 (15 .74  to 16.80)
V =0.6% , P = 0 .150  
Sum of Skinfolds
CC=25.57 (25.38 to 25.76) 
CG=26.24 (25.67 to 26.97)
V=1.6%, P=0.011 
BMI
C C = 15.90  (15.71 to 16.11) 
C G +G G =15.84 (15 .44  to
16.27)
(G G =14.4S  (12 .77  to 18.40)) 
V=0% , P =0.805
Sum of Skinfolds
C C = 25.99  (2 5 .7 4  to 26 .24)  
C G +G G =25.77 (25 ,25  to
26 .35 )
(G G =25.46 (24 .58 to 2 7 .06 ))  
V=0.1% , P =0.439
Arm Circumference
C C = 15.35 (15 .03 to 15.67) 
C G = 15.60  (15 .13  to 16.06)
V =0.4% , P =0.557
Waist Circumference
C C =46.00 (45 .23 to 46 .80 )  
C G =45.91 (43.81 to 48 .24 )
V =0% , P =0.937
Hip Circumference
C C = 48.77  (47 .80  to 49 .77) 
C G = 49.44  (47 .47  to 51 .53)
V = 0 .3 % ,P = 0 .6 1 6
Arm Circumference Waist Circumference Hip Circumference
C C = 16 .00  (15.81 to 16.20) 
C G = 15.92  (1 5 .2 2  to 16.66)
V =0% , P =0.783
C C =49.39 (48 .83  to 49 .95 )  
C G =50.21 (48 .64  to 51 .81 )
V =0.5% , P = 0 .350
C C =52.78 (52 .26  to 53 .31)  
C G =53.71 (51 .98  to 55 .63)
V =0.8% , P =0 .278
Arm Circumference 
CC=16.30 (16.15 to 16.45) 
CG=16.91 (16.50 to 17.34)
V=2.0%, P=0.010
Waist Circumference
C C = 50.92  (5 0 .4 8  to 5 1 .3 7 )  
C G = 5 2 .5 0  (5 1 .2 6  to 53 .7 9 )
V=1.5% , P = 0 .0 2 2
Hip Circumference
CC=55.28 (54.86 to 55.70) 
CG=57.12 (55.98 to 58.32)
V=3.7%, P=0.005
Arm Circumference
C C = 17.04  (16 .85  to 17.24) 
C G +G G =16.91 (1 6 .5 4  to 
17.29)
(G G = 16.47  (15 .55 to 
17.99))
V =0.1% , P = 0 .557
Waist Circumference
C C =53.06 (52 .55  to 53 .59) 
C G +G G =52.94 (51 .86  to
54.07)
(G G =50.24 (46 .06  to 5 9 .25 ))  
V=0% , P=0.841
Hip Circumference
C C = 58.69  (5 8 .1 2  to 59 .28) 
C G + G G =57.70  (56 .62  to
5 8 .83)
(G G =56.23 (51 .85  to 64 .42 )) 
V=0.7%, P = 0 .184
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Table 15 Associations of adiposity-related phenotypes with PPARy Cl 431T polymorphism
in boys.
a
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BMI
C C =16.76 (16 .43 to 17.10) 
C T =16.91 (16 .09 to 17.82)
V =0.1% , P =0.747
Sum of Skinfolds
C C =25.39 (25 .05  to 25 .75)  
C T =26.15 (25 .40  to 26 .99)
V =2.5% , P =0 .129  
BMI
C C = 16 .34  (16 .15  to 16.54) 
C T+T T =16.41 (15 .99 to
16.83)
(T T = 14.74 to 14.74) 
V =0% , P =0.775
Sum of Skinfolds
C C =25.47 (25 .25  to 25 .70)  
C T +T T =25.61 (25.11 to 
26 .15)
(T T = 24.00 to 24 .00)  
V =0.1% , P =0.590
Arm Circumference
C C = 15.49 (1 5 .2 4  to 15 .73) 
C T =15.57 (1 5 .1 4  to 16.00)
V =0.1% , P =0.791
Waist Circumference
C C =46.75 (46 .09  to 47 .41 )  
C T =46.99 (45.73 to 48 .26 )
V =0.1% , P = 0 .784
Hip Circumference
C C =49.29 (48 .58  to 49 .99 )  
C T = 50.02  (48 .63 to 51 .37).
V=0.7% , P = 0 .440
Waist Circumference Hip Circumference
Arm Circumference
C C = 16.00  (15 .85  to 16.15) 
C T +T T =15.86 (15 .5 4  to
16.20)
(T T =14.99 to 14 .99)  
V =0.2% , P =0.501
C C =49.45 (4 9 .0 4  to 49 .87 )  
C T +T T =49.06 (48.11 to
50.06)
(T T =46.94 to 46 .94 )  
V =0.3% , P =0.433
C C = 52 .92  (5 2 .4 8  to  53 .3 7 )  
C T + T T = 51 .82  (50 .81  to  
52 .8 7 )
(T T = 5 2 .0 0  to  5 2 .0 0 )  
V = 1.9% , P = 0 .0 3 6
II
S
BMI
C C =15.98 (15 .82  to 16.14) 
C T + T T = 16.17 (15.81 to 
16.54)
(T T = 15.64  (14 .42  to 17.16)) 
V=0.2%, P = 0 .334
Sum of Skinfolds
C C = 2 5 .19 (25 .02  to 25 .37)  
C T +T T =25.39 (24 .99  to
25 .83 )
(T T =24.61 (23 .27  to 26 .69))  
V =0.2% , P =0.299___________
Arm Circumference
C C =16.33 (16 .19  to 16.48) 
C T +T T =16.63 (16 .33  to 
16.94)
(T T = 16.64  (15 .71 to 
17.71))
V =0.7% , P =0 .105
Waist Circumference
C C =51.25 (50 .86  to 51 .65) 
C T +T T =51.23 (50 .42  to
52.06)
(T T =49.80 (49 .57  to 50 .03)) 
V =0% , P = 0 .964
Hip Circumference
C C =54.89 (54 .5 0  to 55 .29)  
C T +T P=55.43 (54 .44  to  
56 .47 )
(T T =55.66 (53.01 to 58 .75)) 
V =0.3% , P =0.267
BMI
C C =15.91 (1 5 .7 4  to 16.08) 
C T +T T =15.81 (15 .29  to 
16.39)
(T T = 14.20  to 14.20) 
V =0.1% , P =0.686
Sum of Skinfolds
C C = 2 4 .7 5  (24 .5 9  to2 4 .9 3 )  
C T + T T = 25 .22  (2 4 .7 8  to
2 5 .7 4 )
(T T = 2 4 .0 0  to2  4 .00 )  
V= 1.4% , P = 0 .0 3 8
Arm Circumference
C C = 16.69  (16 .53  to 16.86) 
C T +T T =16.93 (16 .52  to 
17.37)
(T P = 14 .99  to 14.99) 
V =0.4% , P = 0 .266
Waist Circumference
C C = 52.80  (52 .32  to 53 .30)  
C T +T T =53.33 (52 .18 to
54 .56)
(T T =46.98 to 46 .98 )  
V =0.2% , P =0 .408
Hip Circumference
C C =57.25 (56 .73 to 57 .80)  
C T +T T =57.90 (56 .68 to 
5 9 .22)
(T T =51.97 to 51 .97)  
V =0.2% , P =0.398
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Table 16 Associations of adiposity-related phenotypes with PPARy Cl 431T polymorphism
in girls.
1
i ls
B M I
C C = 16.80  (16 .44  to 17.17) 
C T = 16.45  (15 .97 to 16.97)
V =0.8% , P=0.411
Sum of Skinfolds
C C =25.19 (24.81 to 25 .57)  
C T =25.59 (24 .77 to 26 .47)
V =0.9% , P =0.339
Arm Circumference
C C =15.35 (15 .06  to 15.63) 
C T = 15.60  (14 .75 to 16.17)
V = 0 .1 % ,P = 0 .7 5 4
Waist Circumference
C C = 46.24  (45 .45 to 47 .06 )  
C T =45.13 (43.91 to 46 .42 )
V =1.7% , P =0 .233
Hip Circumference
C C = 49.10  (48 .18  to 50 .05) 
C T = 49.04  (47 .62  to 50 .5 1 )
V =0% , P =0.953
B M I Arm Circumference Waist Circumference Hip Circumference
C C =16.11 (15 .89  to 16.34) C C =16.01 (15 .80  to 16 .21) C C =49.49 (48 .93  to 50 .05) C C = 52 .84  (5 2 .3 0  to 53 .39)M C T +T T =16.27 (15 .85  to C T +T T =16.09 (15 .66  to C T+T T =49.23 (48 .09  to C T +T T =52.86 (51 .78  to 1
16.69) 16.53) 50.39) 5 3 .99)
(rr=14.13 to 14.13) (T T =14.08 to 14.08) (T T =46.24 to 46 .24 ) (T T =51.63 to 51 .63)
I Il a
ÿ
V =0.2% , P =0 .577  
Sum of Skinfolds
C C =25.69 (25.41 to 25 .98)  
C T +T T =25.38 (24 .82  to 
25 .99)
(T T = 25.90  to 25 .90) 
V =0.2% , P = 0 .359
V =0.1% , P =0.748 V = 0 .1% ,P = 0 .703 V =0% , P = 0 .929  1
B M I Arm Circumference Waist Circumference Hip Circumference
A C C =15.91 (15 .74  to 16.08) C C =16.33 (16 .18  to 16 .49) C C = 51 .08  (50 .63  to  51 .53) C C = 55.40  (54 .98  to 55 .84)C T +T T =16.26 (15 .87  to C T +T T =16.66  (16 .33  to C T + T T = 52 .42  (5 1 .4 0  to C T +T T =56.18 (55 .18  tog K 16.67) 17.01) 53 .47) 57 .23 )
(T T =19.59 to 19.59) (T T =17.93 to 17.93) (T T = 59.91  to  59 .91) (T T =60.98 to 60 .98)IIg V =0.7% , P = 0 .102Sum of SkinfoldsC C =25.56 (25 .36  to 25 .76) C T +T T =25.94 (25 .49  to 2 6 .43)(T T = 26.00 to 26 .00) 
V = 0 .7 % ,P = 0 .1 1 0
V =0.8% , P = 0 .090 V = 1 .6% , P = 0 .0 1 8 V = 0 .6 % ,P = 0 .1 3 5
B M I Arm Circumference Waist Circumference Hip Circumference
TÎ
C C = 15.99  (15 .79  to 16.20) C C = 17.07  (16 .87  to 17.27) C C = 53 .13 (52 .6 2  to 53 .66) C C = 58 .70  (58 .12  to 59 .30)
C T +T T =15.58 (15.21 to C T +T T =16.91 (16 .55  to C T +T T =52.83 (51 .64  to C T + T T = 57.70 (56 .58 toh 15.98) 17.30) 54.12) 58 .89)
i âis'
ÿ
(T T = 15.82  to 15.82) (T T =16.98 to 16 .98) (T T =57.44 to 57 .44 ) (T T = 59.04 to 59 .04)
V =0.9% , P = 0 .090
Sum of Skinfolds
C C =26.05 (25 .80  to 26 .31)  
C T +T T =25.60 (25 .12  to 
26 .14)
(T T =23.99 to 23 .99)  
V =0.7% , P =0.128
V = 0 .1 % ,P = 0 .5 2 5 V = 0 .1 % ,P = 0 .6 4 2 V =0.8% , P = 0 .127  :
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Appendix 2: ANOVA analysis for associations between 
adiposity-reiated phenotypes and A D R B 2  and P P A R y  
diplotypes in different age groups for boys and girls.
Mean values and 95% CIs aie given for the measured parameters for each ADRB2 and 
PPARy diplotype at different ages in boys and girls. Associations between the diplotypes 
and the adiposity-related phenotypes in different age groups were analysed by ANOVA, 
Data have been normalised, then analysed, then back-transformed to values appropriate for 
each age group. For each test, the percentage of variance explained by ANOVA (V) and 
the probability (P) are given. P values are given to three significant figures. Tests were 
considered significant at the level of P<0.05 and they are indicated in bold. N values 
indicate the size of each age group.
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